roche annual report innovate healthcare every life countskey figures roche group index sales mchf equity ratio research development mchf total employee remuneration mchf operating profit mchf total dividend mchf income taxes mchf number employees net income mchf patients clinical trials core earnings per share chf ecoefficiency rate index price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebased key figures indexed figures annual report proposed board directors full index global reporting initiative gri development phase iv indicators used report see calculation ecoefficiency rate see wwwrochecomreportingandindices wwwrochecomenvironment wwwglobalreportscom brief group roche reports strong results challenging market environment group sales significantly increasing local currencies excluding tamiflu pandemic sales strong organic growth key products outweighs lower tamiflu pandemic sales including tamiflu pandemic sales group sales local currencies rise operating profit exceeds last years record local currencies reaching billion swiss francs despite increased level rd investment net income swiss francs billion swiss francs primarily due strong swiss franc also lower net financial income core earnings per share constant exchange rates previous years record level pharmaceuticals pharmaceuticals sales advance twice global market growth rate sixth doubledigit increase many years oncology product sales grow billion swiss francs first time three cancer products achieve sales billion swiss francs operating profit margin increases percentage points despite significantly lower tamiflu pandemic sales increased investments development pipeline avastin receives accelerated approval breast cancer us applications approval brain cancer filed us eu actemraroactemra approved rheumatoid arthritis japan eu switzerland additional data besubmitted us fda twelve major phase iii programmes initiated acquisitions piramed mirus arius significantly strengthen rd pipeline new compounds technology platforms diagnostics divisional sales show doubledigit growth rising operating profit margin declines percentage points mostly due acquisition impacts strong competition us diabetes care market integration tissue diagnostics ventana completed new businesss performance exceeds expectations outlook abovemarket sales growth divisions midsingledigit sales growth divisions group core earnings per share target remain high level spite increased investments inresearch development expected lower net financial result barring unforeseen events unless otherwise stated growth rates local currencies excluding tamiflu pandemic sales core earnings per share target based constant exchange rateswwwglobalreportscomyour life stake thats work day day better treatments tests innovate healthcare expresses purpose company everything aim achieve pharmaceuticals pipeline one key indicator innovative strength filed major new marketing applications received major regulatory approvals innovation also top priority diagnostics division launched new tests instruments early detection prevention diseases diagnosis treatment treatment monitoring roche delivers wide range healthcare solutionswwwglobalreportscomfor researchers another step forward patients huge relief imagine needing injection week instead twice day control blood sugar losing weight time could appealing prospect people type diabetes hopefully soon reality innovate healthcare taspoglutide investigational new diabetes medicine currently phase iii clinical trials better quality life within reach people type diabeteswe take close look treatment lasts longer necessary wwwglobalreportscomthanks combined expertise pharmaceuticals diagnostics patients hepatitis c spared extended therapy innovate healthcare fourmonth course treatment innovative medicines pegasys copegus patients need low levels virus blood treatment viral levels monitored using roches highly sensitive tests hepatitis c virus still gone six months treatment patient considered curedinnovation isnt molecules people wwwglobalreportscomwe try look whole person many interconnected factors determine whether someone falls ill stays healthy explored risk factors metabolic diseases learned influence early could make serious cardiovascular diseases preventable innovate healthcare dalcetrapib new molecule increases good cholesterol thus may protect heart great hope many patients justified hope compound already phase iii clinical trialswwwglobalreportscomstandard therapies dont work everyone well offer solutions monoclonal antibodies offer new ways treating serious diseases well established cancer therapy also proving effective rheumatoid arthritis innovate healthcare mabtherarituxan actemraroactemra two distinct monoclonal antibodies target different parts inflammation process stop disease progressing offer patients better chance achieve remission disease novel medicines give physicians new options patients respond standard treatments chance improve quality lifewwwglobalreportscomthe future still written stars clues disease coded genes successful innovators need follow many leads industry promising leads come analysing genetic profiles diseases diseasecausing pathogens focus areas researchers innovate healthcare help roche nimblegen microarrays miniaturised genetic research labs chip roche developing novel rapid methods deepen understanding diseases enable development new treatmentswwwglobalreportscomwe cant put end cancer sometimes prevent one important medical discoveries recent times infection certain types human papilloma virus lead cervical cancer women giving doctors practical way apply knowledge roche helping help patients innovate healthcare tests roche help physicians diagnose women infected certain strains virus highest risk progressing cervical cancer early diagnosis treatment save lives spare many women tremendous sufferingwwwglobalreportscomwe innovate good reason reliable accurate safe demands preventive screening tests high innovate healthcare reduce risk viral infection contaminated blood transfusions roche developed test simultaneously checks donated blood hiv hepatitis c b viruses test used many countries worldwide improve safety blood supplieswhen youre sick questions new answers wwwglobalreportscomthe integration ventana gives roche access latest advanced knowhow tissuebased diagnostics enables us help physicians give patients new precise answers questions vital importance innovate healthcare tissuebased diagnostics aids tumour characterisation monitoring changes malignancies gives cancer patients continued hope targeted treatmentsit takes decade turn idea medicine good dont give easily wwwglobalreportscomwe innovate healthcare roche means exploring uncharted territory every day objectives clear outcome never nobody predict outset whether particular compound actually benefit patients safe enough use sustaining dynamic innovation strategy like isnt vision also financial strength make risky longterm investments takes drive staying power keep venturing unknown help patients counting ustable contents key figures brief letter shareholders roche group group results outlook group strategy pharmaceuticals pharmaceuticals division brief results therapeutic areas research development diagnostics diagnostics division brief results business areas corporate governance remuneration report corporate governance remuneration report corporate responsibility brief responsible practices patients people society safety security health environmental protection independent assurance report gri statement pharmaceuticals diagnostics pipelines inside back cover wwwglobalreportscom letter shareholders franz b humer severin schwan dear shareholders past year dominated global financial economic crisis nevertheless com pany continued perform strongly building achievements previous years pharmaceuticals diagnostics divisions sales grew well ahead respective markets group sales rose local currencies excluding pandemic tamiflu sales expected declined sharply including pandemic tamiflu sales increased billion swiss francs groups operating profit increased almost billion swiss francs even though increased research development spending promising projects strong development pipeline net income billion swiss francs slightly previous years record high despite marked appreciation swiss franc major currencies lower financial income core earnings per share constant exchange rates higher year view latest strong results board directors propose dividend increased swiss francs per share nonvoting equity security swiss francs subject approval next annual general meeting shareholders roches nd consecutive annual dividend increase todays turbulent economic climate vital ever stay focused developing products significantly improve treatment options available patients recent years strategy yielded major advances notably diagnosis treatment cancer particularly excited many largescale clinical trials group conducting avastin first targeted cancer medicine halts development new blood vessels roche business report letter shareholders tumours trials require substantial investments time money hold promise longer better life countless patients suffering wide variety cancers ventana usbased leader tissue diagnostics acquired billion swiss francs february continues perform even strongly expected access tissuebased diagnostic tests technologies help us efforts develop per sonalised treatments particularly cancer roche also made considerable progress developing biological medicines treatment rheumatoid arthritis ra autoimmune disease affects million people worldwide novel medicine actemraroactemra approved treatment ra japan european union mabtherarituxan leading cancer medicine continues show benefit ra patients well data phase iii clinical trial example show mabtherarituxan prevent structural damage joints patients early ra told twelve projects entered final stage clinical development roche including three promising new molecules treatment breast cancer pertuzumab type diabetes taspoglutide cardiovascular risk reduction dalcetrapib july last year roche announced intention purchase outstanding shares genen tech company held majority stake nearly years remain committed completing transaction believe bringing genentech entirely within roche group significantly enhance groups ability remain innovative long term take necessary care preserve genentechs unique innovation culture group continue encourage promote diver sity research approaches helps create ideal climate medical progress ensure existing research networks technologies expertise pharmaceuticals diagnostics businesses shared across group time leverage scale combined operations us improve operational efficiency roche taking step position strength conviction proposed transaction best interests companies employees patients share holders roches board directors corporate executive committee confident transaction bring us significantly closer goal worlds leading health care company remain committed operating businesses responsible sustainable manner respects needs stakeholders products greatest contribution society provide significant benefits patients tangibly improving peoples health increasing quality length life recognise responsibility help expand global access products primarily partnerships collaboration various stakeholders wwwglobalreportscom last year achieved environmental goals improving energy efficiency reducing emissions greenhouse gases firmly believe sustainable policies business practices create longterm corporate value support innovation recognition efforts roche selected inclusion dow jones world sustainability index fifth consecutive year finally would like take additional opportunity thank roche employees worldwide tremendous dedication professionalism without efforts roche would one worlds successful companies recruiting retaining developing talented people remain among important tasks barring unforeseen events expect group continue perform strongly pharmaceuticals diagnostics division expect fullyear sales grow ahead market increases midsingledigit range local currencies continue invest largescale confirmatory clinical trials vital roches longterm success despite higher research development costs involved expected decrease net financial income aiming core earnings per share core eps constant exchange rates remain high level expect genentech transaction positive impact core epswithin first year closing franz b humer severin schwan chairman board chief executive officerroche group roche group continued strong underlying operating performance recent years roche also expects sales phar maceuticals diagnostics division grow ahead market roche made personalised healthcare cornerstone innovation strategy see key enabler helping us increase success rate drug develop ment bring clinically differentiated medicines patients wwwglobalreportscom group results financial crisis minimal adverse effect net financial income due conservative group continued strong sales per investment approach limited exposure equity formance total sales grew local currencies securities net financial income reached swiss francs us dollars bil billion swissfrancs reduction billion lion swiss francs pharmaceuticals division swiss francs compared primarily due representing group sales diagnostics tolower interest income resulting lower liquid division contributing sales increase funds reductions interest rates underlying business compensated anticipated decline tamiflu pandemic sales due strong swiss franc lower net billion swiss francs local currency sales growth financial income group net income decreased excluding tamiflu pandemic sales billion swiss francs core eps increased pharmaceuticals diagnostics division grew well local currencies swiss francs ahead respective markets group continues strong balance sheet demand groups oncology drugs avastin also compared internationally equity mabtherarituxan herceptin tarceva xeloda including noncontrolling interests representing continued strong additional growth drivers total assets total assets financed pharmaceuticals division bonvivaboniva longterm inmetabolismbone cellcept transplantation diagnostics division main growth areas professional diagnostics applied science outlook business areas growing well ahead theirrespective markets following acquisition barring unforeseen events roche group expects ventana beginning february sales continue perform strongly fullyear inthe tissue diagnostics business grew significantly sales pharmaceuticals diagnostics faster market contributing percentage division expected grow ahead market points sales growth diagnostics division increases midsingledigit range local currencies roche continue invest large groups operating profit increased local scale confirmatory clinical trials vital currencies billion swiss francs operating groups longterm success despite higher profit margin declined slightly percentage research development costs involved points due margin reduction expected lower net financial result group diagnostics division percentage points aiming core earnings per share core eps main reason impact recent acquisitions constant exchange rates remain high strong competition us diabetes care market level following proposed purchase portfolio mix effects pharmaceuticals margin outstanding genentech shares roche expects improved percentage points despite transaction positive impact significantly lower tamiflu pandemic sales core eps within first year closing roche increased investments strong development willupdate targets transaction pipeline beenclosed operating free cash flow increased billion swiss francs despite significant currency translation effects roche business report roche group personalised healthcare key element groups strategy roche one first companies recognise potential personalised healthcare phc today phc central groups strategy see key enabler helping us increase success rate drug development bring clinically differentiated medi cines patients recent roundtable severin schwan ceo roche group william burns ceo pharmaceuticals division jrgen schwiezer ceo diagnostics division talked roches phc strategy implementation phc create value healthcare stakeholders create value roche roche actively pursuing personalised health care made one cornerstones strategy innovation prom ise personalised healthcare schwan first chance roche taken leading role personalised healthcare pharmaceuticals diagnostics divisions began investing early molecular biology expertise given us puts us strong position today move personalised healthcare forward wm burnssciences understanding disease william burns ceo pharmaceuticals division molecular level growing almost exponentially open severin schwan ceo roche group ing real opportunities treat illnesses effec jrgen schwiezer ceo diagnostics division tively right opportunities may lie largely learning adjust use todays medicines better fit needs particular patients possibly help new diagnostics ultimately aim design treatments tomorrow promise personalised healthcare much rooted science intelligently bring together true innovation medicine better tracking disease well able better job tailoring treatment options different patient populations identifying patients likely respond particular option important time clinical hurdles bring ing new medicines market getting higher j schwiezer often medicines either dont work produce unacceptable side effects depending disease drug response rates low wwwglobalreportscom patients promise phc higher week course therapy pegasys response rates fewer patients needlessly exposed recently approved genotype nonresponders risk side effects governments really personalised options available healthcare payers promise able patients combination innovative use resources effectively paying interven medicine genotyping viral load monitoring tions provide benefit interventions however virology proven one dont predictive disease areas others like oncology diagnostics pivotal role play though wealth knowledge finding clinically rele isnt anything new really decades doctors vant biomarkers track easy targeted used blood sugar tests determine insulin needs breast cancer medication herceptin com patients insulindependent diabetes viral panion tests identify patients likely benefit load monitoring viral genotype testing particularly herceptin still exception rule hiv hepatitis c another recent still early stage discovery science example diagnostics guiding therapy tests definitely pointing direction phc need measure amount virus patients blood harness science make work patients detect viral resistance particular medicines dont well missing opportunity capi information helps doctors decide long talise one greatest assets special com aggressively treat patients infection drug bination strengths pharmaceuticals diagnos combination use change drug tics dosage needed schwan expertise weve built years schwan fully agree jrgen sense pharmaceuticals diagnostics gives us sustain personalised healthcare nothing new doctors able competitive advantage something always tried fit therapy patient possible companies duplicate easily quickly depth whats happened recently weve begun breadth pharma diagnostics capabilities go level deeper exploring make us ideally equipped forefront phc biology disease treatment molecular level question whether lead real ques drug research using powerful new technolo tion us want lead answer gies select molecules body could make yes good drug targets design clinical trials differentiated manner progress science wm burns given complexities know opening opportunities tailor treatments specific address within one company hard patient populations better ever imagine pharma company dealing separate diagnostics company finding way plug wm burns hepatitis c jrgen touched play anything complexities likely mag briefly good reallife example weve made nified shared libraries clinical samples abil medicine personalised hepatitis c discov ity design pharma study could also validate ered years ago help diagnostic marker join things correctly genotyping able tell patients within weeks number opportunities us create sus whether theyll respond treatment pegasys tainable competitive advantage patients hcv genotypes know short course therapy likely successful roche business report roche group personalised healthcare create value hurdles roadblocks roche overcome make phc happen wm burns pharma perspective goal schwan biggest challenge think com toachieve kind clinical differentiation plexity science easy develop truly dif make difference practice medicine ferentiated medicine find biomarkers guide able make health economic case prod use think building blocks ucts able distinguish subsets patients likely place make phc happen see two important areas respond medicine subsets shouldnt weve made progress one jrgen mentioned even try one way enhance chances extending portfolio diagnostics technolo achieving clinical differentiation obviously ideal gies part acquiring companies like nimblegen pharmaceutical paired companion diagnostic life sciences recently ventana need realistic expectations weve think second element demonstrates com successes hiv hepatitis todays science mitment phc organisational alignment weve isnt going translate overnight drugdiag carried last two years divisions nostic combinations pursuing projects even support smooth integrated cooperation phar immediately entirely successful unlock pro maceuticals diagnostics building blocks found value organisation however need place time make phc happen continue focusing interest patient j schwiezer roche diagnostics two roles one create novel instruments assays vitro diagnostics market world leader important job support pharma ceuticals division achieving goals providing tools need drug discovery development process roche diagnostics weve taken steps fill roles better including acqui sition technologies giving us wider range capabilities need fullservice partner pharma fact one organisation gives us distinct advantage able work together early discovery launch shareholders theres additional advantage benefit intellectual property generated discovery development regardless division commer cialises wwwglobalreportscom people different diseases people react differently medications patients benefit others experience unwanted side effects today response rates treatments vary depending drug disease roche committed using expertise molecular biology gain deeper insights disease differences patients part broader commitment personalised healthcare phc seeking better drug targets clinically relevant biomarkers one day enable doctors tailor treatments closely patients needs predict patients benefit ones wont essence phc areas oncology virology patients already benefiting safer effective treatments thanks commitment phc diagnostics plays key role personalised healthcare people react differently medications one group patients may benefit treatment others experience unwanted side effects roche personalised healthcare fitting treatment patientspharmaceuticals division delivered strong underlying sales operating profit growth advancing key projects promising rd portfolio roche continue develop clinically differentiated solutions address significant unmet needs treatment cancer complex diseases roche groups pharma ceuticals division made roche pharmaceuticals represented countries majority shareholdings genentech united states chugai japan wwwglobalreportscom pharmaceuticals division brief sales millions chf operating profit millions chf number employees key figures change change millions chf chf local currencies sales sales roche pharmaceuticals genentech chugai operating profit operating free cash flow research development pharma executive committee december william burns ceo division roche pharmaceuticals george b abercrombie north america jennifer allerton informatics silvia ayyoubi human resources lee e babiss pharma research henryvincent charbonn strategic marketing jeanjacques garaud development peter hug western europe jonathan kc knowles group research dominic p moorhead finance controlling christopher murray commercial operations chugai pascal soriot commercial operations jan van koeveringe global technical operations daniel zabrowski pharma partnering extended team roche business report pharmaceuticals pharmaceuticals division sales region pharmaceuticals pharmaceuticals division translated division strong underlying sales growth strong north america delivered strong creasein operating profit addition division asiapacific performance passed keyregulatory development milestones latin america excluding pandemic inprojects expected support roche groups others sales tamiflu pharmaceutical sales future growth important cemai grew around twice themarketing approvals gained chugai theglobal market rochefor novel rheumatoid arthritis medicine growth rate divi actemraroactemra japan switzerland western europe sions operating european union ongoing development key japan profitalso increased marketed products resulted regulatory filings strongly italics growth rates andapprovals important new indications cemai central eastern europe middle east africa mabtherarituxan avastin united states central asia indian subcontinent european union division initiated twelve major new phase iii projects including clinical trials novel compounds pertuzumab regions divisions sales performance broadly forbreast cancer taspoglutide type diabetes based nine products generated annual dalcetrapib cardiovascular risk reduction turnover billion swiss francs three diversified pipeline major line extensions achieved sales ofover billion francs innovative new molecular entities latestage development division unique opportunities pharmaceuticals divisions operating sustained growth years come profit advanced even faster sales rising local currencies swiss francs billion swiss francs corresponding margin increased results percentage points compared despite significantly lower tamiflu pandemic sales pharmaceuticals division maintained strong andincreased investments research develop performance throughout solid growth ment information divisions operating underlying business compensating forthe results see p finance report part expected sharp decline pandemic sales oftamiflu thisannual report togovernments corporations divisional sales increased local currencies swiss francs us dollars billion swiss francsexclud therapeutic areas ing pandemic sales tamiflu pharmaceutical sales grew local currencies around twice oncology key products post sustained global market growth rate sixth doubledigit doubledigit growth increase many years growth driven primarily cancer according latest international key products divisions oncology inflammation agency research cancer estimate transplant virology metabolismbone portfolios million people worldwide diagnosed forfullyear sales growth rates ofindividual prod cancer million died ucts see table topselling pharmaceutical disease iarc anticipates cancer products roche group p basis division recorded abovemarket growth key unless otherwise stated growth rates local currencies wwwglobalreportscom roche continued strengthen position worlds leading supplier medicines treat cancer sales therapeutic area oncology inflammatory autoimmune diseases transplantation central nervous system respiratory metabolic diseases bone diseases infectious diseases cardiovascular diseases virology others renal anemia ophthalmology italics growth rates surpass heart disease leading cause since early currently affects death worldwide also forecasts million people worldwide million new cases million deaths per year cancer chronic lymphocytic leukemia europe alone one three people expect common type leukemia adults accounting develop cancer lifetime cancer approximately forms leukemia one disease group incidence cll western countries distinct disorders medical around per twice com challenges mon men women roche continued strengthen position mabtherarituxanrituximab leading asthe worlds leading supplier medicines treat treatment patients nonhodgkins lymphoma cancer sales pharmaceuticals divisions nhl first selective b cell therapy oncology portfoliorose billion swiss approved treatment rheumatoid arthritis francs year total pharmaceutical see p combined sales product sales key brands contributing doubledigit inthe oncology inflammationautoimmune growth importantly group advanced segments grew versus prioryear period keydevelopment programmes filed marketing billion swiss francs strong solid growth applications aimed making effective wasrecorded europerest world row treatmentoptions available doctors cancer theus japan growth oncology patients expanding range conditions driven sustained expansion use innovative medicines mabthera ofmabtherarituxan induction maintenance rituxan avastin herceptin tarceva xeloda canbe prescribed oncology portfolio main products mabtherarituxan nonhodgkins lymphoma group herceptin avastin tarceva xeloda neorecormon kytril neutrogin neupogen bondronat roferona furtulon vesanoid cancers affect lymphatic system roche defines europerest world covering europe class cancer grown incidence countries except japan united states roche business report pharmaceuticals divisions therapy nhl improved access emerging kidney cancer type cancer newly key cancer medicines markets approved indications diagnosed around people causes contributed double deaths worldwide every year rates digit sales growth year roche partners genentech expected increase renal cell carcinoma inaddition roche biogen idec achieved important milestones accounts kidney cancers partners achieved important intheongoing development mabtherarituxan milestones injanuary roche announced results major global sales avastin bevacizumab worlds development phaseiii trial cll mabthera firstline leading antiangiogenesis treatment advanced mabtherarituxan treatment forchronic lymphocytic leukemia cll colorectal breast lung kidney cancer rose avastin herceptin study showed combined treatment strongly throughout advancing bil tarceva xeloda mabthera current standard chemotherapy lion swiss francs key regions contributing innew treatment achieved significantly better outcomes chemo dynamic sales growth europerow indications therapy alone roche used data support driven primarily increased use medicine anapplication filed july add new indication formetastatic colorectal breast cancer sales medicines eu marketing authorisation jan europe also benefited rollout new uary eus committee medicinal products indications increasing uptake nonsmall cell human use chmp recommended approval lung cancer renal cell carcinoma united mabthera indication indecember roche states solid doubledigit growth continued received approval switzerland mabthera ini driven primarily increased use metastatic non tial firstline treatment certainpatients cll small cell lung metastatic breast cancer following accelerated approval us food anddrug october study mabtherarituxan patients administration fda japan whereavastin relapsed refractory cll reach met approved metastatic colorectal cancersales primary endpoint demonstrating patients treated continue grow strongly mabthera combined current standard chemotherapy showed significant improvement avastin received additional regulatory approvals inprogressionfree survival time patients key markets year january eu livewithout cancer getting worse compared authorities approved extension products received chemotherapy alone metastatic colorectal cancer indication permitting thesedata formed basis regulatory filing thecombination avastin commonly inthe eu indication submitted roche used chemotherapy regimens lines treatment january results cll andreach result virtually patients metastatic presented american society hematology colorectal cancer access proven annual meeting december genentech biogen survival benefits avastin february genentech idec evaluating data trials received accelerated approval fda expect submit supplementary biologic license avastin combination paclitaxel chemotherapy applications indications inthe us firstline treatment patients thethird quarter negative metastatic breast cancer colorectal cancer cancer large intestine july roche filed application expand rectum accounts million update current eu approval avastin meta new cases around newly diagnosed static breast cancer final data avado cancers worldwide year second study also presented meeting common cause cancer deaths europe american society clinical oncology asco third common worldwide june phase iii clinical study confirmed wwwglobalreportscom nine pharmaceutical products generated sales billion swiss francs including three sales billion francs topselling pharmaceutical products roche group sales change millions local product active substance indication chf currencies mabtherarituxan rituximab nonhodgkins lymphoma chronic lymphocytic leukemia rheumatoid arthritis avastin bevacizumab colorectal cancer breast cancer nonsmall cell lung cancer kidney cancer herceptin trastuzumab herpositive breast cancer cellcept mycophenolate mofetil transplantation neorecormon epogin epoetin beta anemia pegasys peginterferon alfaa hepatitis b c tarceva erlotinib advanced nonsmall cell lung cancer advanced pancreatic cancer xeloda capecitabine colorectal cancer breast cancer stomach cancer bonvivaboniva ibandronic acid osteoporosis lucentis ranibizumab wet agerelated macular degeneration tamiflu oseltamivir treatment prevention influenza b xolair omalizumab asthma valcyte cymevene valganciclovir ganciclovir cytomegalovirus infection xenical orlistat weight loss weight control pulmozyme dornase alfadnase cystic fibrosis nutropin somatropin growth hormone deficiency neutrogin lenograstim neutropenia associated chemotherapy rocephin ceftriaxone bacterial infections activase tnkase alteplase tenecteplase acute myocardial infarction heart attack madopar levodopa benserazide parkinsons disease jointly marketed genentech novartis results earlier trial e showing forexpansion products marketing approval avastin combined taxane chemotherapy signifi include nonsmall cell lung cancer cantly improves progressionfree survival setting september genentech filed supplemen important clinical data benefits tary application fda approval avastin avastin breast lung cancer published combination interferon alfa treat advanced year november roche announced renal cell carcinoma november genentech also thata phase iii trial ribbon investigating avastin applied us approval medicine mono firstline metastatic hernegative breast cancer therapy people previously treated relapsed incombination commonly used chemotherapies glioblastoma aggressive form brain met primary endpoint increasing time tumour based positive results phase ii women breast cancer lived without disease clinical trial brain roche applied eu approval advancing progressionfree survival compared avastin alone combined chemotherapy withchemotherapy alone avado e forthe indication december november ribbon third study confirm benefit chugai filed supplementary application japan ofavastin combined chemotherapy women roche business report pharmaceuticals metastatic breast cancer october roche combination hasbeen shown reduce rate announced first results phase iii study heart problemsobserved herceptin given beta lung investigating use avastin withanthracyclinecontaining regimens thereby plustarceva secondline treatment patients potentiallyallowing patients benefit advanced nonsmall cell lung cancer herceptin combination meet primary endpoint overall survival clear evidence clinical final analysis phase iii trial gbg activity improvements secondary end presented asco june confirmed points progressionfree survival response rate herceptin helps women metastatic tarceva added avastin positive breast cancer live longer without cancerprogressing progressionfree survival breast cancer common cancer among theresults also showed herceptin continued women worldwide million women tobe effective women needed additional newly diagnosed die treatment theircancer progressed disease year several different previous herceptin treatment results gepar types breast cancer knowledge tumour quattro noah trials presented medical characteristics important treatment deci conferences april december respectively sions women breast cancer showed herceptin givenin combination tumours abnormally high levels standard chemotherapy surgery known protein known herpositive tumours asneoadjuvant therapy helpsshrink locally particularly aggressive fastgrowing advanced tumours enabling breastconserving likely relapse surgery improving longterm outcomes final analysis noah data showed adding herceptintrastuzumab early advanced herceptin chemotherapy eradicated tumour herpositive breast cancer posted solid doubledigit innearly twice many patients treatment sales growth throughout total chemotherapy alone billion swiss francs growth especially strong japan due continuing uptake approval lung cancer common form cancer herceptin early breast cancer february solid worldwide leading cause cancer deaths singledigit growth recorded united states estimated million new cases doubledigit gains wereachieved annually nonsmall cell lung cancer europerow main contributions growth common form accounting approximately latter region came cemaicountries cases key emerging markets modest growth us western europe reflects products high pancreatic cancer particularly aggressive market penetration regions particularly disease extremely difficult treat kills early breast cancer setting adoption herceptin higher proportion patients first year metastatic breast cancer remained stable january diagnosis cancer fifth fda approved use herceptin single leading cause cancer deaths developed agent adjuvant treatment herpositive world pancreatic cancer claims nearly breast cancer following multimodality anthracycline lives every year based therapy may genentech received fda approval supplemental regimen adjuvant herpositive breast cancer combining herceptin central eastern europe middle east africa central asia docetaxel carboplatin chemotherapy indian subcontinent wwwglobalreportscom tarcevaerlotinib oral medicine target amarketing application new indication ingthe epidermal growth factor receptor proven osipharmaceuticals collaboration genentech andsignificant survival symptom benefits roche expects submit supplemental broad range patients nonsmall cell lung newdrug application us fda first half cancer nsclc since initial launch four years based saturn data ago tarceva approved countries used treat quarter million gastric stomach cancer accounts close patients addition combination chemo million new cases well deaths therapy tarceva first treatment decade year making secondlargest cause shown significant survival benefit treating cancer deaths worldwide vast majority patients pancreatic cancer sales tarceva cases occur asia lung cancer continued increase strongly growing leading malignancy billion swiss francs overall main contributions coming western europe xelodacapecitabine oral chemotherapy asiapacific region market uptake particularly medicine colorectal stomach breast cancer strong japan china market penetration recorded sustained doubledigit sales growth western europe also continued expand strongly throughout sales increasing bil doubledigit sales growth maintained lion swiss francs growth japan particularly united states expanding uptake regions reflects strong solid increases also achieved doctors growing experience confidence united states europerow product november uks national institute sales driven expanded indications approved health clinical excellence nice issued notably stomach cancer finalguidance tarceva alternative doce advanced colorectal cancer along continued taxel chemotherapy secondline treatment uptake breast cancer growth also helped ofnsclc opening way reimbursement new clinical data reimbursement approvals bythenational health service ascombination regimens xeloda gain accept ance standard therapy indications new data phase ii fastact trial presented xelodais generating strong doubledigit sales growth asco european society medical china following approval september oncology meetings showed firstline treatment foradvanced stomach cancer february eu tarceva alternating chemotherapy fol authorities approved xeloda treatment lowed tarceva maintenance therapy significantly metastatic colorectal cancer combination improved progressionfree survival asian patients anychemotherapy lines treatment advanced nsclc compared chemotherapy withoutavastin approval provides new treat alone irrespective tumour type mutation status mentoptions large number patients november roche announced phase iii metastatic disease also february chugai filed saturn study met primary endpoint demon anapplication japan expand products strating firstline maintenance treatment approval allow combination oxaliplatin tarceva given immediately following initial treatment chemotherapy without avastin platinumbased chemotherapy significantly treatment ofmetastatic colorectal cancer extended progressionfree survival patients advanced nsclc results show first transplantation cellcept continues expand timethat earlier treatment tarceva delays market share lungcancer progression roche discuss cellceptmycophenolate mofetil leading com datawithregulatory agencies plans submit ponent immunosuppressant combination therapy roche business report pharmaceuticals broad commitment fighting cancer products clinical development phases ii iii cancer type marketed products including additional indications marketed products gastrointestinal tract avastin furtulon tarceva xeloda avastin herceptin xeloda breast avastin furtulon herceptin xeloda avastin pertuzumab trastuzumabdm xeloda r antiigfr lung avastin tarceva avastin apomab apoltrail tarceva r blood immune system mabtherarituxan vesanoid avastin mabtherarituxan r rd generation anticd dacetuzumab apomab apoltrail genitourinary system avastin furtulon roferona avastin pertuzumab r skin soft tissue r apomab r hedgehog pathway inhibitor brain avastin childhood cancers r xeloda avastin supportive care bondronat kytril neorecormon epogin neulastim neupogen neutrogin includes colon rectum stomach pancreas liver includes nonhodgkins lymphoma chronic lymphocytic leukemia acute promyelocytic leukemia includes kidney prostate ovary cervix information development projects see major development activities p pharmaceuticals pipeline inside back cover toprevent rejection solid organ transplants roche groups anemia franchise includes three recorded doubledigit increase sales erythropoietinstimulating agents esas roches advancing billion swiss francs growth mirceramethoxy polyethylene glycolepoetin beta wasdriven primarily strong demand theus first continuous erythropoietin receptor andjapan see p review ofvalcyte activatorand established shorteracting esas cymevene neorecormonand epogin epoetin beta fromroche chugai respectively three anemia overall sales decline competitive medicines used treat symptomatic anemia costsensitive market patients withchronic kidney disease addition anemia occurs level red blood cells neorecormonis approved treat chemotherapy andor hemoglobin contain falls induced anemia cancer patients normal starving organs tissues oxygen itis seen patients chronic kidney combined sales neorecormon epogin renal disease affects million declined billion swiss francs people worldwide addition anemia affects three inanincreasingly competitive highly costsensitive four cancer patients undergoing chemo market characterised heavily discounted contract therapy patients untreated anemia may tenders group purchasing new guidelines needblood transfusions potential longterm theuse esas cancer renal patients issued effects anemia include cardiovascular disease year european medicines agency inrenal patients patients cancer emea regulators also contributed isassociated diminished quality life theoverall contraction global anemia market ineuroperow erosion neorecormon sales wwwglobalreportscom roche diagnostics highly sensitive cobas pcr tests helping personalise treatment pegasys people chronic hcv infection moderate despite entry several key emerging markets combined solid market pegasys maintained biosimilar versions epoetin alfa since late share growth united states pegasys clear leadership injapan epoginremains market leader accounts new prescriptions global pegylated interferon market decline sales medicine due hepatitis c june eu authorities approved andcontinued gain primarily sustained pricing pressure govern shortened course treatment pegasys plus market share world mentmandated price cuts came effect copegus patients genotype hcv wide expected inapril january mircerahas infection low virus levels show sales tamiflu approved countries worldwide launched rapid virological response approval personalises continued decline including major eu markets physician therapy patients offering chance due substantially reduced pandemic feedback early launch markets positive curewith four months treatment new stockpiling orders salesare modest progressing prod approach made possible roche diagnostics governments uctsglobal rollout continues highly sensitive realtime cobas pcr diagnostic tests corporations november roche also received eu approval virology pegasys maintains clear market theretreatment patients whose chronic hcv leadership expands market share infection respond previous treatment hepatitis b c hepatitis b c viruses interferon alfa pegylated nonpegylated alone hbv hcv commonly transmitted orin combination ribavirin pegasys thefirst bloodtoblood contact cause acute pegylated interferon indicatedfor chronic liver disease potentially leading liver retreatment weeks allowing therapy failure cirrhosis liver cancer worldwide bepersonalised optimised recommended million people thought chronically retreatment period depends hcv genotype infected hbv highly infectious virus type previous treatment andthepatients responsible estimated million deaths virological response retreatment annually million people around world infected hcv million influenza flu highly contagious debilitat new cases occur year hepatitis c main ing viral illness occurs mainly autumn reason liver transplantation recent study winter months temperate climates hcvrelated burden disease euro yearround tropical areas particularly pean countries estimated seven dangerous young children elderly nine million people population people chronic health problems year infected hcv million people fall ill flu europe japan us alone estimated pegasyspeginterferon alfaa indicated people globally die year treatment chronic hepatitis b c used disease complications pandemics alone treatment hepatitis b com global epidemics caused novel strains bination copegus ribavirin treatment influenza people immunity ofhepatitis c addition pegasys pegylated pandemics associated significant levels interferon choice use clinical trials illness death occur every years new generation direct antiviral agents see world health organization medical p expected increase cure rates experts continue warn next influenza andor shorten treatment duration pegasys pandemic may imminent maintained clear leadership global pegylated interferon market continued gain market share forecast total sales antiinfluenza medicine worldwide global sales advanced billion tamifluoseltamivir continued decline swiss francs driven strong growth japan fall million swiss francs due roche business report pharmaceuticals worldwide uptake tosubstantially reduced pandemic stockpiling orders inflammation autoimmune disorders ofmabtherarituxan governments corporations expected actemraroactemra approved rheumatoid rheumatoid sharp falloff pandemic sales billion arthritis japan switzerland eu arthritis isstrong swiss francs compared autoimmune disorders occur result itisnow themarket weighed significant increase seasonal sales mistaken immune response bodys leader outside rose million swiss francs main tissues causes unknown rheumatoid usfor treatment ra contributions seasonal sales came united arthritis multiple sclerosis lupus erythematosus responded adequately states flu season partic among common autoimmune dis tnf inhibitor ularly severe part policy help ensure orders affect millions people worldwide therapy actemra pandemic readiness roche continued work roactemra governments worldwide appropriate tamiflu rheumatoid arthritis ra chronic progressive approved ra stockpiles line recommendations based inflammatory disease joints surround injapan switzerland data provided roche chugai authori ing tissues associated intense pain eu ties united states japan canada australia irreversible joint destruction systemic compli january elsewhere increased shelflife cations b cells type immune cell known government stockpiles tamiflu seven years play key role inflammation associated roche filed data support similar shelflife ra several key cytokines proteins extensions countries also involved including tnf alfa interleukin il interleukin il il iden combined sales valcyte valgancyclovir tified pivotal role inflammation cymeveneganciclovir standard care process around million people worldwide thetreatment cytomegalovirus cmv retinitis thought affected ra patients hivaids prevention cmv disease atrisk transplant patients rose estimated salesof mabtherarituxan rituximab million swiss francs robust growth inthe inflammationautoimmune segment amounted throughout year driven mainly demand approximately million swiss francs ineuroperow strong gains recorded driven strong worldwide uptake product ingermany spain july fda granted treatment severe rheumatoid arthritis thefirst pediatric exclusivity valcyte united states selective b cell therapy approved inthis extends medicines patent protection indication mabtherarituxan rapidly established sixmonths september proven choice ra patients inade quate response tumour necrosis factor tnf third quarter following extensive inhibitor therapy market leaderin toxicology studies roche eu indication outside us observational data showing swiss authorities confirmed presence superiority mabtherarituxan sequential ofachemical impurity batches hiv use tnf inhibitors products increasingly medicine viracept nelfinavir last year positive longterm efficacy safety profile present risk patients authorities deter convincing rheumatologists move mined need follow patients patients mabtherarituxan following inadequate inregistries discovery impurity led response first tnf inhibitor theuse aglobal recall viracept june since mabtherarituxan setting supported viracept reintroduced eu switzer growing body evidence including new clinical trial landand markets roche supplies data presented medical conferences product based data genentech roche territories wwwglobalreportscom eleven major new marketing applications filed major regulatory approvals gained major regulatory filings product active substance indication andor dosage form country avastin bevacizumab metastatic breast cancer combination docetaxel eu switzerland metastatic colorectal cancer combination japan xeloda oxaliplatin firstline metastatic renal cell carcinoma usa combination interferon alfaa relapsed glioblastoma multiforme usa eu nonsmall cell lung cancer japan rituxan rituximab rheumatoid arthritis patients inadequate response usa diseasemodifying antirheumatic drug mabthera rituximab firstline chronic lymphocytic leukemia eu switzerland relapsed refractory chronic lymphocytic leukemia eu xeloda capecitabine metastatic colorectal cancer monotherapy combination japan avastin oxaliplatin major regulatory approvals product active substance indication andor dosage form country actemra tocilizumab rheumatoid arthritis polyarticularcourse juvenile japan idiopathic arthritis systemic juvenile idiopathic arthritis roactemra tocilizumab rheumatoid arthritis switzerland eu avastin bevacizumab renal cell carcinoma switzerland first secondline metastatic colorectal cancer eu switzerland combination oxaliplatin hernegative metastatic breast cancer firstline usa switzerland combination paclitaxel herceptin trastuzumab adjuvant herpositive breast cancer single agent usa following multimodality anthracyclinebased therapy adjuvant herpositive breast cancer combined usa nonanthracycline regimen containing docetaxel carboplatin docetaxel following regimen containing doxorubicin cyclophosphamide adjuvant herpositive breast cancer japan mabthera rituximab firstline chronic lymphocytic leukemia switzerland xeloda capecitabine metastatic colorectal cancer first secondline eu switzerland combination treatment includes supplemental indications updated january january accelerated approval fda roche business report pharmaceuticals groups rd showing sustained improved reduction disease letter roches us marketing application activities focused activity repeated treatment courses sus actemra fda requested additional documen creating clinically tained inhibition progression ofjoint damage tation following discussions result differentiated medi ofthe fdas evolving risk evaluation mitigation cines based small roche genentech biogen idec continued devel strategy rems requirements medications molecules therapeu tic proteins next opment programmes evaluating additional ra settings december agency asked roche prepare generation biologics mabtherarituxan may provide benefit rems plan actemra addition based addition roche patients two major trials phase iii programme evolving requirements approval new biologics rd exploring investigating medicine use ra patients fda asked roche nonclinical animal rna interference withless advanced disease met primary end model data beyond included apromising new points january results serene original marketing application roche performing approach uses study patients inadequate response pre requested preclinical studies expects sub targeted gene silencing vious therapy diseasemodifying antirheumatic mit complete response actemra fda drugs dmards showed significantly third quarter fda requested morepatients treated mabtherarituxan plus additional clinical studies prior approval methotrexate mtx achieved improvement disease signs symptoms compared metabolic disorders bonvivaboniva maintains received mtx alone december roche robust growth competitive market announced image radiographic study osteoporosis systemic skeletal disease assessing ability mabtherarituxan inhibit characterised loss bone mass leading structural joint damage patients previously bone weakness susceptibility fracture treated mtx also met primary endpoint millions people worldwide affected roche plans use signs symptoms data one three postmenopausal women one inconjunction radiographic data support five men age acombined eu regulatory filing additional ra indications september based bonvivabonivaibandronic acid highly effective serene data genentech filed supplementary well tolerated medicine women post marketing application us seeking approval menopausal osteoporosis available forrituxan ra patients inadequate response monthly tablet threemonthly injection dmard therapy increasingly competitive market environment bonviva boniva recorded solid overall sales performance actemraroactemratocilizumab firstinclass sales increasing billion swiss therapy based il inhibition representing novel francs marketshare gains supported robust approach treatment patients moderate growth europerow united states despite severe ra following approval april actemra entry generic versions competitor products ra adults related pediatric disorders us europe new data retrospective subsequent rollout chugai sales uptake observational study postmenopausal injapan encouraging december women vibe presented major european theswiss authorities approved roactemra rheumatology congress june provided additional treatment moderately severe severe active evidence effectiveness oncemonthly rheumatoid arthritis adult patients bonviva compared weekly bisphosphonates responded adequately treatment dmards inpreventing vertebral nonvertebral hip frac ortnf inhibitors roche received eumarketing tures november fda expanded existing approval roactemra indication marketing approval oncemonthly boniva january september complete response include prevention postmenopausal osteoporosis wwwglobalreportscom roche uniquely positioned help realise promise personalised healthcare research development greater value future thus meeting growing global develop stakeholder expectations safer effective ment programme pharmaceuticals division continued andmore costefficient treatments foravastin includes clinical build value research development trials around portfolio advancing twelve projects areas major development activities patients oncology metabolic inflammatoryautoimmune oncology global development programme different diseases phase iii clinical testing see pharma foravastincurrently includes clinical tumour types ceuticals pipeline foldout end trials around patients different phaseiii studies businessreport tumour types phase iii studies diseases avastin colon ovarian prostate asovarian prostate gastric stomach cancer stomach cancer last months roche pharmaceuticals scheduled report next two years final arescheduled decentralised management rd projects results key clinical trial avastin early toreport bycreating five disease biology areas dbas colon cancer setting nsabp c expected nexttwo years theoncology viral diseases inflammation metabolic results another trial diseases andcentral nervous system dbas set setting avant due important milestones priorities make portfolio decisions spe passed several avastin programmes cific diseases already helping streamline beth global phase iii trial avastin combined theresearch portfolio expected increase herceptin adjuvant herpositive breast number quality programmes advanced cancer started may patient recruitment clinical development phase iii avagast trial firstline advanced gastric cancer completed december bernie groups rd activities focused creating aphase ii trial assess avastin combination clinically differentiated medicines based small mol standard chemotherapy children adolescents ecules chemical compounds therapeutic pro sarcoma commenced july october teins mainly monoclonal antibodies peptides euauthorities approved pediatric investigation including glycoengineering nextgeneration bio planfor avastin studies included eventually logics addition roche rd exploring small provide physicians new data dosing interfering ribonucleic acid molecules also known safety improve clinical outcomes specifically asrna interference rnai promising approach children based concept targeted gene silencing thatit hoped eventually yield powerful new collaboration osi pharmaceuticals therapeutic options genentech roche conducting extensive devel opment programme clinical studies addition roche uniquely positioned help tarceva earlier stages lung cancer realise promise personalised healthcare andincombination treatments including approach seeks tailor treatments specific avastin evaluate lifeextending benefits patient subpopulations based knowledge tarceva patients nsclc ongoing thebiological differences patients planned phase iii studies tarceva development characteristics disease see personalised programme include randomised phase iii trial healthcare p roche groups combined atlas evaluating addition tarceva avastin pharmaceuticals diagnostics expertise gives maintenance therapy following firstline treatment usaclear competitive advantage area roche avastin chemotherapy patients hasalready achieved notable successes advanced nsclc initial results trial approach oncology virology expect expected first half ourfocus personalised healthcare contribute roche business report pharmaceuticals first phase iii trial several studies currently evaluating herceptin progress also made range pertuzumab combination avastin pertuzumab patients oncology projects earlier stages development herpositive breast herpositive breast cancer addition beth including one soon move phase iii cancer began see avastin cleopatra neosphere thelast stage clinical testing marketing progress also see pertuzumab herceptin also application filed trastuzumabdmtdm made oncology studied global phase iii study averel r isa novel antibodydrug conjugate linking projects earlier stages develop combination avastin firstline treatment trastuzumab active ingredient herceptin ment including ofadvanced breast cancer herceptin also andthe cytotoxic agent dm targeting novel antibodydrug investigated herpositive advanced gastric cancer proteins expressed tumours conjugate conjugate tdm phase iii toga study around patients deliverschemotherapy cancer cells precise soon gastric cancer herpositive disease manner tdm shown promising clinical enterthe last phase efficacyand good tolerability phase ii clinical trials development interim results phase iii trial women herpositive metastatic breast patients finnish breast cancer group pre cancer roche genentech decided move sented san antonio breast cancer symposium tdm phase iii development secondline december suggest xeloda already herpositive metastatic breast cancer first trial approved advanced breast cancer may also programme scheduled start first reduce cancer recurrence extend survival halfof patients early breast cancer similar roche sponsored study xeloda early breast cancer ris monoclonal antibody targeting igfr ongoing roche plans seek regula receptor igf pathway important growth tory approval xeloda indication phase iii survival variety cancers r well trial medicine early colon cancer tolerated currently phase ii development due report data phase iv sarcoma nonsmall cell lung cancer breast adjuvant study patients gastric cancer cancer expected rga fully humanised type ii glyco pertuzumabr currently studied com engineered thirdgeneration anticd monoclonal bination herceptin standard chemotherapy antibody developed glycart roche herpositive breast cancer entered phase iii codeveloped chugai genentech biogen development pertuzumab inhibits pairing idec treatment cdpositive hemato receptors key mechanism logical malignancies including cll nhl tumour growth cleopatra phase iii study rtargets b cell protein cd evaluating addition pertuzumab herceptin mabtherarituxan engineered chemotherapy firstline treatment patients increase direct andindirect tumour cell death advanced disease commenced first quar thereby enhancing efficacy phase studies r ter addition neosphere phase ii trial shown good tolerability encouraging investigating neoadjuvant presurgical treatment clinical activity inpatients treatment pertuzumab started first half year data options previously received mabthera phase ii trial presented asco rituxan phase ii development nhl commenced showed half patients advanced indecember positive breast cancer whose disease progressed previous treatment regimen including ris novel inhibitor braf kinase herceptin benefited combination herceptin codeveloped plexxikon roche currently pertuzumab phasei testing r selectively targets product wwwglobalreportscom roche currently compounds targeting several mechanisms action development type diabetes themutant brafvegene abnormality discontinued due negative results shown drive certain cancers themutation atrialwith mabtherarituxan similar patient occurs tumour cells found inmany thyroid population cancers malignant melanomas small proportion colorectal cancers adiagnostic test promising earlystage projects inflamma isbeing developed collaboration roche tionautoimmune area proceeding track molecular diagnostics select patientswho carry includingr currently phase ii clinical testing brafvemutation aretherefore likely emphysema rhumab antioxl respond treatment withr anovel biologic jointly developed roche genentech treatment asthma currently rtb human monoclonal antibody phase november actelion roche agreed targeting placental growth factor plgf entered progress r selective sp receptor agonist roche portfolio june via licensing agree phase ii clinical development autoimmune ment thrombogenics bioinvent malignancy diseases solid tumours dependent new blood ves selformation process known angiogenesis metabolic cardiovascular diseases many andplgf important growth factor process people elevated levels certain blood anticipated r used combina fatsremain risk heart attack stroke despite tion antiangiogenic treatments treatment currently available medications avastin r currently tested phase thisrisk may reduced new treatments study patients solid tumours increase highdensity lipoprotein cholesterol hdlc sometimes called good cholesterol dalcetrapib inflammation autoimmune diseases r jtt licensed japan tobacco second quarter roche genentech increases levels hdlc blocking action decided discontinue development mabthera cholesteryl ester transfer protein cetp thereby rituxanin systemic lupus erythematosus potentially reducing risk cardiovascular phase iiiii study failed reach primary endpoint diseaseand deathin highrisk patients phase iii phase iii development drug lupus nephritis morbidity mortality study dalcetrapib continuing planned results clinical daloutcomes started april patient trial lunar investigating benefits adding recruitment proceeding well phase ii data mabtherarituxan cellcept expected presented american congress cardiology first half inmarch show thatdalcetrapib well tolerated andhas good general cardiovascular safety ocrelizumabr humanised anticd profile given alone combination monoclonal antibody developed roche statins additional datapresented atthe american genentech chugai treatment auto heart association meeting november showed immune diseases like mabtherarituxan ocrelizu thatdalcetrapib hasaunique chemical structure mab also targets b cells humanised antibody unlike certain cetp inhibitors ithas potential less immunogenic activateenzymes genes involved bloodpressure bettertolerated convenient administer regulation extensive phase iii programme involving patients rheumatoid arthritis diabetes recognised global epidemic ongoing recruitment phase iii trial lupus world health organization interna nephritis continuing planned may phase iii tional diabetes federation estimates trial ocrelizumab systemic lupus erythematosus million people worldwide diabetes roche business report pharmaceuticals according type adult withintermune phase clinical development onset diabetes accounts around bothofthese oral agents investigated cases incombination pegasys copegus addition roche started clinical trialwith com taspoglutider bim licensed bined rand r important first step ipsen first onceweekly human glucagonlike inevaluating therapeutic potential ofanalloral peptide glp hormone analogue interferonfree combination treatment hepa developed roche type diabetes struc titis c ture molecule similar natural human hormone clinical trials date taspo central nervous system evidence evolving glutidewas generally well tolerated significantly onthe role b cells multiple sclerosis disease improved glucose control weight loss process based promising phase ii data eight weeks treatment roche initiated extensive mabtherarituxanin relapsingremitting multiple phase iii clinical development programme taspo sclerosis rrms roche partners glutide july late fda issued new conducting phase ii dosefinding study guidance clinical testing new treatments thenextgeneration anticd antibody ocrelizu fortype diabetes roche reviewing taspo mabinthis disease april phase iiiii study glutide programme comply recommen olympus ofmabtherarituxan primary pro dations gressive ms ppms led genentech didnot meetits primary endpoint however secondary roche currently compounds targeting several analysis suggests medicine maybenefit mechanisms action development use certain patient subgroups genentech roche patients type diabetes one alegli areevaluating possibilities development tazarr dual ppar agonist ofanticd therapy progressive ms demonstrated effects blood fats blood pressure blood glucose phase ii clinical testing nearing r inhibitor glycine transporter type completion roche expects make decision glyt phase ii development treatment inthe first half phase iii development schizophrenia preclinical clinical evidence ofthe compound phase ii development r suggests novel mechanism action may adipeptidyl peptidase iv dppiv inhibitor improve negative symptoms schizophrenia completed second half year areaof high unmet medical need adequately whiledemonstrating adequate glucose reduction addressed current treatments r nicotinic andexcellent tolerability compound alpha receptor agonist developed treat satisfy roches internal clinical differentiation criteria cognitive impairment schizophrenia alzheimers transition phase iii testing roche disease r expected provide significant therefore decided outlicense improvement memory ability perform activities daily living compared current treat virology development r polymerase ments first results phase ii trial investigat inhibitor investigated treatment ingthe benefit r cognitive impairment hepatitis c infection terminated year associated schizophrenia expected due new unexpected safety findings towardsthe middle phase iib study aphase iib study roches pipeline direct antiviral alzheimers disease isscheduled start agents hcv remains robust polymerase firstpart inhibitor r collaboration pharmasset andthe protease inhibitor r collaboration wwwglobalreportscom division currently operates six major biotech manufacturing facilities worldwide manufacturing infrastructure inmannheim nutley transferred biotech manufacturing uses cellculture tech sites addition cenexi galenical manufacturing nology produce bulk quantities genetically site fontenay sous bois france sold engineered active pharmaceutical ingredients inadditionto steps strengthen monoclonal antibodies andfocus manufacturing network roche therapeutic proteins meeting strict quality improved supply chain management systems requirements manufacturing process ensure continuous worldwide supply innovative comprising cell growth fermentation purification medicines filling operations takes place highly controlled conditions facilities subject rigorous regulatory inspection approval procedures roche groups pharmaceuticals division currently operates six major biotech manufacturing facilities worldwide including roche phamaceuticals basel penzberg sites genentechs plants south san francisco vacaville oceanside chugais utsunomiya facility roches new biotech production facilities penzberg germany basel switzerland fully operational roche received european medicines agency emea approval may production trastuzumab active ingredient herceptin atthe penzberg facility european markets four years start construction work roche filed approval production beva cizumabthe active ingredient avastin newbasel facility emea december group made progress impor tant infrastructure projects construction new tech nical research development building roches basel site commenced october addition new sterile vial filling capacity installed roches kaiseraugst switzerland genentechs hillsboro oregon usa chugais utsunomiya japan sites roche pharmaceuticals continued optimise global manufacturing network year thedecision taken close manufacturing nutley new jersey usa phase chemical manufacturing mannheim germany overthree years products currently manufactureddiagnostics diagnostics increasingly critical component medical care central roches strategy diagnostics division launched wide array new products clinical use research achieved market sales growth division also using knowhow support pharma ceuticals rd roche example helping search relevant biomarkers could accelerate development important drugs cases might yield companion diagnostics enabling targeted therapy wwwglobalreportscom diagnostics division brief sales millions chf operating profit millions chf number employees key figures change change millions chf chf local currencies sales sales professional diagnostics diabetes care molecular diagnostics applied science tissue diagnostics na na operating profit operating free cash flow research development diagnostics executive committee december jrgen schwiezer ceo division roche diagnostics perolof attinger ventana integration manfred baier applied science roland diggelmann asiapacific dirk h ehlers professional diagnostics christopher gleeson tissue diagnostics christian hebich finance services michael heuer emea europe middle east africa latin america alexander keller global platforms support frank lennartz human resources daniel oday molecular diagnostics frank pitzer regulatory affairs quality management clausjoerg ruetsch legal michael tillmann north america robert yates business development tenure ended december since january hany massarany associate member since january roche business report diagnostics diagnostics division sales region roches diagnostics roches diagnostics division leading supplier division remains ofin vitrodiagnostics ivds products used europemiddle worlds number one totest body fluids tissue samples obtain infor eastafrica ivd company mation purpose preventing diagnosing japan sales growth treating monitoring disease approximately asiapacific paced market medical decisions guided results broad based extending across tests although account latin america major regions healthcare spending divisions leadership across four five extends across whole ivd spectrum cen north america divisional business tralised laboratory testing pointofcare diag areas nostics molecular diagnostics diabetes self italics growth rates management addition supplies cuttingedge research tools life scientists pursuing tomorrows medical advances posted rising sales biggest contributions research development facilities europe togrowth coming professional diagnostics theunited states augmented expanding applied science tissue diagnostics units within network alliances partnerships affording broad businesses immunoassay systems dna access key new technologies roche uses sequencing products advanced staining remained capabilities develop products high medical value major growth drivers respectively roche dia patients physicians platforms help betes care posted modest sales decline overall laboratories testing sites operate ahighly competitive market achieved strong efficiently productively growth new products roche molecular diagnostics growth continued driven sales automated realtime pcr virology blood results screening systems roche tissue diagnostics ventana usbased leader automated tissue roches diagnostics division recorded sales staining acquired february posted sales billion swiss francs increase local million swiss francs months currencies swiss francs us dollars december accounting previous yearonce faster divisions fullyear sales global ivd market growth estimated atbetween despite recent sector division continues invest heavily innova consolidation division maintained leading tionin research development rd market position costsincreased million swiss francs reflecting investments sequencing business divisional sales continued grow ahead new immunoassays molecular diagnostic tests linewith market regions doubledigit andplatforms infectious diseases cancer gains north america including positive impact newproducts diabetes care advanced ventana acquisition asiapacific latin stainingsystems laboratory information man america strong midsingledigit growth agement solutions areas continue emea region europe middle east africa japan four five divisional business areas unless otherwise stated growth rates local currencies wwwglobalreportscom divisional rd spending reached nearly sales new technologies new tests major focus areas investment berd priorities rdspending latin america showed strong doubledigit growth percentage ofsales increased gains regions high singledigit range operating profit diagnostics division decreased december roche completed acquisition million swiss francs germanbased swisslab gmbh leading provider operating margin decreased percentage points oflaboratory information systems lis related half margin decline services acquisition complements roches exist resulted impact recent acquisitions ing lis portfolio significantly strengthens including amortisation acquired intangible assets position supplier solutions laboratory investments develop acquired businesses automation data management large laboratory rest mainly due strong competition organisations intheus diabetes care market portfolio mix effects serum work area sales serum work area solutions clinical chemistry immunoassay information divisional operating results systems professional diagnostics largest business see p finance report part annual segment grew significantly faster market report information product launches increasing compared estimated market launches planned see tables growth immunoassay sales instruments inside back cover tests year eighth consecutive year doubledigit sales growth roches immunoassay portfolio new placements business areas cobas instruments helped drive growth strong uptake antihcv assay diagnosis professional diagnostics new tests help ofhepatitis c virus infection launched emea fuel eighth year doubledigit immunoassay region markets first half sales growth theelecsys cardiac assays nt probnp roche professional diagnostics supplies instrument troponin also remained major growth drivers clini systems tests software workflow automation cal chemistry sales advanced amid continuing services help clinical laboratories deliver accurate price erosion market diagnostic results quickly efficiently cost effectively also leader growing market roche continues leading supplier clinical fordecentralised testing products support clinical chemistry immunoassay systems markets decisionmaking close patient doctors except united states global market share offices intensive care units primary approximately specialty care settings dedicated group developslaboratory information workflow demand cobas analyser series datamanagement solutions well connectivity mediumworkload laboratories components tomaximise testing efficiency tests per day remains strong introduced support interpretation increasingly complex first several modular roche testresults platforms designed integrate improve efficiency immunoassay clinical chemistry roche professional diagnostics sales rose testing differentsized laboratories two new million swiss francs compared esti configurations launched completing mated market growth sales asiapacific theseries increasing competitiveness roche business report diagnostics roche rolled rollout smaller cobas series instru lowprice competitors full commercial launch dozen serum ments small tomediumworkload laboratories cobas u standalone urinalysis system small work area tests continued successful july launch mediumworkload laboratories successfully eu important clin cobas c clinical chemistry analyser markets completed outside united states uptake ical uses diag except united states us launch scheduled system significantly exceeded expectations nosing kidney failure first quarter detecting hepatitis roughly half decentralised testing sales decentralised tests also roche professional diagnostics supplies one testing products rose helped continued launched us comprehensive menus clinical chemistry trend towards diagnostic testing point care test launches immunoassay tests industry twelve new fully follow automated serum work area assays launched pointofcare cardiac assays posted strong double markets late rolled year digit growth fuelled increased uptake across europe markets major new roche cardiac probnp assay diagnosis assess assays included elecsys antitsh receptor anti ment heart failure cobas h portable body assay diagnosis graves disease cardiac testing device launched cobas common autoimmune thyroid disease h provides highly reliable results eight elecsys anticcp antibody assay highly specific toten minutes test menu includes testto aid diagnosis rheumatoid arthritis major blood markers heart attack heart roche cystatin c clinical chemistry test early failure assessing patients risk future cardio detection impaired kidney function fourth vascular events quarter roche professional diagnostics launched anticmv igg anticmv igm immunoassays overall sales ambulatory caremonitoring solutions diagnosis cytomegalovirus infection almost showed solid doubledigit growth coagulation moni half assays rolled europe toring instruments test strips continued post yearwere also launched united states strong doubledigit sales increases driven mainly bythe coaguchek xs monitor professional use coagulation hematology urinalysis roches patient selftesting accutrend plus handheld laboratory coagulation portfolio generated solid device measures important indicators cardiac growth placements instru risk cholesterol glucose triglycerides tissue menttypes significantly previous year hypoxia lactate contributed high singledigit sales sales grew particularly strongly europe latin growth across several ambulatory care segments america highvolume analysers coasys launched first markets november plusc fully automated lowvolume coagulation device professional selftesting environments analyser launched third quarter available worldwide wereimportant growth drivers uptake accuchek inform ii first hematology sales also showed solid midsingledigit wireless system hospital glucose testing moni growth placements new instruments toring particularly intensive care settings strongly expected growth seen across strong since device launched outside regions covered roches exclusive distribution united states june us approval launch agreement sysmex corporation japan growth expected march continued driven mainly sysmex xs one line compact fully automated analy research development roche professional sers launched urinalysis roche maintained diagnostics single important launch number two position despite strong pressure cobas series modular serum work wwwglobalreportscom roches pointofcare tests heart failure heart attack provide reliable results within minutes area instruments highvolume laboratories diabetes care new products deliver cobas series thisaddition cobas instrument family strong growth instruments one ofthe fastest integrated systems available diabetes results bodys inability regulate offer large labs speed efficiency offer awider choice configurations blood glucose often leads serious complica unmatched flexibility highworkload solution currently market tions including heart kidney disease stroke make roche itreplaces existing roche systems expected blindness worldwide diabetes affects million aneven stronger tosignificantly enhance roches competitiveness people leading cause premature death competitor inboth immunoassays clinical chemistry number people disease immunoassay launches inmost key markets outside united expected reach million cure clinical chemistry segments one states areplanned us launch people diabetes take steps manage number new expected disease lower risk complications diagnostic systems debut significant new systems system enhance roche diabetes cares products designed ments reaching market include make living diabetes easier portfolio covers cobas p cobas p postanalytical sample entire diabetes selfmanagement spectrum storage retrieval modules launched glucose monitoring insulin delivery monitoring globally cobas b multiparameter blood systems integrated lancets test strips gas analyser use critical care settings sched software storing analysing data uled launch year europe japan important part roches diabetes care portfolio united states cobas elabperformance portal improve blood glucose control many forbenchmarking serum work area results users addition offering greater convenience rolled first quarter roche diabetes care remains global market roche also continues expand immunoassay leader sales reached million swiss clinical chemistry menus number important francs decline singledigit sales new tests scheduled launch see table increases emea region asiapacific major product launches scheduled japan doubledigit increase latin america inside back cover quite offset lower us sales following strong second quarter us sales fell third fourth roche professional diagnostics pharma quarters result accelerating decline sales ceuticals division working closely number older monitoring products strong competition ofareas support groups strategic focus continued pricing pressures older products personalised healthcare include joint market phased portfolio account ing activities use elecsys bone markers forless roche diabetes cares sales tomonitor osteoporosis patients receiving bonvivaboniva also include joint exploratory blood glucose monitoring new generation biomarker programmes using innovative multiplex ofaccuchek blood glucose monitoring systems technology developed roche programmes delivered robust growth accuchek aviva roche supporting latestage drug development projects diabetes cares largestselling glucose monitoring rheumatoid arthritis oncology additionally system posted strong doubledigit sales increase synergies two divisions utilised accuchek performa launched develop new highmedicalvalue diagnostics mostmarkets first half two important disease areas experienced strong uptake global rollout con tinued december launch china isnowalmost complete roche business report diagnostics topselling global rollout accuchek compact plus control premarketing activities already started accuchek aviva system completed november combined sales secure current customer base preparation delivering strong accuchek compact plus test strips grew launch new system growth itwill adoubledigit rate countries device joined waslaunched late research development research devel fournew meters opment spending went support new targeted different market segments coming months roche diabetes care product launches planned develop asroche continues launching four important new diabetes monitoring future technology platforms nearterm investment torevitalise glucose products accuchek aviva nano accuchek focused particularly new accuchek mobile monitoring portfolio performa nano blood glucose meters available integrated blood glucose monitoring system european union first market starting updated accuchek aviva accuchek performa inthe first quarter offering func platforms slated launch first quarter tionality accuchek aviva accuchek roche diabetes care stepped investment performa systems sleeker discreet design incommercially developing proprietary continuous nano meters aimed especially young high glucose monitoring technology longterm frequency testers new accuchek active project aimed producing small easytouse targeted particularly emerging markets also continuous monitoring system suitable broad begin rolling first quarter spectrum customers roche continues investi gate value blood glucose monitoring dia fourth new offering accuchek mobile expec betes management particularly type diabetes ted strengthen roche diabetes cares lead inclinical trials activities aimed integrating glucose market segment integrated blood glucose moni monitoring data management insulin delivery toring systems accuchek mobile offers complete ongoing may one day result systems integration testing lancing single device closely mimic way healthy pancreas regulates features unique stripfree technology blood glucose levels employs continuous tape tests instead singleuse test strips molecular diagnostics year major assay launches first quarter roche diabetes care roche molecular diagnostics develops commer willstart updating glucose monitoring systems cialises innovative diagnostic blood screening new testing method avoids risk maltose platforms tests based roches proprietary interference offer additional safety certain realtime polymerase chain reaction pcr techno dialysis patients also monitor blood glucose logy products directly detect genetic material dna rna infecting patho insulin delivery innovative accuchek combo gens hiv hepatitis viruses iden system scheduled launch european union tify quantify infections earlier specifi first quarter strong addition cally tests based bodys immune response roche diabetes cares insulin delivery portfolio infection result patients treated accuchek combo combines accuchek spirit monitored greater precision risk insulin pump highend glucose meter infecting others blood organ donations remotecontrol bolus calculator capabilities reduced addition tests hiv hepatitis users deliver bolus insulin dose anytime roches molecular diagnostics portfolio includes tests anywhere without touch pump infectious diseases tests identify accuchek combo also offers small dose increments patients likely respond particular cancer optimised insulin dosing finetuned glucose therapies wwwglobalreportscom cobas taqscreen mpx test comprehensive blood screening test kind roche molecular diagnostics remains industry european union new hiv test unique since october leader share fastgrowing dualtarget design enabling simultaneous detection roches full suite increasingly competitive market sales totalled oftwo separate regions hiv genome automated viral load tests hiv hepatitis c million swiss francs increase provides greater test reliability viral mutations hepatitis b ayear earlier sales showed doubledigit present addition new tests even available health growth asiapacific latin america broader dynamic ranges ability quantify low professionals singledigit growth north america emea high viral loads earliergeneration us uptake region tests critical advantage since high hepatitis tests low levels virus indicate need launched us inthe second half virology virology testing roche molecular diag less aggressive therapy regulatory filings nostics largest segment sales remained new capctm hiv hbv tests currently strong second significant contributor growth virology sales grew review japan generation versions led demand automated realtime pcr ofthe hiv hepa platforms tests hiv common blood screening sales blood screening prod titis b tests formof virus causes aids humans ucts molecular diagnostics secondlargest segment approved launched eu hepatitis c hepatitis b virus hcv hbv roche sales advanced year additional indecember molecular diagnostics virology portfolio includes blood centres europe asia pacific latin systems automated sample preparation america began routine screening multiplex realtime pcr analysis combined cobas cobas taqscreen mpx test fully automated ampliprepcobas taqman capctm system cobas platform decline seen theonly platform available worldwide offers segment earlier year resulted price customers fully automated realtime pcr testing pressure ongoing effect accounts lost forclinical diagnostic use levelling growth expected october us food drug administration fda approved capctm hcv test quan december fda approved cobas taqscreen tifies amount hepatitis c virus viral load mpx test use cobas system test apatients blood month earlier september comprehensive nucleic acid test kind cobas taqman hbv test became first hepatitis b available today offering unique ability detect viral load test receive fda approval along hiv groups hiv hcv hbv fully automated capctm hiv test single automated assay originally launched europe approved completed initial automation cobas taqscreen mpx test already roches major virology products us market widely adopted demonstrated excellent physicians use tests establish baseline levels performance blood centres worldwide japan infection prior treatment monitor patients test used since september fully inte responses therapy tracking changes grated cobas system screen virus levels treatment numerous us labora japanese blood supply tories already signed contracts hcv hbv tests including one nations largest sexually transmitted diseases oncology reference laboratories converted roche cobas taqman ct test v improved detection hbv test weeks approved ofchlamydia trachomatisct launched clini cal use europe asiapacific latin america secondgeneration versions capctm hiv second half transition new hbv tests received ce mark certification test runs automated cobas taqman december allowing sold clinical use realtime pcr analyser completed roche business report diagnostics majority markets available continue trial evaluating tests cobas taqman ct test v simultaneously detects performance detecting highgrade cervical disease two targets within chlamydiacryptic plasmid women undergoing routine cervical cancer screen genome target dna result able detect ing infections caused known strains ct even ifthere unexpected changes bacterial development test screen methicillinresist genome case recently discovered ant staphylococcus aureus mrsa form staph swedish variant chlamydial infection one infection difficult treat commonly reported sexually transmitted deadly also track launch reducing diseases left untreated lead serious spread mrsa major public health concern complications pelvic inflammatory disease worldwide infertility women business area continues work closely amplicor linear array tests detecting roches pharmaceuticals division others com andidentifying low highrisk strains human panion tests new therapeutics microarray papillomavirus hpv showed doubledigit growth based test identify mutations p tumour persistent infection certain highrisk strains suppressor gene example explored hpv progress precancerous conditions companion diagnostic new class anticancer cervical cancer amplicor hpv test approved drugs called nutlins currently early development launched japan september roche work also progressing realtime pcr test screen common cancercausing mutation june roche signed exclusive deal dxs braf kinase gene braf test may aid ltduk distribution therascreen kras development targeted cancer therapy mutation test roche began distributing roche plexxikon inc working december therascreen egfr mutation selectively inhibits mutated form braf gene test tests realtime pcr assays cemark certification used conjunction applied science sequencing quantitative pcr clinically relevant information kras egfr muta arrays drive strong growth genomics tion testing aid doctors determining patients life sciences encompass disciplines ranging suitability certain cancer therapies biology biotechnology medical research major disease areas like cancer virology roche research development roche molecular diag applied science supplies broad growing array nostics pursuing new tests automation platforms instruments highly specific reagents test improve diagnosis treatment ofdisease kits use diverse research market prod focus infectious disease oncology uct portfolio capabilities especially strong ingenomics proteomics sciences development cobas system new plat transforming understanding treatment form combining fully automated dna extraction ofdisease realtime pcr amplification detection track european launch planned ini roche applied science recorded sales tially offered assays hpv chlamydia million swiss francs increase trachomatis neisseria gonorrhoeae year three times estimated market growth rate sales dna sequencing enrolment roches clinical trial support us regi products led ultrafast genome stration hpv tests well way sequencer flx gs flx nearly doubled despite wwwglobalreportscom xcelligence cell analyser could reduce need animal testing research increased pressure competitors roche applied cell analysis second half roche new products science market leader placements ofnext applied science successfully launched single launched worldwide generation sequencing systems products real multiplate versions xcelligence cell analyser roches leading edge genome time quantitative pcr qpcr analysis particularly system codeveloped acea biosciences inc sequencer flx thelightcycler instruments reagents deliv analyser uses technology eliminates system offer laborato ered robust doubledigit growth strong sales need labour costintensive steps like cell ries greater efficiency increases north america china total instru labelling cell fixation measures changes even better ment placements roughly doubled microarray incell morphology cell proliferation cell death results lower costs systems made significant contribution tofullyear inreal time importantly could significantly sales sequential quarterly sales growth reduce use animal testing pharmaceutical products steady strong since roche research toxicology among areas initial acquired nimblegen august placements already occurred regions biochemical industrial reagents account research development efforts roche major part roche applied sciences revenues applied sciences research development facilities showed moderate growth overall market impacted penzberg germany branford madison flat government funding life science research us remain focused enhancing efficiency expanding range uses lightcycler genomics portfolio late september roche genome sequencer nimblegen microarray tech applied science launched gs flx titanium series nologies resulted example nextgeneration sequencing products including launch new generation genome discovery new reagents software compared standard arrays nimblegen hd combining speed gs flx sequencing titanium increases throughput efficiency multiplex platform ability factor five roche nimblegens seqcap deliver highresolution highquality data another sequence capture arrays help laboratories ongoing priority integrate increase totake full advantage sequencing capacity throughput lightcycler magna pure plat introduced initial markets march forms supporting roche groups strategic focus available worldwide highdensity arrays personalised healthcare roche applied science produce targeted sequencingready samples much pharmaceuticals division pursuing proj faster costeffectively conventional ects aimed discovering validating biomarkers methods sample preparation thus easing major may facilitate drug development poten bottleneck genomic research tial diagnostic applications particularly areas oncology inflammatory disease addition major launches included magna pure potential uses microarrays genome sequenc redesigned improved instrument automated ing investigated across pharma qpcr sample preparation first new ceuticals divisions major research areas interest family preplated readytouse qpcr assays called similar joint evaluation xcelligence realtime ready realtime assays make analyser also way lightcycler systems even competitive expected important sales driver light tissue diagnostics strong yearonyear growth cycler series also strengthened launch launch two major new systems ofthe lightcycler ii first half ventana medical systems also known roche thenew lightcycler instrument features enhanced tissue diagnostics worlds leading tissue analysis software greater efficiency range based cancer diagnostic company roche tissue ofapplications diagnostics develops manufactures medical roche business report diagnostics roche tissue diagnostic instruments reagent systems benchmark ultra new system performs diagnostics strength provide leadingedge automation technology use immunohistochemistry situ hybridisation testing ened core diagnosis prognosis cancer infec simultaneously single continuous random advanced staining tious disease addition company offers premier access platform launched united states business workflow solutions designed improve laboratory canada august europe november launch bench testing efficiency providing automated safeguards benchmark ultra individual staining mark ultra system helps laborato enhance quality patient healthcare worldwide chambers accessed ries work effi also discovery research aids pharmaceutical timewithout interrupting workflow result ciently shortens andbiotech companies accelerate identification testturnaround times reduced significantly time diagnosis potential biomarkers new drug targets stat samples requiring rush testing added time expedited patient diagnosis roche tissue diagnostics demonstrated strong market response benchmark ultra yearof solid revenue product development per positive significant number place formance since acquired february commer ments substantial sales acceleration cial operations integrated roche expected efforts well way expand business intonew markets europe latin america asia roche tissue diagnostics expanded pacific business area remains headquartered immunohistochemistry menu total ten new inthe united states continue tooperate confirm antibodies various cancers including ventana medical systems inc innorthamerica thyroid lung prostate breast cancers lymphoma roches consolidated fullyear results include roche tissue diagnostics sales million primary staining us placements symphony swiss francs representing sales date instrument hematoxylin eosin staining acceler acquisition february december ated second half following upgrades additional sales contributed four percentage points enhance system reliability staining tothe diagnostics divisions localcurrency sales interpretation symphonys commercial performance growth standalone basis roche tissue diag highvolume primary staining market expec nostics sales entire year reached million ted improve launches europe us dollars increase local currencies australia planned second third us dollars significantly quarters year overall sales primary faster estimated market growth rate staininginstruments reagents sales increased abovemarket rates north forthe year america emea asiapacific helped new products advanced primary staining workflow management uptake vantage workflow management workflow solution launched united states april even stronger expected advanced staining advanced tissue staining orders well forecast vantage immunohistochemistry situ hybridisation complete workflow information management system remained business areas biggest growth driver anatomical pathology laboratory providing delivering robust reagent sales even stronger tracking capabilities streamline integrate lab increase instrument sales sales fully auto work information flows greater productivity mated benchmark xt benchmark lt instruments patient safety product rolled immunohistochemistry reagents increased europe australia starting third quarter high doubledigit growth rates wwwglobalreportscom research development roche tissue diag nostics multiple platforms technologies various stages development continue advance anatomical pathology increased test efficiency enhanced medical value together roches pharmaceuticals division business area continues develop exploratory tests view capturing longterm companion diag nostics opportunities roche therapies notable projects include development dual colour immunohistochemistry situ hybridisation assays tests part trend personalised healthcare towards evaluating one analyte per diagnostic kit quantum dot qdot assays expand multiplexing even oncology work isunder way automated qdot assay detect protein levels human tissue samples using mono clonal antibodies collaboration also way enhanced test expected available outside united states second quarter corporate governance roches commitment stakeholders reflected operating businesses focus value creation management culture conforms modern standards corporate governance groups policy communicating transparently remuneration report roches success depends abilities dedication people recognition forms basis remuneration policy system wwwglobalreportscom corporate governance roche complies relevant corporate gover effective date reason role nance requirements particular applic responsibilities independent lead director ablelaws swiss stock exchange six swiss position held bruno gehrig incorporated exchange directives including commentaries role chairman board part thereto swiss code best practice ofthe independent lead directors remit corporate governance promulgated swiss reassigned vicechairmen bruno gehrig business federation economiesuisse companys andr hoffmann internal governance framework particularly articles incorporation bylaws embodies organising meeting immediately following theprinciples needed ensure companys agm board directors approved businesses managed supervised manner committees structure committee memberships consistent good corporate governance includ shown ingthe necessary checks balances agm march board printed annual report contains selected links directors nominate john bell andr hoffmann tothe roche website wwwrochecom readers franz b humer reelection board thus provided snapshot com pany reporting date also directed sources consult time corporate executive todate information corporate governance committee roche whereas annual report covers single financial year ending december website con tains information permanent nature well severin schwan succeeded franz b humer ceo latest roche news amendments com ofthe roche group agm march panys articles incorporation bylaws changes curricula vitae members jrgen schwiezer appointed corporate board directors corporate executive com executive committee ceo division roche diag mittee published timely fashion website nostics effective january accessed anyone looking information gottlieb keller appointed position ofroche general counsel effective march ashead corporate services continues serve board directors corporate executive committee role secretary board directors expanded thannual general meeting agm toinclude additional tasks within responsibility rocheholding ltd march shareholders ofthechairman board approved reduction board directors term office four three years reelected agm gottlieb keller stepped bruno gehrig lodewijk jr de vink walter frey head corporate human resources silvia ayyoubi andandreas oeri members board appointed corporate executive com directors mittee head corporate human resources effec tive march senior human agm march franz b humer resources executive role group stepped ceo roche group focusing role chairman board directors wwwrochecomcorporategovernance roche business report corporate governance board directors per december left dr franz b humer prof bruno gehrig andr hoffmann prof pius baschera prof sir john irving bell peter brabeckletmathe lodewijk jr de vink dr andreas oeri dr deanne julius walter frey prof beatrice weder di mauro prof horst teltschik dr wolfgang ruttenstorfer wwwglobalreportscom board directors name year birth term ends first elected board directors dr franz b humer e chairman profbruno gehrig c e vicechairman andr hoffmann c e vicechairman prof pius baschera e prof sir john irving bell c e peter brabeckletmathe e lodewijk jr de vink c e walter frey b e dr deanne julius b e dr andreas oeri e dr wolfgang ruttenstorfer b e prof horst teltschik b e prof beatrice weder di mauro b e secretary board directors dr gottlieb keller honorary chairman board directors dr fritz gerber corporate governance sustainability committee b audit committee c remuneration committee presidiumnomination committee e nonexecutive director committee chairperson january roche business report corporate governance corporate executive committee name year birth position corporate executive committee dr severin schwan ceo roche group dr erich hunziker chief financial officer deputy head ofthe corporate executive committee william burns ceo division roche pharmaceuticals dr jrgen schwiezer ceo division roche diagnostics prof jonathan kc knowles head group research dr gottlieb keller general counsel head corporate services silvia ayyoubi head human resources enlarged corporate executive burkhard g piper head business area roche diabetes care committee pascal soriot head commercial operations pharmaceuticals division rolf schlpfer head corporate communications osamu nagayama president ceo chugai secretary corporate executive committee ren kissling statutory auditors kpmg klynveld peat marwick goerdeler sa since roche holding ltd principal auditor john morris since group compliance officer dr urs jaisli wwwglobalreportscom corporate executive committee per december left dr severin schwan william burns dr jrgen schwiezer dr erich hunziker silvia ayyoubi prof jonathan knowles burkhard g piper pascal soriot dr gottlieb keller osamu nagayama rolf schlpfer ren kissling roche business report corporate governance rolf schlpfer head corporate communications consolidated financial statements related resigned position end effec parties note financial tive january perolof attinger appointed statements roche holding ltd board head corporate communications member andexecutive remuneration enlarged corporate executive committee report relationships exist theshareholders ing severin schwan ceo roche group pooled voting rights succeeding rolf schlpfer crossshareholdings capital structure information relating information roches capital structure pro vided finance report notes financial corporate governance statements roche holding ltd additional details contained group structure shareholders articles incorporation roche holding ltd roches operating businesses organised changes equity detailed finance two divisions pharmaceuticals diagnostics report notes financial statements roche pharmaceuticals division comprises three holding ltd business segments roche pharmaceuticals company share capital genentech chugai swiss francs divided fully paid diagnostics division consists following bearer shares nominal value swiss four business areas applied science diabetes franceach restrictions care molecular diagnostics professional exercise voting rights shares diagnostics business activities carried upondeposit shares voted without group subsidiaries associated compa restrictions nies significant subsidiaries associated com authorised conditional capital panies listed finance report note addition nonvoting equity securi tothe roche group consolidated financial state ties nes issued bearer form ments subsidiaries associates pages donot form part share capital confer voting rights nes confers rights major shareholders listed finance asone share participate available earnings report notes roche group con andin liquidation proceeds following repayment solidated financial statements equity attributable share capital roches nes rights roche shareholders related parties pertainingthereto including provisions protect pages note financial ing interests nes holders described statements roche holding ltd significant articles incorporation roche holding shareholders ltd andr hoffmann vicechairman board information debt instruments ofdirectors andreas oeri chairman issued outstanding bonds provided boards corporate governance sustainability inthefinance report note roche committee serve respective capacities groupconsolidated financial statements debt board committees representatives ofthe shareholders group pooled voting additional information employee stock options rights receive remuneration set forth provided finance report note theremuneration report financereport note roche group wwwrochecomarticleofincorporation wwwglobalreportscom roche group consolidated financial statements board directors roche holding ltd employee stock options equity com organised ensure groups busi pensation benefits nesses conducted responsibly focus roche issued options apart employee longterm value creation end stock options stocksettled stock appreciation rocheboard delegated certain responsibilities rights ssars options issued connection several committees composition debt instruments chairpersons january described neither options awarded employees committees authorities debt instruments issued responsibilities defined detail bylaws effect roches share capital board directors committees except presidium board directors corporate executive chaired independent directors committee according bylaws board direc information member board torsat request members board directors including years meeting without chairman present may elected years terms end convened roche board meets year member corporate executive assess chairmans performance meeting committee listed pages curricula attended chairman chaired vitae information including information one vicechairmen board memberships available board directors established system internet ofcontrols continuously monitored annual general meeting elects members audit committee corporate governance board directors staggered elections sustainability committee consists inwhich nominee voted separately following elements see articles incorporation roche reports financial operating risks risk holding ltdand minutes thannual management system general meeting roche holding ltd held system internal controls financial report march ing see finance since march director serving report executive capacity roche majority internal audits seats board directors held inde compliance officer pendent directors safety health environmental protection except franz b humer none members department board directors member roches corporate sustainability committee corporate executive committee served scientific ethics advisory group seag executive capacity group subsidiary issues relating genetics genetic three financial years preceding current engineering established reporting period internal organisation board directors division authority responsibilities wwwrochecomboardofdirectors board management remits wwwrochecomexecutivecommittee ofthe board committees information wwwrochecomarticleofincorporation control mechanisms available board wwwrochecomannualgeneralmeetings wwwrochecomarticleofincorporation dealings corporate management governed wwwrochecomcommittees bylaws wwwrochecomarticleofincorporation roche business report corporate governance year several blackout periods imposed therisk management system subject senior employees prohibited continuous review findings presented trading company stock following blackout audit committee full board periods effect internalauditregularly briefs audit com january february mitteewith reference ongoing audit reports april april members internal audit attend audit july july committeemeetings asdo external auditors october october forinformation external auditors blackout periods changed chair see man board directors circumstances management contracts fall warrant within scope subsection six board directors met five meet directive information relating corporate ings hours length governance afullday meeting threeday official trip included board directors remuneration shareholdings loans meeting board committees met follows details regarding remuneration shareholdings loans set forth separate remunera presidium board directorsnomination tion report pages finance committee five meetings approx hours report notes roche group consolidated financial statements equity attribut audit committee three meetings approx able roche shareholders related parties hours pages listed notes corporate governance sustainability financial statements roche committee three meetings approx hours holding ltd board executive remunera tionand board executive shareholdings remuneration committee two meetings pages approx hours chairman secretary board participatory rights shareholders directors always present board meetings participatory rights shareholders defined except board discussing per roches articles incorporationas roche formance remuneration members shares issued bearer restric ofthe corporate executive committee invited tions admission annual general meetings attend report person exception shares must deposited agenda items concerning situation within specified period date warrants members enlarged corporate meeting admittance card must issued executive committee may also invited attend inthe shareholders name provided board committees invite chairman articles incorporation shareholder board corporate executive committee members deliver reports committee meetings remuneration committee members permitted may elect commission independent expert contribute attend remuneration committee meetings reports call services consultants atwhich matters concerning deliberated decided additional information provided finance report figures indicate actual length meetings noteto roche group consolidated financial statements include directors extensive premeeting preparations risk management postmeeting followup activities wwwrochecomarticleofincorporation wwwglobalreportscom elect represented another shareholder kpmg received following remuneration atan annual general meeting articles incor services statutory auditors roche hold poration contain restrictions exercise ing ltd roche companies voting rights quorum requirements stipulated conformity swiss code obligations millions chf articles incorporation auditing services shareholders representing shares nominal auditrelated services value least million swiss francs tax consultancy services requestthe placement items agenda total ofan annual general meeting must doneno later days date statutory auditors elected year themeeting annual general meeting change control defensive measures ernst young ltd received following remuner articles incorporation contain provisions ation services auditors genen mandatory bid rule swiss law applies tech chugai changeofcontrol clauses components remuneration based roche nes would terminated event acquisition millions chf vesting period restrictions preexisting genentech chugai awards would removed options audits could exercised immediately consulting services provided genentech relationship statutory auditors chugai annual general meeting roche holding total ltd march shareholders voted appoint kpmg klynveld peat marwick goerdeler information policy sa kpmg statutory auditors information provided articles incorpo long auditors principal auditor rationcorporate notices published serving capacities provided swiss official gazette commerceand statutory auditors participate audit daily newspapers designated board committee meetings prepare written oral directors basler zeitung finanz und wirtschaft reports results audits audit lagefi le temps neue zrcher zeitung committee oversees assesses auditors roche reports halfyear fullyear results makes recommendations board forinforma inbusiness reports published print online tion responsibilities audit committee formats media events addition detailed see article bylaws thestatutory first thirdquarter sales figures published auditors participated three meetings year april october current audit committee list publication dates available english reports statutory auditors con andgerman internet solidated financial statements financialstatements found pages wwwrochecomarticleofincorporation respectively years finance wwwrochecomarticleofincorporation report wwwrochecommedia roche business report corporate governance relevant information documents includ ingall media releases investor updatesand presentations analyst investor conferences available internet publications ordered email fax telephone baselwebmasterrochecom tel fax contact address investor relations f hoffmannla roche ltd investor relations corporate finance basel switzerland tel fax additional information including details specificcontact persons available internet group compliance officer group compliance officer committed ensuring roche corporate principles consistently complied throughout roche group also serves contact person shareholders employees customers suppliers andthe general public issues relating implementation compliance principles employees parties become aware ofviolations roche corporate principles bring attention theirmanagersorsupervisors report group compliance officer urs jaisli direct phone number email ursjaislirochecom disclosures treated confidentially employees make disclosures penalised company however persons notimmune prosecution forlegal violations thegroup compliance officer reports regularly tothe corporate governance andsustainability committee nonapplicabilitynegative disclosure expressly noted information contained mentioned herein nonapplicable orits omission construed negative declaration provided six swiss exchange corporate governance directive wwwrochecominvestors thecommentary thereto wwwrochecomcontacts wwwglobalreportscom remuneration report roches success depends abilities dedi base pay cation people recognition forms base pay levels determined according market basis remuneration policy system data specific positions individual employees remuneration report inform shareholders abilities experience performance time pay andinterested members general public increases linked individual performance remuneration paid directors senior also take account prevailing market conditions executives see also finance report note affordability companys situation tothe roche group consolidated financial state ments related parties notes bonuses financial statements roche holding ltd bonuses awarded recognition individual con board executive remuneration board tributions value creation go beyond normal job andexecutive shareholdings pages expectations meant incentive thisremuneration report separately sub create strengthen new business opportunities mittedfor approval annual general strive outstanding results bonus amounts linked meeting group divisional business performance achievement individual functional performance remuneration policy objectives first time remuneration roche revised global remuneration policy committee board directors defined part framework employee policies aimed corporate executive committee members bonuses motivating retaining current employees attracting january based results achieved prior talented new ones helping roche employees year therefore bonuses shown together perform consistently high levels remunera compensation paid tion policy designed foster value creation inforce culture performance innovation stocksettled stock appreciation rights ssars applies nonmanagerial employees well stocksettled stock appreciation rights intro managers key principles underpinning policy duced january thus establishing uniform system remuneration throughout roche ssars focus value creation entitle holders benefit financially increase pay performance value roches nonvoting equity securities enabling employees share companys grant date exercise date detailed success information available fairness transparency remuneration decisions performance share plan remuneration targeted market median levels members corporate executive committee balanced mix long shortterm remunera members senior management currently tion components individuals worldwide participate marketcompetitiveness performance share plan psp psp estab lished periods three years base pay bonuses awards stocksettled stock based three year comparison total share appreciation rights ssars performance holder return tsr competing companies share plan support principles remunera tion components linked companys financial peer set abbott laboratories amgen astellas performance commercial success thus align astrazeneca bayer beckton dickinson biogen idec bristolmyers squibb eli lilly gilead glaxosmithkline interests roche employees johnson johnson merck co novartis pfizer sanofiaventis shareholders scheringplough takeda wyeth roche business report remuneration report three overlapping performance following pages provide detailed information cycles psp psp remuneration paid member board psp psp closed directors member corporate ondecember executive committee together figures previous years details psp calculation additional information set forth remuneration remuneration members corporate executive committee remuneration members board cperformance share plan psp directors members board directorsreceived remuneration shown remuneration board directors table remuneration members board corporate executive committee directors board activities year remuneration committee entirely comprised independent external members exception chairman two ofthe board directors sets remuneration vicechairmen members board directors members board directors corporate received remuneration since executive committee cash payments bonuses thetotal remuneration paid members options stocksettled stock appreciation rights theboard directors shown f highest total policy decisions pension benefits terms remuneration member board directors ofthe performance share plan determined annually total remuneration board directors board directors acting upon recommen page dations remuneration committee remu neration committee continuously tracks salary trends nonexecutive members board directors market reports board ofdirectors awarded shares nonvoting equity formation committees remit andits procedures securities stocksettled stock appreciation rights making remuneration decisions befound ssarsor stock options bylaws roche board directors horst teltschik received honoraria including following detailed review including market com expenses amounting euros swiss parisons worlds major pharmaceutical com francs serving boards several roche panies remuneration committee concluded subsidiaries germany roches current remuneration policy continues tobe appropriate suitable achieving otherwise additional remuneration paid intended objectives members board directors addition base salaries allocations stock remuneration members corporate settled stock appreciation rights determination executive committee general provisions bonuses allocation nonvoting equity assigning authority decisions corporate execu securities psp linked achieve tive committee remuneration remuneration ment sales profit individual goals toroches current future tsr performance relative defined peer set companies wwwrochecomarticleofincorporation seepage type amount compensation list members positions committee memberships chairmanship see received member corporate executive see stock optionsstocksettled stock appreciation rights committee set report ssars wwwglobalreportscom remuneration members board directors additional compensation remuneration members remuneration committee memberschairs board directors chf chf additional special compensation fb humer see remuneration chairman board directors ceo march see b gehrig hoffmann p baschera ji bell p brabeckletmathe ljr de vink w frey da julius oeri w ruttenstorfer h teltschik compensation serving boards roche subsidiaries see b weder di mauro exception members presidium vicechairmen board members receive chf year committee serve chf year committee chair chairman board received chf see f highest total remuneration member board directorstotal remuneration board directors remuneration serving independent lead director march vicechairman board remuneration serving vicechairman board remuneration members corporate executive committee cash payments chf annual salary annual salary annual salary bonus bonus bonus schwan ayyoubi wm burns e hunziker ga keller jkc knowles j schwiezer total member corporate executive committee roche business report remuneration report b stocksettled stock appreciation rights ssars ssars ssars ssars value chf value chf value chf schwan ayyoubi wm burns e hunziker ga keller jkc knowles j schwiezer total member corporate executive committee see stock optionsstocksettled stock appreciation rights ssars blackscholes value described stock optionsstocksettled stock appreciation rights ssars values according annual report business report committee board directors outlined provisions plan number non remuneration report voting equity securities nes reserved participants cycle number securi year members corporate ties actually awarded depend whether executive committeereceived salaries bonuses extent investment roche securities shares stocksettled stock appreciation rights non nes outperforms average return voting equity securities shown tables investment securities issued peer set com parator companiescomparisons based securities market prices dividend yields ie members corporate executive committee total shareholder return tsr reduce effect additionally receive annual expense allowances shortterm market fluctuations security prices swiss francs members ofthe averaged three months october decem corporate executive committee received expense ber prior start performance cycle allowances totalling swiss francs three months october december end cycle roche securities perform well c performance share plan psp orbetter peer set members corporate executive committee addition roches tsr increases least members senior management currently acycle board directors elect increase individuals worldwide participate maximum nes award much twofold performance share plan psp inthe event investment roche securities underperforms average return delivered psp moved overlapping threeyear peer companies fewer nes awarded performance cycles new cycle beginning year thus three cycles progress nes reserved plan mem psp psp psp bers corporate executive committee shown psp ended december list members positions see see footnote wwwglobalreportscom table board directors decide swiss francs tsr roche securities actual level nes cash equivalent awards nesand shares ranked compared cycles peer set companies operating industry close financial years respec tively aim psp provide incentive chart shows roches market participants achieve steady value growth capitalisation declined since beginning consequently originally targeted psp threeyear cycle ended nes awarded psp participants december based results achieved performance cycle current value entire period members corporate nes reserved psp participants respect executive committee received originally performance cycles targeted nes permitted terms reduced addition ssars programme plan see table details created value participants last three years result corporate executive committee end psp cycle based members compensation turned athreemonth moving average constant exchange lower reported past three years rates distributed dividends totalling billion absolute decline price roche swiss francs billion swiss francs securities period important billion swiss francs billion toremember however psp performance share plan psp total estimated total estimated value value value psp number nes psp awards psp awards awards awarded psp target number target number nes psp nes psp total number year period value chf value chf value chf schwan sayyoubi wm burns e hunziker ga keller jkc knowles j schwiezer total member corporate executive committee total estimated value psp originally targeted nes awarded spread relevant period time ie year value calculated using yearend price december chf per nonvoting equity security nes psp estimated value calculated using yearend price december chf per non voting equity security nes based number nes originally targeted subject changes number value nes awardable plan december december respectively spread relevant period time ie year board ofdirectors vote actual allocation nes originally targeted december december respectively according tsr achieved detailed calculation see annual report business report roche business report remuneration report roches performance roche tsr average tsr peer group companies jan dec jan dec roches average market capitalisation billions chf q q roche securities price averaged months octdec octdec nonvoting equity security nes share prices translated constant chf exchange rates including roche based daily month average tsr stock price appreciation plus dividends performance cycle ended psp cycles committee shown table indirect benefits ofthe equity incentive programmes remain inplace andprovide powerful incentive participants contribute improving roches future performance roche connect voluntary stock purchase planoffering employees opportunity buy dindirect benefits rochenonvoting equity securities nes employer contributions made social anamount equal annual salary securityschemes pension plans groupwide ata discountnespurchased plan employee stock purchase plan roche connect subjectto holding period four inrespect members corporate executive yearsinswitzerland indirect benefits payments pension fundsmgb ahvivalv roche connect tax consulting services chf chf chf chf schwan ayyoubi wm burns e hunziker ga keller jkc knowles j schwiezer total mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits ahvivalv swiss social security programmes providing retirement disability unemployment benefits wwwglobalreportscom e remuneration emoluments loans onmarch receive additional pensions totalling swiss ssars nes new psp cycles francswere paid two former corporate executive longer enrolled roche stock option plan committee members orssars erich hunziker william burns salary shown includes jonathan kc knowles received total hisremuneration ceo march usd swiss francs serving inaddition possible future values psp awards onthechugai board received past ceo subject changes inallocations computations relating f highest total remuneration member threeyear performance share plan psp period board directorstotal remuneration ofthe board directors franz b humer chairman member members board directors ofthe board highest total remuneration received remuneration totalling swiss see remuneration members board francs ofdirectors chairmans remuneration consists base salary bonus awards chair man board handover executive see remuneration members board directors function ceo annual general meeting page highest total remuneration member board directors chf cash payments salary bonus ssars none performance share plan total pension fundsmgb roche connect total value detailed calculation remuneration chairman ceo see annual report business report page franz b humer take part psp psp originally targeted nes awarded nes spread relevant period oftime ie year value calculated using yearend price december chf per nonvoting equity security nes psp estimated value calculated using yearend price december chf per nonvoting equity security nes based number nes originally targeted nes subject changes number value nes awardable plan december spread relevant period time ie year board ofdirectors vote actual allocation nes originally targeted december according tsr achieved mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits includes annual expense allowance payments tax consulting services remuneration serving chugai board notincluding employer contribution ahvivalv chf roche business report remuneration report g total remuneration members corporate attheend group held shares executive committeetotal remuneration issued shares detailed information corporate executive committee aboutthis group found finance report severin schwan ceo member note roche group consolidated financial corporate executive committee highest total statements related parties remuneration see remuneration note financial statements roche members corporate executive committee holdingltd significant shareholders ae inaddition december members highest total remuneration member corporate executive committee chf cash payments salary bonus stock optionsssars blackscholes valueat grant minus performance share plan total pension fundsmgb roche connect total value blackscholes value described stock optionsstocksettled stock appreciation rights ssars basic rules detailed calculation see remuneration members corporate executive committee c performance share plan footnote respectively mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits includes annual expense allowance payments tax consulting services excluding ahvivalv payments remuneration shown subject ofthe board directors persons closely asso future changes allocations computations ciated members executive relating threeyear performance share plan committee persons closely associated psp periods themheld shares nes shown table members corporate executive committee received remuneration totalling stock optionsstocksettled stock appreciation swiss francs rights ssars december franz b humer member board additional remuneration paid current directors holding options january former members corporate executive commit ssars due former position ceo tee members corporate executive committee held options stocksettled stock appreciation rights security holdings directors andr hoffmann ssars first introduced january andreas oeri members founders families closely associated belong see remuneration members corporate executive ashareholder group pooled voting rights committee ae excluding ahvivalv wwwglobalreportscom security holdings december close relatives shares nes security holdings others number number numbertype number members board directors fb humer stock options ssars see b gehrig hoffmann ubs longshort certificate roche bearer shares versus roche nonvoting equity securities isin ch valor otc call options ubs ag roche nonvoting equity securities valor p baschera ji bell p brabeckletmathe ljr de vink american depository receipts adr rhhby us isin us w frey da julius oeri ubs longshort certificate roche bearer shares versus roche nonvoting equity securities valor w ruttenstorfer h teltschik b weder di mauro total members corporate executive committee schwan nes stock options ssars see ayyoubi stock options ssars see wm burns stock options ssars see e hunziker stock options ssars see ga keller nes stock options ssars see jkc knowles stock options ssars see j schwiezer stock options ssars see total nes figure include shares held shareholders group pooled voting rights sharesettled loan transaction august reported six swiss exchange roche business report remuneration report shown table stock options ssars period three years unvested options lapse without compensation employment terminated voluntarily reasons retirement vested options shown table issued options must exercised within limited period roche employee stock options option time fair value options calculated entitles holder purchase one roche nonvoting date issue using blackscholes formula equity security nes options tradable deduction average twoyear vesting period terms multiyear option plan strike price options shown closing price ssars shown table intro roche nes last day trading prior duced roche january place stock roche annual media conference options options ssars entitle holders benefit financially shown nontradable onethird options increase value roches nes subject vesting period one year onethird grant date exercise date vesting period two years onethird vesting strike price ssars terms multi stock options ssars number stock options ssars held current former members corporate executive committee december ssars first issued total schwan ayyoubi wm burns e hunziker ga keller jkc knowles j schwiezer fb humer none total strike price chf market price per nes december chf expiry date grant value per option starting per ssar chf blackscholes value minus ssars stock options franz b humer receive additional ssars wwwglobalreportscom year plan closing price roche nes first day trading roche annual media conference ssars vest within three years grant date ie onethird vest end one year onethird end two years onethird end three years vested ssars must exercised converted nes within seven years grant date unexercised ssars lapse without compen sation fair value options calculated date issue using blackscholes formula options tradable deduc tion average twoyear vesting period strike prices expiry dates grant values foroptions ssars shown table numbers options ssars calculated time issue entered values table remuneration members thecorporate executive committee b stocksettled stock appreciation rights ssars corporate responsibility leading healthcare company goal develop make available products services address unmet medical needs real value society aim provide tangible improvements patients health quality length life core contribution responsible sustainable manner respects needs individual society environment make possible committed finding retaining talented people developing skills wwwglobalreportscom brief approach data monitor manage topics key roche viewed one sustainable longterm sustainability success table shows highly responsible companies industry progress made approach corporate responsibility provide value stakeholders millions people management responsibilities around world influence inter corporate responsibility integral part est business engage key groups business csc together line management benchmark achievements industry identifies assesses significant social ethical best practice convinced constructive dia environmental risks opportunities long logue improves way formulate implement term business reputation responsible com business strategy helps us better understand pany fourth consecutive year csc held needs communities weoperate twoday workshop around employees corporate sustainability committee csc variety functions discuss emerging sustainability identified six areas high importance business related issues ensure continue progress stakeholders well key performance strategy performance csc pro indicators kpis measuring progress area posed new updated positions guidelines began collect data kpis several important topics implemented csc corporate executive committee use throughout group see table progress achievements responsible practices established excellence innovation awards included djsi world index fifth consecutive year ftsegood introduced new guidelines working government officials revised position paper guidelines working patient groups establishedonline database introduced several compliance initiatives including webbased system report business ethics incidents developed influenza preparedness plan roche employees worldwide established awebsite us businesses collaboration european centre disease prevention launched r awards animal welfare patients access began partnership oneworld health healthcare ran care programme information exchange share best practices africa developed rolled three new position papers access tomedicines diagnostics pricing rd neglected diseases developed new principles health technology assessment five drugs eight indications approved twelve major phase iii projects initiated people roche named sixth genentech first sciencemagazine ranking best employers inthe healthcare industry launched new make mark employer branding campaign society launched chocos project people affected earthquake inperu continued projects malawi collaboration ecpp unicef launched international postdoctoral fellowship programme safety security developed position paper pharmaceuticals environment health environ achieved greenhouse gas voc emission reduction target mental protection achieved energyefficiency target roche business report corporate responsibility responsible practices healthcare company like roche one based clinical research associates collect input research innovation many responsibilities fromthe field feed back new clinical risks opportunities innovation based science development technology support product pipeline advisory boards opinion leaders feedback overthe next decade emerging technologies development programmes publication support product development onward plans thislongterm focus requires sustainable business disease management programmes managed practices section describe manage care agencies related responsibilities health awareness programmes government departments customer relationship management support education caregivers consider customer needs expectations help improve customer satisfaction commercial customer satisfaction integral diagnostics effectiveness highly value customer feedback division third half diagnostics use range initiatives respond questions employees work customer service sup requests use customer input develop local portinconsumer businesses diabetes regional action plans build strengths carecustomer satisfaction directly linked identify potential weaknesses customer loyalty reason local sales offices carry market analyses assess satisfied set quantitative qualitative targets regu customers products results fed larly measure progress also carry com backto customer service support prehensive market research analysis often implementation divisional local level best meet specific market needs uk example oncology division public private healthcare payers also runs annual satisfaction survey leading oncol important decisions grant deny access ogists analyse feedback individual prod health technologies profound implications ucts overall portfolio see bet patients families society engage ter meet patients needs working payers throughout products lifecycle includes leading clinicians opinion leaders guidance assessing value products important part business provide input andservices health technology assessment hta target product profiles improve attractive priorto deciding reimbursement funding ness relevant stakeholders including payers conditions clinical development plans eg designing participating trials business integrity compliance publication trial results corporate principles directives guidelines regulatory filing strategy andpolicies form code conduct guides development health outcome studies allemployees acting integrity times disease awareness plans product messages andhow voice concerns employees complete initial treatment guidelines mandatory training ensure understand ourcode conduct made available also engage customers onour intranet video raise awareness ofthe legal medical liaisons gather information business risks carelessly written emails clinicians patients share internally education development programmes took several steps strengthen opinion leaders integrity introduced online business wwwglobalreportscom ethics incident reporting system beir enables organisations help establish preparedness group compliance officer capture track plans increased capacity manufacture monitor alleged violations initial reports local tamiflu oseltamivir antiviral used prevent compliance officers resolution beir treat influenza governments others could system led increase ethical incidents reported stockpile drug case pandemic took corrective governments corporations done measures necessary employment manufacturing capacity outstrips current contracts terminated due unethical behaviour demand could quickly change pandemic compared wetherefore continue stress importance ofstockpiling tamiflu work governments risk crisis management toensure preparedness risk management charter defines risk management approach responsibilities typical responsible marketing risks business include investment research roche committed high standards marketing yield results product safety issues activities strict regulations sale extensive list risks website marketing pharmaceutical diagnostic products help make sure healthcare professionals pre every business unit global function conducts scribe administer medicines correctly arisk assessment least year develops patients understand associated benefits risks plans address serious risks aremanaged locally expertise available list external guidelines codes practice linemanagers responsible taking required follow marketing products available action corporate risk management team coor website dinates process reports results corporate executive committee audit european federation pharmaceutical industries committee board reviewed associations efpia issued latest revision effectiveness risk management system code practice late member asso ciations country updated codes corporate sustainability committee holds regular accordingly pharmaceutical research meetings workshops identify assess social manufacturers america phrma also revised environmental ethical risks opportunities code interactions healthcare professionals based expertise experience well adapted internal guidelines stakeholder feedback material risks identified standard operating procedures globally align included group risk management process revisions introduced additional employee training ensure compliance introduced risk management section ourintranet raise awareness among july uk affiliate accepted prescription employees site contains risk management medicines code practice authoritys decision guidelines frameworks tools well suspend association british pharma calendar riskrelated lectures discussions ceutical industry six months breaching andenables employees share best practices code unintentionally selling slimming drug xenical unlicensed clinic roche uk responded also help others manage risks potential immediately implementing broad intensive crises influenza pandemic example training based updated compliance policies wework governments corporations health procedures roche business report corporate responsibility advertising directly patients allow provision suppliers must meet safety health accurate balanced easily digestible informa environmental protection standards tion also motivates patients learn included procurement contracts disease discuss healthcare new program labour standards human rights provider public advertising diagnostics legal suppliers regions problems inmost markets educational areas common plan extend sustainable forexample millions diabetes patients worldwide procurement activities suppliers nonproduction benefit frominformation provided accuchek materials services brand patient brochures diabetes diaries andregular newsletters covering topics pharmaceuticals division carries audits diabetesmanagement recipes lifestyle identify correct problems businesscritical behaviourtips suppliers assess new ones support suppliers implement required improvements unlike countries usa permits advertise sharing expertise documentation running ment prescription medicines directly consumers workshops providing training audited endorse laws regulate pharmaceutical safety health environmental standards key advertising usa member company suppliers nine existing suppliers seven pharmaceutical research manufacturers potential suppliers two following america phrma also fully endorse strength previous audits ened directtoconsumer dtc guiding principles announced december effective carried audits total march confident dtc adver thelast five years half produced good tising complies principles well good results less suppliers applicable laws food drug administration barely met meet acceptable standards regulations including division drug werejected stopped business six sup marketing advertising communications addi pliers unable help improve main tion wewelcome eu commissions proposal areas improvement identified audits directive information patients see lack knowledge insufficient industrial hygiene anopportunity improve eu citizens access worker protection especially handling highquality information health prescription hazardous substances medicines diagnostics division plans incorporate sustain sustainable procurement ability elements regular suppliers auditing pharmaceutical diagnostics divisions starting important sup spendroughly billion swiss francs annually pliers basedon spending business criticality products services suppliers ranging wewillroll process suppliers fromitems raw materials active pharma necessary ceutical ingredients equipment laboratory office supplies computer equipment services roche hosted world environment center likeconsultancy travel marketing global roundtable discussion effectively integrating strategic procurement organisation helps us select sustainability procurement forty sustainability reliable suppliers secure supplies increase representatives industry government science supplier performance financial control improve consultancies concluded even advanced procurement expertise apply best practices companies still struggle successfully integrate worldwide theconcept sustainability procurement wwwglobalreportscom butthat risks significant participation organisation economic group also reviewed best practice examples cooperation developments oecd working group guidelines human biobanks public policy genetic research databases honest transparent dialogue govern participation projects related future ments private sector fundamental health technology assessment hta europe development public policy general public sponsored eu commission health policy particular private sector vital role play developing laws regulations combating counterfeits counterfeit pharma policies enable best possible patient care ceutical diagnostic products illegal wetake part dialogue appropriate poseasignificant global public health problem professional manner theyendanger patients undermine confidence inhealthcare systems companies infringe introduced good practice guidelines onintellectual property rights waste valuable working government officials distri healthcare budgets buted general country site managers implementation area responsibility andare continuously monitor improve product secu available website rity using technology quickly identify counterfeits participate national international industry carry much public policy work governmental efforts develop stronger laws membership industry bodies improve enforcement educate public efpia european diagnostics manufacturers train local officials association edma international federation pharmaceutical manufacturers associations european commission held public ifpma well national members also consultation combating counterfeit medicines meet directly policymakers including members developed proposed legislation support legislative ofthe european parliament health bodies reform believe focus integrity theeuropean centre disease control world original packaging throughout pharmaceutical sup health organization policy think tanks health ply chain along efpia call stringent policy academics examples public policy controls manufacture trade distribution engagement include active pharmaceutical ingredients andmedicines response european commission ec consultation information patients generic biosimilar products patent peri prescription medicines ods first innovative biological products contribution uk house lords inquiry proteins antibodies starting come onthe impact genomics clinical practice end relatively easy manufacturers personalised healthcare copy chemical products biological products response ec consultation medical complex molecular structures obtained devices legislation includes vitro living systems using extremely complex processes diagnostics support development welldefined trans comments japanese draft guidelines parent regulatory framework development followon biologics approval postauthorisation procedures participation meetings world health biosimilars based original organization guidelines abbreviated licensing products pathways certain biological therapeutics roche business report corporate responsibility held meetings opinion leaders global ethics liaison office received queries health authority representatives parliamentarians resolved without escalation many different countries discuss issue exchange information welcomed creag meets annually review concerns feedback issues relating safety efficacy raised global ethics liaison office andquality biosimilars complex understand todiscuss relevant ethical topics manage meeting creag briefed recent workof global ethics liaison office also keep employees date dedi reviewed current topics including revisions cated section intranet recently updated declaration ofhelsinki world medical version position statement available association conduct clinical trials website developing countries political contributions us federal law prohibits another panel independent advisors science usfrom making political contributions federal ethics advisory group seag advises didates although employees may make personal guides us genetics genomics proteomics contributions hoffmannla roche good following discussions seag government committee ggc voluntary political published revised group policy standardised action committee participate roche action procedures human specimen repositories reposi programme employees contributed us tories biological materials tissue organs dollars mechanisms blood bodily fluids invaluable exploring aspects disease might eventually research practices lead better treatments also contain sensitive develop innovative medicines diag information person sample nostics without pushing scientific boundaries belongs dedicated protecting rights exploring new technologies ethical concerns privacy donors providing informa arise result must explore manage tion aspects specimen donation effectively capture opportunities theyagree give sample ourresearch brings animal welfare recognise take seriously ethics rd global position clinical public concerns animal research important research commits us tohigh ethical standards explain ongoing needs animal research makes clear position specific areas industry efforts develop alternative methods concern scientific limits alternatives clear procedure resolving ethical time using animals development dilemmas employees encounter work drugsand technologies necessary scientific ifan issue resolved within affected andlegal reasons would able develop team employees contact global ethics lifesaving medicines cancer drugs without liaison office consult peers internal animal testing committed using animals experts find solution remaining concerns appropriately responsibly complying elevated internal committee finally applicable laws meeting exceeding industry independent advisors clinical research standards commitment applies employees ethics advisory group creag also provide external contractors perform animal testing continual online ethics training employees us wwwglobalreportscom breakdown animals used research us enter new fields point whenthey already well enough developed us apply inour work soon enough us todevelop micerats leading position nanotechnology manipulation materials ascale times smaller diameter human hair potential many areas particularly dogs innovative drug delivery updated rabbits others internal position nanotechnology primates also explore technologies could changethe way drugs work administered total number animals used research webought american company mirus dropped animals llcto build work ribonucleic acid inter researchers contractors use experiments ference rnai technology rnai potential mice rats provide new type treatment difficulttotreat diseases introduced rs award innovation con tinual improvement animal welfare within roche begun trials partnership halozyme rs concept means replacing animal therapeutics drug formulations allow medi tests possible reducing number animals cines previously administered intravenous required refining existing scientific practices injectionto injected skin recently animal welfare husbandry twentyfour teams also made exciting progress development ofscientists animal care specialists ofa new treatment nonhodgkins lymphoma research sites entered awards two categories following theacquisition glycart biotechnology wehave developed compound enhanced scientific category first place went project abilities kill targeted cells predicting bone marrow toxicity using artificial environments mathematical modelling reducing consider stem cell biology important opportu number animals needed winning project nity research tool potential novel inthe lab care animal management category therapeutic approach particularly field involved special behavioural training primates regenerative medicine currently use allows researchers interact animals human embryonic stem cells either purpose help get used new environments stem cell taskforce actively monitors assesses peopleand procedures taking blood innovation area particularly production samples implement projects stem cells alternative sources example operations wherever possible run recently signed cooperative research agreement thers award develop new technology using adult cells fatty tissue zerbini foundation paulo innovation new technologies closely university hospital heart institute monitor development evolving technologies nanotechnology stemcell research roche joined consortium pharmaceu systems biology identify potential bene ticalcompanies biotechnology firms uk fits pharmaceuticals diagnostics allow government aims advance application roche business report corporate responsibility stem cell technology toxicology testing work taking place independent notfor profitcompany called stem cells safer medicines wwwscsmorg provides guidance funding research stem cells suitable toxicol ogy testing hope initiative help us gain insight role stem cells could play drug development especially assessing safety new medicines reducing need animal testing web sustainability principles strategy management wwwrochecomprinciples stakeholder engagement wwwrochecomstakeholderdialogue responsible marketing risk management compliance wwwrochecombusinessintegrityandmarketingpractices wwwrochecomriskmanagementandcompliance patents counterfeiting biosimilars wwwrochecommedicalvaluepatentsandpricing wwwrochecompatents innovation new products technologies wwwrochecomcsrresearchanddevelopment wwwrochecominnovationandtechnologies list positions wwwrochecompoliciesguidelinesandpositions website us businesses pandemic planning wwwpandemictoolkitcom wwwglobalreportscom patients products services provide vital benefits global access healthcare tosociety patients across healthcare committed improving access spectrum diagnostic tests used screen products longterm strategy includes detect diagnose select treatment monitor improving reimbursement systems advocating disease medicines prevent cure disease greater patient access majority healthcare alleviate symptoms hasten recovery systems recognise clear medical economic value products result engagement primary role develop products clear example cancer drugs medical benefits also responsibility herceptin xeloda ease pressure health helpimprove global access products supply care budgets delaying reducing preventing safe medicines reliable tests give value hospital visits surgery need palliative money provide factual information products care many cases help patients return carry clinical trials ethically importantly workmore quickly must also understand respond patients views patients access products doctors value medicines diagnostics hospitals laboratories pharmacies roughly unique approach personalised healthcare countries although majority business phc helps us develop novel products patients isin developed countries advanced need governments regulators demand phc healthcare systems public health policy standards means tailoring treatments patients improve clin healthcare vary greatly public awareness ical outcomes expertise diagnostics gives us ofthe causes prevention treatment disease great competitive advantage use diagnos healthcare industry important role play tics deepen understanding disease helping raise standards part medicines work differences patients amuch bigger picture many systemic helps us develop better safer drugs targeted problems prevent equal access healthcare patients benefit globally good patient also appeal payers regulators due greater efficacy hence work governments nongovernmental costeffectiveness organisations ngos patient groups healthcare providers tackle health inequalities increase understand tough decisions healthcare access products provide sustainable providers make employ experienced health healthcare economists work partnership local health authorities address specific needs regarding issued position statement access access medicines teams involved tomedicines diagnostics developed development process right new drug reaching input broad range employees market liaise local sales marketing divisions designed provide information teams payers clinicians patients perform market stakeholders seek research incorporate patient payer perspectives development ensure clinical trials access need worlds least designed demonstrate economic well health developed countries ldcs hardest hit benefits information generated clinical tri disease poorest healthcare systems als along evidence research activities deal burden hospitals economic modeling used todemonstrate total laboratories healthcare professionals meet value product lifecycle demand international aid focuses aids roche business report corporate responsibility tuberculosis malaria public health policy provide drugs neglected diseases limited local investment initiative free access compounds knowledge treating chagas disease aim provide sustainable access healthcare sleeping sickness poor countries developed hiv testing drug formulations fair patent pricing policies infants significantly neglected area identified research development ngos partnerships governments ngos others provide diagnostics early detection education training knowledgetransfer andmonitoring hiv tuberculosis file enforce patents least began research collaboration developed countries defined united nations institute oneworld health increase rd inaddition file enforce patentson neglected diseases oneworld health screen ourantiretroviral drugs subsaharan african compounds roche library identify new country region affected drugs treating acute diarrhea diarrhea kills hivaids approximately two million children developing countries year currently updated position statement effective drugs widely available pricingto include six guiding principles apply toboth divisions result review aids technology transfer initiative tti assessing structure feasibility special another example working others provide pricing schemes improve access products sustainable healthcare since shared services especially less affluent economies knowledge required produce hiv treatment continue supply antiretroviral therapies saquinavir local manufacturers ldcs forhivaids noprofit prices ldcs subsaharan africa free charge dont subsaharan africa pricing policy covers enforce patents countries manufacturers ofpeople hiv globally freely produce generic version drug increasing local supply early signed also updated position rd neglected agreements four manufacturers bringing tropical disease focus rd total ten also expanded tti include area expertise search differentiated training seminars good manufacturing practices innovative medicines lifethreatening diseases aim improving quality locally inareas unmet medical need produced essential medicines first two seminars wecan make difference diseases took place tanzania south africa include oncology viral diseases hepatitis b attended delegates organisations c diseases central nervous system participant bangladesh commented far likealzheimers diabetes reaching asiam aware roche company offering epidemic proportions developed developing training seminars countries announced agreement clinton foun longstanding commitment addressing dation hivaids initiative chai february diagnosis treatment neglected diseases providing dry blood spot tests eas developed antimalaria drugs lariam ily administered stored transported substan fansidar offpatent available tially reduced prices used diagnose hiv local generic production children younger months fast reliable wwwglobalreportscom testing infants essential fight ificneeds often work partnership govern hivaids children susceptible ments help establish processes education disease must start treatment soon possible clinical trial programs example estab agreement aims improve access testing lished dedicated medical affairs group develop subsaharan africa roughly hiv specific programmes targeted individual emerging infected children live countries also supply products private healthcare systems countries since early offered valcyte substantially reduced price international ngos continue supply hiv medicines reduced treating aidsrelated cmv cytomegalovirus prices low lowertomiddle income coun discount exclusive use aids patients least tries defined world bank developed countries subsaharan africa recently extended low lower middle access developed world work closely income countries covering people living local payers demonstrate thevalue hivaids worldwide products agree level reimbursement enables access however arestill many people facilitated information exchange developed countries afford healthcare symposium partnership pharmaccess insurance pay usa foundation attended healthcare thereis currently universal healthcare system professionals african asian countries weprovide drugs charge need whoshared insights best practices hivaids roche patient assistance program pap management lowerincome countries also roche set standard assisting patients need partnered physicians albert einstein becoming one first companies college medicine train ethiopian inthe usa establish pap since pro doctors nurses clinical officers finalyear medical gramme provided free drugs worth billion students usdollars patients benefited pap wealso support industrys efforts unique employee secondment policy enables toraise awareness assistance programs available roche employees use skills expertise via partnership prescription assistance primarily ldcs interested employees partner organisations aim prevent manage genentech access solutions programme disease worlds poorest countries company provides patients healthcare weapproved two new secondments communica providers coverage reimbursement support tions manager roche sweden seconded patient assistance informational resources project focused mental health children patient assistance support eligible patients traumatised aids crisis swaziland united states insurance information systems specialist roche canada coverage afford outofpocket began work world vision canada systems copay costs since first product helpimprove health nutrition africa wasapproved genentech donated approximately asiaand south america billion us dollars free medicine uninsured patients genentech access care foun access emerging markets middleincome dation gatcf charitable programmes countries often require different business model gatcf helped approximately new developed markets countrys healthcare system patients different stage development spec roche business report corporate responsibility examples access programmes sion diabetes hepatitis hivaids influenza obesity website visits hivinfected patients living countries eligible patients globally also access details noprofit medicines trialsin patients ifpma clinical trials hivinfected patients portal wwwifpmaorgclinicaltrials living countries eligible usanational institutes healths global registry reducedprice medicines atwwwclinicaltrialsgov committed patients benefiting usa publishing clinical trial data good bad patient assistance programmes inreputable peerreviewed journals clinical trials collect information gained clinical clinical trials new medicines demonstrate trials postmarketing surveillance feed safety efficacy drug also provide thisback development program also educational financial medical support forpartici provide information regulatory authorities pating hospitals access latest treatments asrequired cancer arthritis serious diseases patients taking part trials receive freemedical apply strict data protection principles treatment often trialuntil personal medical data collected clinical drug available sale prescription trialsin line directive protection wedonot perform clinical trials countries ofpersonal data principles apply equally wewill seek marketing approval todata ourcustomers suppliers employees patients benefiting clinical trials patient safety almost medicines side effects number clinical trials patients priority make certain bene number healthcare centres fits taking drug outweigh undesirable involved effects reduce likelihood number patients ofadverse events rigorously test monitor phase iiv clinical trials analyse effects products relevant patient groups development continue patients seeking new clinical trials participate tomonitor launch inand people wishing learn results completed trials access information investigate reported adverse events ascer wwwrochetrialscom trial registry results tain related products database hosted third party ensure link reevaluate whether benefits drug independence still outweigh risks also robust proce dures place promptly inform patients physicians december site contained details healthcare providers regulators new pharmaceutical protocols diagnostic protocols product safety information trial results studies cover conditions including alzheimers disease asthma reported recall hiv drug around cancers cardiovascular disease depres viracept following evidence contamination wwwglobalreportscom thechemical ethyl methansulphonate began also worked european genetic theprocess establishing registers patients alliances network egan produce patient tookthe drug affected time period faqand glossary clinical trials patient representa wecould monitor support may tives provided questions patients often ask takencontaminated drugs however research supplied answers address docu confirmed ill effects taking ments aim provide clear straightforward informa affectedbatches viracept relevant tion aboutenrolling clinical trial example health authorities told us registries egan published documents website arean unnecessary precaution made efforts genetics interest group keep affected informed throughout member organisations process number roche companies launched local patient advocacy initiatives support patients patient groups patient groups important partners roche country example roche austria launched weshare interest helping patients lebens hilfe life rescue fund provide financial standand manage disease gain access aid cancer patients returning regular life tothe information treatment need beating disease weonlywork patient groups activities benefit thepatients group represents web policyis betransparent activities personalised healthcare torespect theindependence patient orga wwwrochecomphcinrd roche position statements access medicines nisation diagnostics pricing neglected diseases working patient groups revised position statement guide wwwrochecomaccesstohealthcare lines working patient groups adapt wwwrochecommedicalvaluepatentsandpricing wwwrochecomrocheaccesshealthcarepdf tothe recently approved efpia code one major programmes ldcs wwwrochecom change must publicly list patient groups programmesinleastdevelopedanddevelopedcountries support financially whereas previously programmes developed countries wwwpparxorg onlydisclosed receiving swiss francs wwwgenentechaccesssolutionscom list patient groups receiving financial roche trials patient safety sponsorship march patient groups give wwwrochetrialscom nonfinancial support must publicly listed wwwrochecomclinicaltrials wwwrochecommanagingmedicationsafety thesupport significant meaningful guided working patients byefpia member associations wwwrochecompatientgroups egan website also launched internal database wwweganeupublicationspublicationsandpresentationshtm track patient group partnerships roche affiliates western europe database contains details patient groups work funding given year individual projects worked group provide clearer understanding ofour partnerships patient groups help us share learning experience database isfully running western europe plan toroll regions roche business report corporate responsibility people people core factor business success employees fulltime equivalent fte need people enthusiastic job regions employer enthusiasm infec tious customers pick helping build trust roche wolfgang troebs general manager roche asia diagnostics switzerland latin america total employees fte number north america growth rate europe growth related acquisitions employees contract types headcount employees fte operating divisions variance permanent temporary genentech apprentices full time chugai part time employer choice roche determined remain employer choice diagnostics seek attract recruit retain right roche pharmaceuticals employees drive innovation business built talent management achieving starts value proposition roche talent management helps us identify recruit current prospective employees slogan develop lead reward employees whilethe focus make mark improve lives employer brand identifying employees key positions talent embodies differentiates roche management involves developing thepotential employers presents us winning company offer employees help achieve ourgoals ing opportunities professional personal growth collaborative stimulating work envi corporate executive committee identified ronment new employer brand integrated talent management key people priority local career websites end forroche drive measure progress areas attraction retention per group values leadership competencies formance management compensation succession introduced reinforce roches principles management learning development andthe work environment seek offer integrated talent management attraction competition talent around world processes fierce size global workingage popula wwwglobalreportscom global standardized processes systems recruitment rate internal versus external performance talent compensation management external internal attraction leadership pipeline retention succession learning management development career website opportunities cumulative tion developed countries decreasing talented people emerging markets increasingly registered people returning home countries shortage site means difficult attract right people new employees recruited innovative researchdriven healthcare com internal moves pany roche operates industry adirect benefit lives millions people introduced standardised recruiting worldwide aspect business play process rolled across organisation critical part attracting retaining enables roche drive quality motivated people position leading multi consistency recruiting across operations national company moreover enables us offer helps us hire candidates line renewed prospects growing industry career oppor values leadership competencies tunities globally overall roche new hires careers website remains widestreaching effective tool recruitment retention year characterised million visitors acquisitions also significant optimisation restructuring initiatives pharma division global careers site enables prospective cur reduced primary care sales force optimised rent employees search positions role local operations finance hr region roche uses application countries headoffice functions manufacturing reorganisations attract source hire candidates also initiated latin america united employees used system move differ states voluntary severance plans offered ent positions within roche group thelatter overall optimisation restructuring initiatives accounted employerdriven approximately percent total new hires movements sourced externally talent pool prospective candidates registered dealing acquisitions reorganizations details careers site place emphasis ability retain valued roche business report corporate responsibility employees roche offers support measures employees countries asrelocation retention incentives new career eligible participated roche connect orientation support turnover nonvoting equity securities awarded man agers based performance roche longterm plan introduced total total took part europe joining first time latin america north america moved providing definedbenefit asia plans pay depending formula defined employees salary age retirement factors definedcontribution plans reasons leaving payout according contributions subsequent investments defined benefit plans honoured foremployees already enrolled employerrelated employeerelated range programmes encourage neutral staff look wellbeing include free medical checkups workplace ergonomic evaluations compensation benefits wellbeing total counselling healthy options available staff compensation package pay benefits offer restaurants makes significant contribution attracting retaining talent within group equally important offer parttime flexitime homeworking longterm job stability development opportunities options appropriate approximately good working environment employees work parttime sabbaticals regularly arranged past year roche salaries roche reflect employees contributions introduced paternity leave several countries business pay rises bonuses reflect business maternity leave statutory minimum personal performance pay performance several countries philosophy encapsulates regular benchmarks confirm roche offers competitive pensionand performance development help employees benefits programmes employees countries achieve full potential provide regular feed usually supplement local socialsecurity pro back performance encourage grammes follow local market practices discuss career goals development opportunities managers employees remuneration packages offered local affiliates took part performance management programmes aligned group remuneration policy formal career development planning revised total remu neration cost billion swiss francs staff performance development employee responsibility management accounta roche connect programme employees bility performance management processes countries purchase roches nonvoting reviewed increase dialogue man equity securities discount agers employees tight line management allows wwwglobalreportscom us differentiate high low performers secondment programme gives employees give appropriate feedback support employees chance work capability healthcare building professional growth programmes developing countries three months two new secondments succession management strengthening approved talentpipeline critical seekto maintain competitive success continue drive culture learning development roche invested ofinnovation weintroduced acorporate million swiss francs skills training educa wide approach talent management enabling us tion providing total approximately mil tonurture highpotential employees lion hours nearly hours per employee talent framework provides us global training includes technical skills programmes approach identify develop guide highpoten meetcompliance requirements language courses tialemployees framework highlights talented interpersonal skills training individual coaching individuals provides access broad pool programmes leadership change management ofemployees take key positions intheshort long term training courses run global func tionsbusiness areas individual affiliates step talent pipeline supported tailored meet local needs groupwide development programmes pro grammes target top employees roche affiliates offer comprehensive appren amount approximately total spending ticeships roche normally offers apprentices several learning development alternatives including temporary assignments addi tional time university oneyear internship development opportunities also offered company half apprentices hired international assignments helping distinguish roche finish training currently roche attractive employer apprentices working across group including new apprentices approximately employees long shortterm international assignments coun diversity tries want ensure employees international worked different parts globe assignments perform successfully new sur experienced value diversity strengthens roundings introduced cultural awareness anorganisation richness ideas courses facilitate integration host country opinions brought people different gender interactive training gives employees tools ethnic cultural origins understand local culture social busi pascal soriot head commercial operations ness point view launched year pharmaceuticals division berolled widely diverse workforce critical success also established support programmes help aglobal company like roche visible char partners employees international assignments acteristics age race gender diversity integrate new country programmes comprises experience competencies mindset provide information networks clubs webelieve diversity promotes innovation allows social organisations career support enable flexibility inspires creativity help roche tackle asuccessful job search future challenges roche business report corporate responsibility tolerate form discrimination woman never career barrier wefoster inclusion integrating diversity vesna cizej adriatic management centre head employee management systems general manager slovenia dif ferent intelligence independent race gender diversity flourishes environment exists geography says strength acknowledged understood valued talent combined differences fostered reflected processes structures become foundation success encourage employee diversity formal acknowledging diversity roches workforce training diversity management allowed vesna cizej adapt leadership trainingprogramme policies including style meet needs individual employees prevention abuse power workplace knows importance overall wealso embed inclusion processes vision team communicating vision dailyactivities requires finetuning must fully engaged communicating vision every person basel example ensure diversity ways meaningful motivational recruiting process mixed gender interview vesna cizej says panels ongoing improvements family support flexible work arrangements ensure constant high ultimately employer offers return rate maternity leave example staff keeps inspired roche opened second day care centre opportunity part something offer emergency day care support important see contribution making real difference peoples lives number women key positions levels renews passion energy ofthe organisation continues increase work vesna cizej concludes corporate executive committee welcomed first female member silvia ayyoubi global head human roche represents nationalities worldwide resources women account total work headquarters basel half employees force managers senior originate switzerland roche managers approximately top employees affiliates local nationals account majority women compared respec workforce approximately tively previous year management teams helps ensure ourgroup policies work reflect diversity gender diversity ofour global operations employee engagement women total communicate employees features workforce intranet internal newsletters women management town hall meetings employee magazines various number women languages hexagon worldwide employee magazine top management appears quarterly eight languages also avail positions able roche intranet restated due reporting error annual report hold facetoface lunch meetings seven eight times year employees meet members wwwglobalreportscom corporate executive committee senior man agers ask questions employees abroad canattend live webcasts human rights roche comprehensive employment policy covers human rights defined united nations group compliance officer monitors policy throughout roche serves contact employees end roche among companies recognised realizing rights business human rights resource centre public commitment human rights roche respects right employees freedom ofassociation collective bargaining employees represent colleagues unions memberships members organisations freely represent including roche europe forum representing ouremployees across countries directive protection personal data pro tects information employees complies relevant local legislation appropriate negotiated data privacy agreements different parts business works councils web employees wwwrochecomemployees group policies positions guidelines wwwrochecompoliciesguidelinesandpositions global careers portal httpcareersrochecom employment policy wwwrochecomemploymentpolicypdf core standards wwwrochecomcommitments roche business report corporate responsibility society supporting communities corporate donations supporting scientists future sponsorship employee volunteering extends roche foundations including fondation beyond philanthropy promotes sciencebased dentreprise roche france roche foundation industry inspires staff help make roche us global roche organ transplantation successful sustainable business committed research foundation support research edu corporate citizen focus programmes cation programmes around world promote aligned business model innovation advances science medical scientific education sustainability impact collaboration support young scientists encourages innovation business depends business enables us help need nurtures next generation scientists need around world promote sustainable access tosustain success medicines diagnostics drug donations donot generally form part access strategy since offered twopart genetics however donate medicines disaster relief education programme educators switzerland pandemic situations value forexample germany combines genetics science roche shanghai supplied vials theory education practical laboratory exercises rocephin antibiotic treat infections course raises awareness ethics provided funding local red cross assistance policies relevant genetics science demon programmes wake sichuan earthquake strates science behind modern lifesaving inchina medicines publish detailed financial information us roche collaborating science regarding community investment instead education leaders years provide twoday measure success support impact workshop resources teaching bioethics example roche childrens walk secondary school teachers teachers enabled children villages malawi participated challenging students receive hot meals health checkups education innovative approaches contemporary science atday centres primary school children learning benefit eight new classrooms students toattend secondary school partnership new jersey institute tech nology roche supports oneday continuing educa set standards communicating measuring tion programme primary secondary teachers impact donations noncommercial sponsor first session engaged teachers ship development guide align andprovided handson activities addressed best practice throughout organisation national standards science mathematics education community support area roche research foundation concluded total itssponsorship activities new distinct initiative humanitarian social projects launched promote young talent research science education excellence globally international roche postdoc arts culture fellowship programme aims support outstanding community environment young scientists cooperative research devel opment projects roche academic institutions wwwglobalreportscom programme strengthen international scientific vision materials needed rebuild houses exchange nurture development specialist local community buildings also enabled knowledge new ideas creative talent construction dam aid economic far awarded fellowships next two years social recovery plan award various scientific disciplines roche childrens walk formerly global encouraging innovation arts roche employee aids walk extended scope roche patron contemporary arts vulnerable children employ music since inception believe innovation ees sites walked around five kilometres music art closely related scientific raise estimated swiss francs includ innovation heart business ing amount matched company contributed via company affiliates local chil roche continents launched collabora drens charities balance donated tion salzburg festival austria encourage react longterm partners european young people explore contemporary classical music coalition positive people wwwecppcouk invited second group students unicef switzerland work malawi european universities festival partici pants attended series lectures workshops roche provided funding phelophepa creativity art science well concerts health care train since began years ago year mobile clinic delivers health care roche commissionssponsors new musical works rural south africans outstanding contemporary composers thecountrys remote areas george benjamins duet piano orchestra justone doctor every patients received premiere next commission wasawarded toshio hosokawa roche also sponsors number initiatives encourage involvement sciences promote aware supporting communities ness health issues help address critical com roche strives make difference local munity needs examples include communities encourage employees identify brighton science festival uk community local projects make valuable contri based promotion science creative artistic bution make contribution novel way people ages volunteering fundraising world kidney day spreading message kidney disease common harmful treatable employee donations diverse community projects roche blue bicycle project turkey public globally disaster relief coordinated awareness campaign cancer roche employee action charity trust react heart stopper challenge raising funds set independent charitable heart children new zealand organisation join smile outreach programme localchildren families suffering poverty example roche employees supported emergency inargentina relief efforts peru react devastat ing earthquake since continued web support longterm project reconstruct roche n jazz httpwwwrochenjazznet destroyed village chocos continuing partnership react httpreactrochecom react provided skills technical super roche business report corporate responsibility safety security health environmental protection safety security health environmental protection held global conference integral business success take officers ensure roche corporate policy responsibility area seriously throughout guidelines revised guidance notes issued lifecycle products corporate principles implemented appropriately policy commit us highest standards conference also discussed progress towards ofshe invested million swiss francs corporate goals infrastructure million swiss francs operating costs including services personnel important employees embrace standards throughout group sitespecific training management includes lectures practical handson courses everyone roche responsible ensuring employees took part hours health safety around training minimising environmental impacts ofour operations dedicated team handling chemicals inherent risk pharmaceuti fulltime employees departments cal diagnostic research development manu across roche group including people facturing employees handle chemicals part corporate team coordinates within role trained use appropriately roche corporate security officer appointed havepublished safetydata sheets detailing theproper within function built ties correct handling specific network local security officers coordinate chemicals security activities across business threeyearly ecompetition encourages employ local sites ensure policy guide ees suggest innovative ways reduce environ lines implemented appropriately individ mental impacts annual responsible care ual site managers officers ecodelegates network awards ask individual sites come working diagnostics pharmaceuticals solutions improve energy efficiency make divisions raise awareness environmental issues environmentally friendly initiatives among colleagues led number innovative proposals implemented risks identified assessed across businesses affiliates listed webbased health safety inventory enables us evaluate risks safe healthy workforce essential ensure develop measures mitigate corporate employee wellbeing productivity level goal reduce roche accident rate monitor policy regular site baseline audits audited sites major defi ciencies uncovered findings related roche accident rate rar measures sites risk analysis processes requiring updates number working days lost due occupational insufficient training emergency management accidents per employee per year oroccupational hygiene assessments needing updates use audits improve per rar represents formance recommendations made audited increase excluding fatal traffic accident sites implementation supervised year still remain track achieve audit team goal wwwglobalreportscom health safety performance environmental footprint busi ness calculated basis ecobalance method designed swiss agency roche accident rate environment bafu ecobalance reflects occupational total environmental impacts operations accidents use resources raw materials energy occupational illnesses well generation emissions waste workrelated fatalities workrelated ecobalance improvement accidents per million reflects reductions working hours achieved across environmental indicators except nitrous oxide air emissions particulates number accidents associated contractors increased slightly year currently increased due reduced number operating within target ecobalance hours worked contractors associated injury maintain level recognise need frequency rate increased contractors work tocontinuously cut resource use reduce ing premises obliged follow amount waste emissions generate safety rules employees important understand environmental expen cases occupational illnesses dropped diture relation sales allows us number lost days reduced quantify environmental impacts operations diseases musculoskeletal use information target investment system accounted twothirds areas greatest impacts theselost work days ecoefficiency rate eer combines data strive reduce number severity occu energy use waste emissions air water pational accidents illnesses incidents expenditure environmental protection investigated relevant findings communi sales full explanation eer found cated across company onour website eer improvement individual sites play vital role achieving long term global goals set sites ecoefficiency rate followed action plans developed atthe conference september help achieve goals plans assessed sales corporate measures continuously millions chf implemented environmental expenditure environmental footprint millions chf monitor environmental footprint research environmental production packaging transport distribution damage millions use disposal environmental damage units goal improve total ecobalance eer baseline pointsemployee roche business report corporate responsibility energy climate change greenhouse gas emissions relative sales aim reduce energy use emissions green increased year tonnes per million swiss house gases carbon dioxide co francs sales equates total decrease operations approximately since exceeds reduction goal end goal reduce total energy consumption baseline gjemployee greenhouse gas emissions tonnes co equivalent goal reduce greenhouse gas emissions baseline co equivalent unitsales total emissions performance roche used terajoules total emissions energy decrease terajoules per million chf previous year equivalent gigajoules sales per employee slight decrease group strategy decreasing greenhouse energy use terajoules gasemissions guided position paper greenhouse gases climate change paper stresses connection co emissions total energy use andenergy use implementing measures total energy use toreduce energy consumption improve effi per million chf sales ciency total energy use per employee believe allowing individual sites develop theirown emissions reduction strategies maximises emissions energy use together efforts familiar greenhouse gas emissions totalled million tonnes withlocal conditions sites guided group co equivalent absolute increase directive energy conservation enforces rise emissions despite lower energy asystematic approach includes energy effi consumption due increased car plane travel ciencystandards onthe design new equipment optimisation ofexisting energy consuming items energy use type directive requires site energy audits carried fuel used issued guidance ensure structured company vehicles approach audits carried oil third parties sites select sites fuel due business audited according circumstances air travel energy consumption result audits may cover entire site may concentrate particular waste system use results develop initiatives grid electricity goals reduce future energy use district heating one winning entries roche respon renewable energy siblecare network awards came natural gas headquarters basel adjusting sites air wwwglobalreportscom conditioning rooms slightly higher tempera ozone depletion ture aslightly lower humidity energy use halogenated hydrocarbons cfcs cut increased risk damage hcfcs damage ozone layer affect cli toour equipment mate roches directive phasing cfcs hcfcs commits us eliminate entries shortlisted awards coolingsystems fire extinguishing systems year include roche carolina energy monitoring system fordata collection data analysis allows however several projects replace hcfcs thesitetomonitor manage optimise energy refrigeration units held lack use ofaccepted alternatives countries roche burgdorf new heating system using wood reorganisation plans put phasingout projects pellets rather fossil fuels cut co emis onhold important sites target date sions total energy used eliminate compounds therefore beingrenewable extended roche brussels new building includes special sun shading prevent offices getting hot hfcs hydrofluorocarbons pfcs perfluorinated summer use rain water toilet flushing carbons often used replacements energy efficient lighting car park tohcfcs cfcs affect ozone layer however considerable global warming encourage employees toconsolidate travel potential persistent atmosphere several destinations one trip invest video consider suitable longterm teleconferencing facilities travel alternative aim phase com necessary promote use oftrains rather poundsby appropriate plans place flights investment projects implemented meet goal changing rules invest energy savings world business council sustainable ozonedepleting chemicals tonnes development wbcsd exemplified roche case study efforts analyse lifecycle costsand impact energy efficiency investments halogenated wbcsd published study stimulate similar hydrocarbons approaches companies paper highlights holdings roches innovative method calculating value halogenated ofenergyefficiency investments hydrocarbons emissions wbcsd noted converting social environmental economic benefits time emissions air asingle financial figure compared volatile organic compounds vocs particulates upfront costs valuable tool promoting contribute air pollution smog nitrogen business case investment energyefficiency oxides sulphur dioxide x initiative roche enabled managers contribute acid rain emissions air throughout business rigorously assess included overall goal reduce total envi feasibility energy efficiency investments ronmental impacts pursue opportunities value creation roche business report corporate responsibility performance manufacturing processes ment necessary landfills sustainably remedi combustion plants emitted tonnes vocs ated made approximately million swiss means surpassed francs available purposes ourgoal reduce voc emissions per tonne unit sales baseline levels waste tonnes ofparticulates continue fluctuate x atalow level total emissions tonnes tonnes ten tonnes respectively general waste produced emissions air tonnes general waste per million chf sales vocs chemical waste particulates produced nitrogen oxides chemical waste sulphur dioxide per million chf sales waste roches operations produce chemical waste water needs disposed safely clean water integral roches manufacturing processes withdrew million mfor chemical waste amounted thesepurposes various sources approximately tonnes decrease reflects amount last year smaller production volume incinerating waste isthe responsible way dispose global reporting initiative defines water con majority dealt manner sumption water used products cooling air conditioning irrigation increased waste streams originating particular manu consumption based definition facturing processes reused compa million continually strive reduce nies sold tonnes waste water consumption globally recycled chemical waste amounted tonnes consisting mainly solvents manufacturing processes often release contaminated wastewater byproduct treat wastewater produced tonnes general waste toensure safe environment humans previous year considerable release watercourses aim increase mainly due construction waste increase capacity treat wastewater building activities different sites counting business continues grow approximately tonnes incinerated sent landfill mainly building rubble extension biotechnological production werecycled tonnes general waste roche penzberg example required increased last year capacity treat wastewater installed innova tive membrane technology increases capacity landfill sites containing chemical waste requires less space less energy premises monitored regularly make sure previous installations solution winning pose risk human health environ entry years responsible care network awards wwwglobalreportscom discharged tonnes organic roche aims minimise release pharmaceuti materialinto water courses treatment cals environment wherever possible decrease compared heavy metals manufacturing sites designed operated aschromium copper zinc removed ensure far practicable active pharmaceuti frompiping wastewater year released cal ingredients discharged waste kilograms heavy metals decrease water compared offer financial incentives encourage retailers water others value chain return unused dated products ensures incinerated rather disposed landfills promote new water withdrawn takeback programmes already million cubic metres exist water used million cubic metres roche published global position statement wastewater discharged pharmaceuticals environment outlining treatment plant intentions monitor risks human health million cubic metres environment organic matter discharged acknowledge longterm effects pharma watercourses ceuticals environment need researched treatment tonnes participate international local heavy metals bodies dedicated study impact trace chemi discharged cals including pharmaceuticals surface watercourses groundwater treatment kilograms compliance incidents pharmaceuticals environment goal receive significant sherelated fines concerns raised traces pharma ceutical active ingredients detected environ performance significant fines reported ment current research shows quantities found rivers lakes water supplies generally far level would thera integrity business compromised peutic adverse effect human health aquatic fail comply relevant legislation regula life watercourses tions group policies often surpass local laws regulations minimum roche committed manufacturing processes improper disposal comply local requirements unused medicines may lead pharmaceuticals enter ing environment normal patient use recog substances well biological materials nised main contributor risk pharma used pharmaceutical manufacturing regulated ceuticals entering environment important potential misused element lifecycle approach environmental forexample production narcotics toxins protection product development chemical weapons keep substances small quantities rigorous control line applicable legislation roche business report corporate responsibility web performance wwwrochecomkeyfiguresandfacts safety security health environmental protection wwwrochecomenvironment safety security health environmental protection policy wwwrochecomreportingandindices group fact sheets positions policies guidelines wwwrochecompoliciesguidelinesandpositions wwwglobalreportscom independent assurance report corporate sustainability committee roche corporate sustainability committee roche holding ltd basel roche responsible subject matter evaluation criteria responsibility provide performed assurance procedures provide aconclusion subject matter based assurance following aspects sus assurance procedures accordance interna tainability reporting roche tional standard assurance engagements isae subject matter data information disclosed sustainability main assurance procedures reporting roche consolidated subsidiaries assurance procedures included following excluding chugai pharmaceutical co ltd genen work tech inc year ended december evaluation application group following aspects guidelines reviewing application management reporting processes roche internal sustainability reporting guidelines respect sustainability reporting site visits visiting selected sites roches preparation people key figures pharmaceuticals diagnostics divisions wellas control environment relation switzerland france uk canada mexico data aggregation key figures brazil selection based quantitative key figures tables pages qualitative criteria interviewing personnel respon selected people key figures sible internal reporting data collection disclosed pages roche atthe sites visited group level business report todetermine understanding application ofthe guidelines criteria assessment key figures performing tests roche group internal sustainability reporting ona sample basis evidence supporting selected guidelines based responsible care health people key figures roche accident rate safety environmental reporting guidelines pub energy consumption co emissions related lished european chemical industry council energy consumption general wastes use water cefic sustainability reporting guide fines inrelation safety environmental lines g published october global protection headcount data staff turnover women reporting initiative gri senior management positions cost defined procedures training concerning completeness accuracy people key figures gathered collated adequacy andconsistency aggregated internally review documentation analysis ofrelevant policies basic principles responsibility methodology reviewing relevant documentation sample accuracy completeness sustainability indi basis including group sustainability policies cators subject inherent limitations given management reporting structures nature methods determining calculating documentation estimating data assurance assessment processes data forebe read connection roches internal consolidation reviewing appropriateness guidelines definitions procedures report ofthe management reporting processes ing sustainability performance sustainability reporting assessing consolidation process data group level roche business report independent assurance report conclusions global reporting opinion initiative sustainability internal sustainability reporting guidelines applied properly reporting guidelines internal reporting system collect aggre gate people key figures functioning previous years aligned designed provides appropriate basis sustainability reporting guidelines global forits disclosure reporting initiative gri based work described report second time roche opinion assessment criteria nothing come thea level gri g guidelines applies attention causes us believe data annual report checked information mentioned subject matter confirmed gri disclosed sustainability reporting roche business report give fair details report indicator picture roches performance found wwwrochecomreportingandindices zurich january pricewaterhousecoopers ag dr thomas scheiwiller juerg hutter severin schwan wwwglobalreportscompublished cautionary statement regarding forwardlooking f hoffmannla roche ltd statements basel switzerland annual report contains certain forwardlooking state tel ments forwardlooking statements may identified fax words believes expects anticipates projects intends seeks estimates future similar expressions discussion among things media office strategy goals plans intentions various factors may corporate communications causeactual results differ materially future basel switzerland reflected forwardlooking statements contained tel inthis annual report among others pricing product fax initiatives competitors legislative regulatory developments economic conditions delay inability investor relations obtaining regulatory approvals bringing products market fluctuations currency exchange rates basel switzerland general financial market conditions uncertainties tel discovery development marketing new products fax new uses existing products including without limitation negative results clinical trials research projects world wide web unexpected side effects pipeline marketed products wwwrochecom increased government pricing pressures interrup tions inproduction loss ofor inability obtain adequate corporate sustainability committee protection intellectual property rights litigation loss key executives orother employees tel adverse publicity news coverage email corporatesustainabilityrochecom statement regarding earnings per share growth order publications aprofit forecast interpreted mean tel thatroches earnings earnings per share fax subsequent period necessarily match exceed email baselwebmasterrochecom historical published earnings earnings per share roche trademarks mentioned enjoy legal protection next annual general meeting march roche annual report published german english printed nonchlorine bleached fsccertified paper roche annual report issued f hoffmannla roche ltd basel corporate communicationspharmaceuticals pipeline pharmaceuticals divisions rd activities focused creating clinically differen tiated medicines division continued build value research development portfoliotwelve major phase iii projects initiated including clinical trials novel compounds pertuzumab taspoglutide dalcetrapib wwwglobalreportscomrd pipeline pharma partnering pharmaceuticals division filed major licensing targeted acquisitions play impor new marketing applications gained major tantrole strengthening roches rd portfolio regulatory approvals beginning expanding companys technology capabilities divisions rd pipeline comprised clinical roche pharmaceuticals signed total new projects including new molecular entities nmes agreements including seven product transactions additional indications forty nmes research technology collaborations currently phase phase ii six inphase iii filed regulatory review may roche acquired piramed limited uk company therapeutic research programmes roche pharmaceuticals research projects targeting pikinase pathway oncology major therapeutic areas january andinflammatory disease june roche consolidated leading position antiangiogenesis field licensing agreement thrombogenics central nervous bioinvent jointly developed anticancer system diseases agent tb r acquisition mirus cardiovascular biocorporation roche madison inc sep metabolic diseases tember enables roche advance research field ribonucleic acid interference rnai delivery viral diseases oncology september roche completed acquisition inflammatory ofarius research inc proprietary autoimmune diseases antibody platform rapidly identifies selectsantibodies based functional ability toaffect disease following merger agreement roche pharmaceuticals currently projects andsuccessful tender offer january roche inpreclinical research across five therapeutic areas acquired usbased memory pharmaceuticals development projects five therapeutic areas whichdevelops innovative drug candidates including five phase transition preclinical treatment debilitating central nervous system toclinical development disorders alzheimers disease schizo phrenia memorys nicotinic alpha agonist twelve rochemanaged projects drugcandidates disease areas already terminated six phase four phase ii andtwo partnered programmes roche inphase iii two projects reverted ourrd partners decisions taken tooutlicense another two quarterlypharmaceuticals pipelineupdates posted wwwrochecompipelinepharmaceuticals pipeline building value opportunities growth project id projectproduct pharmacological class indication phase partner generic name oncology cid r mabtherarituxan rituximab anticd monoclonal antibody chronic lymphocytic leukemia st line filed eu genentech biogen idec cid r mabtherarituxan rituximab anticd monoclonal antibody chronic lymphocytic leukemia relapsed filed eu genentech biogen idec cid r xeloda capecitabine fluoropyrimidine metastatic colorectal cancer st line combo approved eu filed us cid r xeloda capecitabine fluoropyrimidine metastatic colorectal cancer nd line combo approved eu filed us cid r avastin bevacizumab antivegf monoclonal antibody renal cell carcinoma approved genentech eu filed us cid r avastin bevacizumab antivegf monoclonal antibody metastatic breast cancer st line filed eu genentech combo docetaxel cid r avastin bevacizumab antivegf monoclonal antibody glioblastoma multiforme relapsed filed us genentech eu cid r avastin bevacizumab antivegf monoclonal antibody nonsmall cell lung cancer nsclc ii genentech previously treated cns metastases filed eu cid r avastinherceptin antivegf monoclonal antibody metastatic breast cancer st line iii genentech cid r bevacizumabtrastuzumab antiher monoclonal herpositive antibody cid r avastin bevacizumab antivegf monoclonal antibody ovarian cancer st line iii genentech cid r avastin bevacizumab antivegf monoclonal antibody prostate cancer hormonerefractory iii genentech cid r avastin bevacizumab antivegf monoclonal antibody metastatic breast cancer st line iii genentech combo standard chemotherapies cid r avastin bevacizumab antivegf monoclonal antibody metastatic gastric cancer iii genentech cid r avastin bevacizumab antivegf monoclonal antibody adjuvant colon cancer iii genentech cid r avastin bevacizumab antivegf monoclonal antibody adjuvant nsclc iii genentech cid r avastin bevacizumab antivegf monoclonal antibody adjuvant breast cancer hernegative iii genentech cid r avastin bevacizumab antivegf monoclonal antibody adjuvant breast cancer herpositive iii genentech cid r avastinmabtherarituxan antivegf monoclonal antibody aggressive nonhodgkins lymphoma iii genentech cid r bevacizumabrituximab anticd monoclonal antibody cid r herceptin trastuzumab antiher monoclonal antibody gastric cancer herpositive iii cid r mabtherarituxan rituximab anticd monoclonal antibody indolent nonhodgkins lymphoma iii genentech maintenance st line biogen idec cid r tarceva erlotinib egfr inhibitor nsclc st line maintenance iii genentech osi pharmaceuticals cid r tarceva erlotinib egfr inhibitor adjuvant nsclc iii genentech osi pharmaceuticals cid r avastintarceva antivegf monoclonal antibody nsclc st line maintenance iii genentech cid r bevacizumaberlotinib egfr inhibitor osi pharmaceuticals cid r xeloda capecitabine fluoropyrimidine adjuvant breast cancer iii cid r xeloda capecitabine fluoropyrimidine adjuvant colon cancer combo oxaliplatin iii cid r xeloda capecitabine fluoropyrimidine adjuvant colon cancer combo avastin iii cid r pertuzumab dimerisation inhibitor metastatic breast cancer herpositive st line iii genentech cid r pertuzumab dimerisation inhibitor neoadjuvant breast cancer herpositive ii genentech cid r pertuzumab dimerisation inhibitor ovarian cancer ii genentech cid r trastuzumabdm antiher monoclonal metastatic breast cancer herpositive ii genentech antibodycytotoxic conjugate cid r avastin bevacizumab antivegf monoclonal antibody nsclc squamous ii genentech cid r avastin bevacizumab antivegf monoclonal antibody glioblastoma multiforme st line ii genentech cid r tarcevaavastin egfr inhibitor antivegf nsclc st line ii genentech cid r erlotinibbevacizumab monoclonal antibody cid r antiigfr monoclonal antibody ewings sarcoma ii genmab cid r antiigfr monoclonal antibody metastatic breast cancer ii genmab cid r antiigfr monoclonal antibody nsclc ii genmab cid r rdgeneration anticd nonhodgkins lymphoma ii glycartga antibody cid r hedgehog pathway inhibitor cancer ii genentech cid r solid tumours cid r braf kinase inhibitor malignant melanoma plexxikon cid r mdm antagonist cancer cid r solid tumours glycartga cid r solid tumors chugai cid r solid tumors chugai cid r solid tumors genentech cid r antiplgf humab solid tumors thrombogenics bioinvent tb glycart whollyowned subsidiary roche wwwglobalreportscomproject id projectproduct pharmacological class indication phase partner generic name inflammatory autoimmune diseases cid r actemra tocilizumab humanised antiil receptor rheumatoid arthritis filed us chugai monoclonal antibody approved jpn eu cid r actemra tocilizumab humanised antiil receptor systemic onset juvenile idiopathic arthritis iii chugai monoclonal antibody approved jpn cid r mabtherarituxan rituximab anticd monoclonal antibody rheumatoid arthritis dmard inadequate iii genentech responders filed us biogen idec cid r ocrelizumab humanised anticd rheumatoid arthritis iii genentech monoclonal antibody cid r ocrelizumab humanised anticd lupus nephritis iii genentech monoclonal antibody cid r cellcept impdh inhibitor pemphigus vulgaris iii aspreva mycophenolate mofetil cid r nuclear receptor agonist emphysema ii cid r sp receptor agonist autoimmune diseases actelion cid r chronic obstructive pulmonary disease cid r asthma cid r oxl humab asthma genentech cardiovascular metabolic diseases cid r taspoglutide glp analogue type diabetes iii ipsen bim cid r dalcetrapib cetp inhibitor dyslipidemia iii japan tobacco jtt cid r aleglitazar dual ppar agonist cardiovascular risk reduction ii cid r type diabetes chugai cid r glucokinase activator type diabetes cid r type diabetes cid r type diabetes cid r type diabetes cid r peripheral vascular disease genmab cid r dyslipidemia cid r polycystic kidney disease plexxikon plx viral infectious diseases cid r valcyte valganciclovir inhibitor cmv replication cytomegalovirus extension treatment iii cid r hpv vaccine cervical neoplasia ii transgene tg cid r polymerase inhibitor hepatitis c pharmasset cid r protease inhibitor hepatitis c intermune itmn central nervous system cid r ocrelizumab humanised anticd relapsing remitting multiple sclerosis ii genentech monoclonal antibody cid r glyt inhibitor schizophrenia ii cid r nicotinic alpha receptor alzheimers disease schizophrenia ii memorymem agonist cid r antiamyloid peptide alzheimers disease morphosys antibody cid r pain cid r nicotinic alpha receptor alzheimers disease memory agonist mem cid r alzheimers disease optin opportunities cid r avastin bevacizumab antivegf monoclonal antibody gastrointestinal stromal tumour iii genentech cid r avastin bevacizumab antivegf monoclonal antibody adjuvant rectal cancer iii genentech cid r avastin bevacizumab antivegf monoclonal antibody metastatic breast cancer nd line iii genentech cid r avastin bevacizumab antivegf monoclonal antibody metastatic hernegative breast cancer iii genentech combo hormonal therapy cid r avastin bevacizumab antivegf monoclonal antibody high risk carcinoid iii genentech cid r avastin bevacizumab antivegf monoclonal antibody metastatic head neck cancer iii genentech cid r avastin bevacizumab antivegf monoclonal antibody ovarian cancer nd line iii genentech cid r mabtherarituxan rituximab anticd monoclonal antibody lupus nephritis iii genentech cid r mabtherarituxan rituximab anticd monoclonal antibody ancaassociated vasculitis iii genentech memory pharmaceuticals acquired roche january project id projectproduct pharmacological class indication phase partner generic name cid r avastin bevacizumab antivegf monoclonal antibody relapsed refractory multiple myeloma ii genentech cid r avastin bevacizumab antivegf monoclonal antibody extensive smallcell lung cancer ii genentech cid anticd dacetuzumab anticd monoclonal antibody diffuse large b cell lymphoma ii genentech seattle genetics cid apoltrail cancer ii genentech cid apomab nonsmall cell lung cancer nonhodgkins ii genentech lymphoma cid arq cancer ii arqule cid anticd dacetuzumab anticd monoclonal antibody diffuse large b cell lymphoma nonhodgkins genentech lymphoma multiple myeloma seattle genetics cid apomab colorectal cancer genentech cid mek inhibitor cancer genentech cid iap antagonist cancer genentech cid rdgeneration anticd hematologic malignancies genentech antibody cid anticmet cancer genentech cid pik alpha pi kinase inhibitor cancer genentech cid tp colorectal cancer chugai cid antiil antiil asthma ii genentech cid antiifn alfa systemic lupus erythematosus genentech cid vap inflammatory diseases biotie cid antioxldl antioxldl secondary prevention cardiovascular events genentech cid na hepatitis c chugai cid rhumab rhumab beta ulcerative colitis genentech beta cid anticd anticd rheumatoid arthritis genentech cid antiabeta antiabeta alzheimers disease genentech participation chugai cid epoch epogin epoetin beta chemotherapyinduced anemia iii cid ed activated vitamin derivative osteoporosis iii cid gm mitemcinal fumarate motilin agonist gastroparesis irritable bowel syndrome ii participation genentech cid lucentis ranibizumab antibody fragment vegf diabetic macular edema iii cid lucentis ranibizumab antibody fragment vegf retinal vein occlusion iii cid tnkase tenecteplase thrombolytic agent catheter clearance iii cid xolair omalizumab antiige antibody pediatric asthma filed us novartis cid raptiva efalizumab humanised anticda renal transplant ii merck serono monoclonal antibody cid abt solid tumours ii abbott cid abt solid tumours hematologic malignancies abbott beginning divisions rd pipeline comprised clinical projects including new molecular entities nmes additional indications forty nmes currently phase phase ii six phase iii filed regulatory review cid therapeutic protein first indication blue type phase initial studies healthy volunteers possibly patients cid small molecule additional indications black type phase ii efficacy tolerability dosefinding studies patients cid peptide current january phase iiilargescale studies patients statistical confirmation safety cid therapeutic vaccine efficacy cid antibody fragment wwwglobalreportscomdiagnostics pipeline roches diagnostics division working raise rd productivity increase percentage young products portfolio launch new tests high medical valuethe divisions rd spending nearly sales measure determination launches listed measure successproduct launches diagnostics division major product launches business area product professional diagnostics additional cobas configurations suit wider range laboratory workloads cobas euus cobaseu cobas c clinical chemistry analyser completing cobas series serum work area instruments forsmall tomediumworkload laboratories ex us accuchek inform ii first wireless hospital blood glucose meter ex us elecsys antihcv immunoassay hepatitis c infection eu elecsys anticcp anticyclic citrullinated peptide antibody assay diagnosis rheumatoid arthritis eu elecsys antitshr antithyroid stimulating hormone receptor assay diagnosis graves disease euus brahms procalcitonin assay aid early detection monitoring sepsis selected eu markets elecsys anticmv igg anticmv igm assays detection cytomegalovirus infection eu roche cystatin c test clinical chemistry test early detection impaired kidney function eu elecsys toxo igg immunoassay detecting acute latent infection parasite toxoplasma gondii us secondgeneration elecsys nt probnp immunoassay use aid diagnosing heart failure assessing risk patients stable coronary artery disease eu us diabetes care accu chek compact plus blood glucose monitor builtin lancing device test strip drum us asiapacific japan molecular diagnostics cobas ampliprepcobas taqman hcv test fully automated realtime pcr test monitoring hepatitis c viralload us cobas taqman hbv test automated realtime pcr test monitoring hepatitis b viral load us cobas taqscreen mpx test detects multiple viral pathogens hiv groups hiv hepatitis b hepatitis c inasingle fully automated assay us japan cobas taqman tb test automated realtime pcr test tuberculosis eu cobas taqman ct test v nextgeneration automated realtime pcr test chlamydia trachomatis eu cobas ampliprepcobas taqman hiv test v nextgeneration fully automated realtime pcr test monitoring hiv viral load eu cobas ampliprepcobas taqman hbv test v nextgeneration fully automated realtime pcr test monitoring hbv viral load eu therascreen kras mutation test aid doctors determining patients suitability certain cancer therapies eu applied science titanium series software reagents genome sequencer flx worldwide lightcycler system ii enhanced platform realtime pcr detection analysis worldwide nimblegen seqcap arrays microarrays enabling preparation targeted genomic regions samples dna sequencing worldwide xcelligence system single multiplate versions enables noninvasive realtime analysis cellular events worldwide magna pure lc enhanced automated system pcr sample preparation worldwide nimblegen cgh hd arrays next generation highdensity highthroughput microarrays comparative genomic analysis worldwide tissue diagnostics vantage workflow optimisation instrument integration software anatomical pathology laboratories us benchmark ultra advanced staining system continuous random processing stat capabilities us canada eu ten new confirm antibodies immunohistochemcial stainingmonitoring major cancers us canada japan major eu markets wwwglobalreportscommajor product launches scheduled business area product professional diagnostics cobas analyser series nextgeneration modular serum work area instruments highvolume laboratories series includes two clinical chemistry two immunoassay analysers offer choice configurations eu selected key markets cobas b benchtop multiparameter analyser blood gas electrolytes cooximetry metabolites foruse point care worldwide sysmex xti newgeneration automated hematology analyser test capabilities additional body fluids contractual territory emea cobas academy elearning platform delivers customised user training certification courses several pointofcare instruments worldwide cobas elabperformance portal online benchmarking laboratory results obtained serum work area analysers worldwide cobas p cobas p automated storage retrieval modules barcoded primary secondary sample tubes worldwide novel elecsys immunoassays plgf placenta growth factor sflt soluble fmslike tyrosine kinase diagnosis preeclampsia eu elecsys il interleukin immunoassay aid management critically ill patients eu highsensitivity elecsys troponin immunoassay diagnosis heart attack cardiac risk stratifi cation eu us elecsys troponin assay test cardiacspecific troponin levels predict mortality risk patients acute coronary syndromes eu crp gen nextgeneration clinical chemistry reagent inflammation marker creactive protein eu clinical chemistry drug monitoring reagents amphetamines benzodiazepines eu us ddimer gen secondgeneration clinical chemistry test exclude deep vein thrombosis pulmonary embolism worldwide diabetes care accuchek mobile integrated lancing blood glucose monitoring device employing unique strip technology replaces singleuse test strips continuous tape tests eu accuchek aviva nano accuchek performa nano sleeker versions accuchek aviva andaccuchek performa meters offering enhanced feature set accuchek aviva nano eu us accuchek performa nano eu accuchek active new version existing meter featuring extended test memory number failsafe capabilities eu accuchek combo diabetes management system combining insulin pump glucose meter also functions pump remote control eu us molecular diagnostics cobas platform automated dna extraction realtime pcr amplification detection withtests human papillomavirus chlamydia trachomatisneisseria gonorrhoeaeeu mrsa advanced test realtime pcrbased test methicillinresistant stapholococcus aureusus eu therascreen egfr mutation test aid doctors determining patients suitability certain cancer therapies eu cobas taqman mai test automated realtime pcr test mycobacterium avium intracellulareinfection japan amplichip cyp test comprehensive microarraybased detection variations cytochrome p c genes japan applied science new titanium kit software reagents enhanced resequencing pcramplified dna genome sequencer flx worldwide magna pure highthroughput system preparing nucleic acid samples worldwide ms highresolution microarray scanner use nimblegen hd highdensity microarrays worldwide tissue diagnostics benchmark ultra advanced staining system continuous random processing stat capabilities additional european markets latin america australia japan benchmark xt advanced staining instrument latin america asiapacific symphony primary staining instrument major eu markets australia vantage workflow optimisation instrument integration software anatomical pathology laboratories major european markets australia immunohistochemistry probes assessing status met egfr oncogenes cancer patients launches clinical use eu asiapacific wwwglobalreportscomroche finance report table contents roche group finance brief finance brief financial review roche group consolidated financial statements notes roche group consolidated financial statements report roche management internal control financial reporting report statutory auditor consolidated financial statements report independent auditor internal control financial reporting multiyear overview supplementary information roche securities roche holding ltd basel financial statements notes financial statements including board executive remuneration disclosures required swiss law appropriation available earnings report statutory auditor financial statements wwwglobalreportscom roche finance report roche group finance brief finance brief key results local sales growth operating profit margin sales pharmaceuticals diagnostics group change sales mchf mchf chf lc sales research development operating profit operating free cash flow net income free cash flow core eps chf dividend per sharein chf december december change chf net cash equity equity ratio see definition core eps proposed board directors lc local currencies finance executive committee erich hunziker chief financial officer hubert buck management development peter eisenring tax insurance marco frei pension asset management andreas knierzinger treasury steve krognes corporate development karl mahler investor relations carole nuechterlein venture funds erwin schneider accounting controlling finance brief roche finance report finance brief sales group sales increase local currencies billion swiss francs excluding tamiflu pandemic sales declined sharply expected increase local currencies pharmaceuticals sales increase billion swiss francs local currencies excluding tamiflu pandemic sales twice global market growth thanks key oncology products also bonvivaboniva cellcept oncology sales grow local currencies billion swiss francs representing pharmaceuticals sales diagnostics sales increase local currencies billion swiss francs organic growth acquisition ventana tissue diagnostics business adds percentage points operating results operating profit increases local currencies billion swiss francs thanks strong underlying sales growth continuing productivity improvements despite substantially lower tamiflu pandemic sales strong increases rd operating profit margin decreases percentage points mainly driven lower diagnostics margin following recent acquisitions competition us diabetes care market increase ofthe pharma margin rd expenditure increases local currencies billion swiss francs representing ofgroup sales substantial unfavourable exchange rate impact swiss franc denominated consolidated results july roche made offer purchase outstanding shares genentech us dollars per share cash announced reorganisation us pharmaceuticals business treasury minimal adverse effect financial crisis due conservative investment approach limited exposure equities net financial income reaches billion swiss francs reduction billion swiss francs compared primarily due lower interest income resulting lower liquid funds reductions interest rates redemption maturity billion swiss francs capital market debt financial condition strong financial condition free cash flow billion swiss francs net cash billion swissfrancs increase equity ratio following announcement intent take genentech fully private moodys put roches aa rating review downgrade standard poors lowered roches rating aa aa net income core eps net income billion swiss francs primarily driven strong exchange rate impact core eps constant exchange rates record level shareholder return roches market capitalisation decreases billion swiss francs broadly line european global pharmaceuticals sector increase proposed dividend swiss francs representing ndconsecutive year dividend growth approved shareholders result increased payout ratio higher dividend yield roche share nonvoting equity security based yearend prices wwwglobalreportscom roche finance report roche group financial review roche group financial review group operating results sales billions chf operating profit billions chf lc growth sales group continued strong underlying operating performance previous years pharma ceuticals division increased operating profit margin growth underlying business compensated expected sharp decline tamiflu pandemic sales planned increases research development diagnostics division impact recent acquisitions competition us diabetes care market resulted decline operating profit margin strengthening swiss franc currencies substantial negative impact groups overall operating results translated local currencies swiss francs total sales grew local currencies swiss francs us dollars billion swiss francs pharmaceuticals division representing group sales diagnostics division con tributing sales increase underlying business compensated anticipated fall tamiflu pandemic government corporate sales billion swiss francs million swiss francs local currency sales growth excluding tamiflu pandemic sales strength theswiss franc last twelve months resulted approximately billion lower sales translated swiss francs demand groups oncology drugs avastin mabtherarituxan herceptin tarceva xeloda con tinuedto grow strongly additional growth drivers pharmaceuticals division bonvivaboniva metabolismbone cellcept transplantation diagnostics division main growth areas professional diagnostics applied science tissue diagnostics business areas growing respective markets following acquisition ventana beginning february sales new tissue diagnostics business area million swiss francs contributing percentage points localcurrency sales growth diagnostics division groups operating profit increased local currencies billion swiss francs operating profit margin declined percentage point due margin reduction diagnostics division percentage points pharmaceuticals margin increased despite signifi cantly lower tamiflu pandemic sales increased investments strong development pipeline half fall margin diagnostics division due impact recent acquisitions onetime charges amortisation acquired intangible assets investments develop acquired businesses rest mainly due strong competition us diabetes care market portfolio mix effects average us dollar exchange rate swiss franc lower comparative period euro lower whereas japanese yen higher movements exchange rates significant impact swiss franc growth rates sales operating profit growth rates reported inswiss francs percentage points local currency growth respectively natural hedges inthe structure groups operations meant group operating margin significantly impacted foreign exchange movements pharmaceuticals division two exceptional items income million swiss francs thesettlement genentechs litigation city hope medical center expenses million swiss francs initial stages pharmaceuticals division us reorganisation net impact onthe group divisional results significant group operating results pharmaceuticals diagnostics corporate group mchf mchf mchf mchf sales operating profit exceptional items margin sales operating free cash flow margin sales group operating results development results compared pharmaceuticals diagnostics corporate group sales increase local currencies operating profit exceptional items increase local currencies margin percentage point increase operating free cash flow increase local currencies margin percentage point increase pharmaceuticals operating results pharmaceuticals division increased sales local currencies swiss francs usdollars billion swiss francs excluding tamiflu pandemic government corporate sales local sales growth outpacing global market growth factor around two operating profit exceptional items billion swiss francs corresponding margin increase per centage points compared despite significantly lower tamiflu pandemic sales increased investments research development marketing costs increased moderately local currencies spite continued support growing oncology rheumatoid arthritis portfolios investments made broader indications particularly foravastin well investments launch actemraroactemra strong expected increase inresearch development expenses significantly increase sales due continued high investments strong pipeline expanded portfolio well large number clinical trials information divisional business pipeline see business report part annual report wwwglobalreportscom roche finance report roche group financial review pharmaceuticals division results change change mchf mchf chf local currencies sales royalties operating income cost sales marketing distribution research development general administration operating profit exceptional items margin sales operating free cash flow margin sales sales major growth drivers key products therapeutic areas oncology inflammation autoimmunetransplantationvirology excluding tamiflu pandemic sales metabolismbone sales thetherapeutic area renal anemia decreased increasingly competitive costsensitive market pharmaceuticals division sales therapeutic area sales change therapeutic area mchf sales local currencies oncology virology inflammationautoimmunetransplantation metabolismbone renal anemia others total excluding tamiflu pandemic government corporate sales top pharmaceuticals products represented pharmaceuticals portfolio grew excluding tamiflu pandemic sales majority products showing sales growth local sales growth pharmaceuticals division driven seven products avastin mabtherarituxan herceptin bonvivaboniva cellcept tarceva xeloda products represent portfolio together generated billion swiss francs additional sales compared despite strong negative currency impact mainly us dollar sales tamiflu declined due nonrecurring pandemic sales sales declines primarily due generic erosion following patent expiry strong competition certain franchises return chugai group marketed products injapan sanofiaventis pharmaceuticals division sales top products sales change product mchf sales local currencies franchise mabtherarituxan oncologyiat avastin oncology herceptin oncology cellcept iat neorecormonepogin renal anemia oncology pegasys virology tarceva oncology xeloda oncology bonvivaboniva metabolismbone lucentis ophthalmology tamiflu virology pandemic virology xolair respiratory diseases valcytecymevene virology xenical metabolismbone pulmozyme respiratory diseases nutropin metabolismbone neutrogin oncology rocephin infectious diseases activasetnkase cardiovascular diseases madopar nervous system total top products products total excluding tamiflu pandemic government corporate sales total top products products total inflammationautoimmunetransplantation mabtherarituxan doubledigit sales growth driven increasing use oncology indications rheumatoid arthritis europe us oncology sales growth due increasing usage ofmabtherarituxan following firstline therapy indolent nonhodgkins lymphoma nhl including maintenance use already high penetration rates firstline treatment indolent aggressive nhl sustained us europes five largest markets france germany italy spain united kingdom increasing adoption settings seen emerging markets adoption rheumatoid arthritis ra continued increase us europerest world row estimated mil lion swiss francs sales generated ra indication avastin sales increased worldwide compared strong growth regions particularly europerow us growth driven primarily increased usage metastatic breast cancer following accelerated approval us food drug administration fda february sales growth europe driven primarily increased use medicine metastatic colorectal breast cancer sales europe also benefited rollout new indications increasing uptake nonsmall cell lung cancer renal cell carcinoma wwwglobalreportscom roche finance report roche group financial review herceptin growth continued driven increasing adoption adjuvant early stage herpositive breast cancer roche estimates end products market share adjuvant setting approximately versus year earlier five largest european markets elsewhere market penetration setting also continues build us penetration market flattened due earlier rapid adoption herceptin adjuvant treatment metastatic setting adoption rates treatment duration remained stable us top five european markets cellcept immunosuppressant cellcept continued record double digit sales growth worldwide driven solid demand us europe growth continues driven physicians recognition longterm protective benefits cellcept transplant patients compared moretoxic therapeutic options neorecormonepogin combined sales roches neorecormon chugais epogin epoetin beta market remains highly competitive due pricing pressure branded compe titors entry biosimilar versions epoetin alfa europe market share neorecormon decreased slightly global sales japan epogin remains market leader decline sales medicine due primarily sustained pricing pressure pegasys pegasys maintained clear leadership global pegylated interferon market con tinued gain market share global sales increased billion swiss francs driven strong growth japan growth key emerging markets combined solid growth united states pegasys accounts new prescriptions hepatitis c tarceva tarceva recorded strong growth particularly europerow sales region accounts overall sales us sales increased competitive market environment tarceva still epidermal growth factor receptor inhibitor proven survival benefit advanced lung pancreatic cancer xeloda xeloda recorded sustained doubledigit sales growth throughout growth japan partic ularly strong solid increases also recorded us europerow sales driven expanded indications approved notably stomach cancer advanced colorectal cancer along uptake breast cancer bonvivaboniva highly competitive market sales bonvivaboniva ibandronic acid treatment postmenopausal osteoporosis increased million swiss francs billion swiss francs compared majority sales come us products market share remained robust despite entry generic versions competitor products bonviva gained reimbursement status launched many european markets lucentis sales lucentis treatment neovascular wet agerelated macular degeneration wet amd us grew driven primarily increased number lucentis dosage per patient new patient share broadly stable offlabel usage unapproved therapy wet amd remained high outside us lucentis marketed novartis tamiflu sales tamiflu declined billion swiss francs versus seasonal sales million swiss francs higher pandemic sales decreased billion swiss francs compared stockpiling programmes governments corporations completed seasonal sales tamiflu japan negatively affected mild flu season addition asubstantial decrease pandemic sales japanese government see business report information roches pharmaceutical products including rd pipeline end pages business report sales region sales excluding tamiflu pandemic government corporate sales continued grow across regions growth north america local currencies compared almost stagnant market driven products marketed genentech oncology products lucentis xolair pulmozyme well roche pharmaceuticals products tamiflu seasonal sales bonvivaboniva cellcept pegasys andxeloda roche pharmaceuticals continued gain market share western europe latin america regions driven strong sales growth avastin mabtherarituxan herceptin bonvivaboniva tarceva cellcept sales japan increased launches avastin combination therapy pegasys plus copegus tarceva compensated normal biennial price cuts japan became effective april return group marketed products sanofiaventis tamiflu sales decreased sharply due completion pandemic stockpiling orders governments corporations particularly western europe japan cemai region pharmaceuticals division sales region sales change region mchf sales local currencies north america western europe cemai japan latin america asiapacific regions total central eastern europe middle east africa central asia indian subcontinent excluding tamiflu pandemic government corporate sales operating results royalties operating income increase million swiss francs local currencies due higher royalty income gains disposal products offset million swiss francs lower income outlicensing agreements fall outlicensing income mainly due number significant milestone payments orlistat otc rights glaxosmithkline million swiss francs part thirdparty collaboration agreement genentech million swiss francs relating lucentis approval european union filing japan gains product divestments mil lion swiss francs higher include gain million swiss francs second stage disposal three products actavis gain million swiss francs disposal products turkey well gain million swiss francs meda gain million swiss francs sale product rights part continuous realignment product portfolio increase royalty income driven genentech royalties operating income percentage sales increased percentage points pharmaceuticals division royalties operating income change mchf mchf local currencies royalty income income outlicensing agreements income disposal products total wwwglobalreportscom roche finance report roche group financial review cost sales costs remained stable local currencies mainly driven decline manufacturing cost goods sold period costs due manufacturing efficiencies favourable product mix effects comparison period including million swiss francs viracept recall costs amorti sation intangible assets decreased local currencies intangible assets became fully amortised compensated local currency increase collaboration profit sharing agreements local currency increase royalty expenses product sales million swiss francs million swiss francs genentechs collaboration profitsharing expenses partners biogen idec novartis osi increased due higher sales mabtherarituxan tarceva xolair respectively reached million swiss francs million swiss francs despite impacted weaker us dollar gross profit share glaxosmithkline increased million swiss francs million swiss francs following increased bonvivaboniva sales royalty expenses tamiflu lower due less pandemic sales however offset strong growth royaltybearing products particular cellcept autoimmune tarceva herceptin avastin additionally often royalty rates tiered certain sales levels percentage sales cost sales decreased pharmaceuticals division cost sales change mchf mchf local currencies manufacturing cost goods sold period costs royalty expenses collaboration profitsharing agreements amortisation intangible assets impairment property plant equipment impairment intangible assets total marketing distribution costs increased local currencies reached billion swiss francs billion swiss francs significant investments continued leveraging rich oncology portfolio rollout additional approved indications particular pantumour positioning avastin heavy levels investment continued bonvivaboniva pegasys additionally preparations launch actemraroactemra rheumatoid arthritis increases offset absence oflast years prelaunch preparation mircera united states marketing distribution costs apercentage sales decreased percentage points research development increase local currencies almost billion swiss francs reflectscontinued investment realise full potential strong development portfolio investment includes latestage clinical testing promising compounds dalcetrapib cetp inhibitor dyslipidemia ocrelizumab autoimmune disorders pertuzumab breast cancer taspoglutide glp analogue type diabetes investments also made numerous programmes aimed expanding use roches leading anticancer medicines additional indications avastin adjuvant colon cancer moreover impairments intangible assets higher comparative period research development costs percentage sales compared first half pharmaceuticals division total spent million swiss francs inlicensing pipeline compounds technologies capitalised intangible assets required ifrs total division spent billion swiss francs internal purchased rd inlicensing alliance deals representing sales addition roche pharmaceuticals spent million swiss francs acquisitions biotechnology companies piramed mirus arius pharmaceuticals division investments research development change mchf mchf local currencies research development expenses less noncash items amortisation intangible assets impairment intangible assets research development expenses excluding noncash items product intangibles available use technology intangibles research development related capital expenditure total investments research development general administration overall costs remained stable local currencies due lower legal restructuring expenses lower implementation costs business harmonisation project including establishment european shared services centre budapest spite loss divestment ofmillion swiss francs cenexi business france general administration expenses percentage sales decreased pharmaceuticals division general administration change mchf mchf local currencies administration legal environmental settlements business combinations transaction expenses gain loss divestment businesses restructuring expenses gains losses disposal property plant equipment general items total subdivisional results pharmaceuticals subdivisional results operating operating profit profit exceptional exceptional operating operating sales items items free cash flow free cash flow mchf mchf sales mchf sales roche pharmaceuticals genentech chugai elimination within division pharmaceuticals division unrealised internal profits inventories sold one subdivision another yet sold toexternal customers balance sheet date eliminated consolidation entry wwwglobalreportscom roche finance report roche group financial review operating operating profit profit exceptional exceptional operating operating sales items items free cash flow free cash flow mchf mchf sales mchf sales roche pharmaceuticals genentech chugai elimination within division pharmaceuticals division unrealised internal profits inventories sold one subdivision another yet sold toexternal customers balance sheet date eliminated consolidation entry roche pharmaceuticals sales increased local currencies despite impact declining tamiflu pandemic government corporate sales excluding local sales growth operating profit margin exceptional items decreased percentage points higher investments research development higher expenses alliance collaboration partners well lower income outlicensing agreements outweighed favourable developments cost sales manufacturing efficiencies product mix impacts inclusion viracept recall costs results royalty expenses third parties million swiss francs million swiss francs royalty expenses genentech million swiss francs million swiss francs following thecontinued success ofthe oncology portfolio outside us genentech sales grew local currencies operating profit margin exceptional items improved percentage points main drivers strong sales growth higher royalty operating income third parties roche pharmaceuticals compensated continued heavy investments research development higher collaboration profit sharing expenses biogen idec chugai sales decreased local currencies driven primarily governmental tamiflu pandemic stockpiling excluding tamiflu pandemic sales increased local currencies driven successful launches avastin combination therapy pegasys plus copegus tarceva outweighed lower epogin sales decline sales return group marketed prod uctsto sanofiaventis early product group sales value around million swiss francs reduced chugais reported sales growth percentage points operating profit decreased local currencies driven lower sales spite lower sales increased support prod uct launches stable high level research development expenses operating profit margin slightly lower compared june group increased ownership interest chugais outstanding shares tender offer additional information pharmaceuticals divisions subdivisional results given note con solidated financial statements information genentech chugai given notes exceptional items major legal cases following california supreme court decision april genentechs litigation city hope national medical center settled positive net impact operating results million swiss francs additional information given note consolidated financial statements changes group organisation july group announced proposal purchase outstanding shares genentech also reorganisation groups us pharmaceuticals business expenses million swiss francs incurred already committed costs mainly termination costs closure manufacturing operations nutley new jersey research site atpalo alto california additional information given note consolidated financial statements pharmaceuticals division total operating results roche pharmaceuticals pharmaceuticals genentech chugai division mchf mchf mchf mchf mchf mchf mchf mchf operating profit exceptional items major legal cases changes group organisation operating profit includes unrealised internal profits million swiss francs million swiss francs inventories sold fromone subdivision another yet sold external customers balance sheet date eliminated consolidation entry operating free cash flow three subdivisions pharmaceuticals division continue generate strong cash flows cash gener ated supports expansion business investments new production facilities intellectual property inlicensing deals genentech particular asignificant part free cash flow usually used equity compensation plans including thepurchase equity maintain roches ownership percentage equivalent million swiss francs million swiss francs considerable fall due theprepayment repurchases genen tech end increased cash inflows exercise options genentech employees overall operating free cash flow increased local currencies driven improved net working capital management lower capital expenditures outflows equity compensation plans percentage sales operating free cash flow pharmaceuticals division increased compared pharmaceuticals division operating free cash flow roche elimination within pharmaceuticals pharmaceuticals genentech chugai division division mchf mchf mchf mchf mchf operating profit operating profit cash adjustments increasedecrease net working capital investments property plant equipment investments intangible assets operating free cash flow sales operating profit operating profit cash adjustments increasedecrease net working capital investments property plant equipment investments intangible assets operating free cash flow sales unrealised internal profits inventories sold one subdivision another yet sold ontoexternal customers balance sheet date eliminated consolidation entry operating profit cash adjustments consist elimination depreciation amortisation impairment charges replacement operating incomeexpenses provisions equity compensation plans disposals property plant equipment intangibles assets cash equivalents adetailed breakdown provided pages wwwglobalreportscom roche finance report roche group financial review diagnostics operating results diagnostics division increased sales billion swiss francs growing local currencies swiss francs us dollars leveraged additional sales ventana acquisition strength ening leading market position existing businesses operating profit decreased inlocal currencies billion swiss francs corresponding margin declined percentage points half decline due acquisition impacts including amortisation acquired intan gible assets investments develop acquired businesses remainder decline mostly due strong competition us diabetes care market portfolio mix effects first half division completed acquisition ventana total consideration billion swiss francs information divisional business pipeline see business report part annual report diagnostics division results change change mchf mchf chf local currencies sales royalties operating income cost sales marketing distribution research development general administration operating profit margin sales operating free cash flow margin sales sales diagnostics continued grow well market increase local currencies previous year major drivers sales growth professional diagnostics leveraged immunodiagnostics applied science particular dna sequencing business tissue diagnostics sales advanced staining instruments reagents roche diabetes cares sales decreased mainly result strong competition us diabetes care market molecular diagnostics sales increased driven sales automated realtime pcr virology blood screening products acquisition ventana completed beginning february sales new tissue diagnostics business area million swiss francs eleven months december contributed percentage points local currency sales growth diagnostics division diagnostics division sales business area sales change business area mchf sales local currencies professional diagnostics diabetes care molecular diagnostics applied science tissue diagnostics na total professional diagnostics roche professional diagnostics continued gain market share sales increased local currencies billion swiss francs immunochemistry sales rose local currencies billion swiss francs showing doubledigit sales growth eighth consecutive year growth fuelled strong uptake antihcv assay diagnosis hepatitis c infection launched first half outside us growth also driven continued demand elecsys ntprobnp troponin cardiac tests new immunoassays launched early wererolled across european markets providing growth included tests antitsh receptor thyroid marker toxo igg toxoplasmosis vitamin osteoporosis anticcp rheumatoid arthritis anticmv iggigm diagnosis cmv infection brahms procalcitonin sepsis first two also approved us third quarter strengthening offering largest market launch new tests roche one broadest immunoassay menus rollout new markets continue drive growth clinical chemistry business grew line market amid continuing price erosion mature segment demand cobas analyser series mediumworkload laboratories remained strong additional configurations launched increasing competitiveness rollout smaller cobas instruments small mediumsize laboratories continued thejuly launch cobas c clinical chemistry analyser markets outside us sales decentralised testing products rose local currencies million swiss francs helped continued move towards testing pointofcare poc coagulation monitoring sales grew doubledigit driven coaguchek xs monitor healthcare professionals patient selftesting accutrend plus first handheld device capable measuring cholesterol glucose triglycerides lactate impor tant indicators cardiac risk available markets initial release end poccardiac assays posted doubledigit growth fuelled continual uptake roche cardiac probnp assay cobas h portable cardiac testing system also runs tests troponin ddimer heart type creatine kinase myoglobin july accuchek inform ii first wireless system hospital glucose testing launched outside us diabetes care roche diabetes care maintained market leadership sales billion swiss francs adecrease local currencies primarily impacted strong competition us market new blood glucose monitoring products accuchek aviva accuchek performa accuchek compact plus almost compensated declining sales older accuchek advantage older products process phased account less diabetes care sales accuchek aviva largest selling system strong doubledigit growth accuchek compact plus launched theus japan april june respectively global rollout complete systems roches insulin delivery business declined due strong competition us market four important new product launches planned support sales accuchek aviva nano accuchek performa nano meters start rollout first markets first quarter meters sleeker discreetly versioned targeting young testers segment accuchek mobile offers complete integration testing lancing single device features unique stripfree technology employs continuous tape tests instead singleuse strips rollout commence first quarter also scheduled eu markets beginning accuchek combo system combines accuchek spirit insulin pump glucose meter remotecontrol bolus calculator capabilities molecular diagnostics roche molecular diagnostics remained market leader increasingly competitive market sales billion swiss francs overall increase local currencies sales virology products largest segment grew local currencies driven continued demand forthe automated cobas ampliprepcobas taqman capctm platform europe japan asiapacific fda approved automated cobas taqman hbv test fullyautomated hcv test september october respectively combined cobas taqman hiv test launched initial automation virology trio completed us blood screening sales increased local currencies additional blood centres europe asiapacific latin america converted fully automated cobas platform comprehensive cobas taqscreen mpx multiplex test detects hiv groups mo hiv hcv hbv donated blood plasma december fda approved multiplex test use cobas system earlier september japanese red cross jrc completed transition fully automated cobas system cobas taqscreen mpx multiplex test used screen japanese blood supply june roche signed exclusive deal dxs ltd uk distribution therascreen kras mutation test therascreen egfr mutation test tests realtime pcr assays ce mark certification used conjunction clinically relevant information kras egfr mutation testing aid doctors determining patients suitability certain cancer therapies wwwglobalreportscom roche finance report roche group financial review applied science roche applied sciences sales grew three times life sciences market rising local currencies million swiss francs main growth drivers lightcycler system reagents highthroughput realtime pcr along ultrafast genome sequencer systems dna sequencing business area gained significant market share leader instrument placement biochemical industrial reagents showed moderate growth market impacted byflat government research funding decreased biotech spending microarray systems also contributed strongly increasing demand since roche acquired nimblegen august tissue diagnostics roche tissue diagnostics sales totalling million swiss francs representing salesfrom date acquisition february december contributed percentage points divisions localcurrency sales growth standalone basis roche tissue diagnostics sales entire year reached million us dollars increase local currencies significantly exceeding estimated market growth rate increase due robust instrumentation sales benchmark xt lt immunohistochemistry reagent sales advanced staining segment commercial operations outside north america largely integrated roche focus market expansion europe andlatin america significant number distributor relationships replaced dedicated roche sales teams two major new systems benchmark ultra vantage launched benchmark ultra first automated system simultaneously perform immunohistochemistry situ hybridisation single platform launched unites states canada europe second half year vantage workflow solution launched us april complete workflow information management system anatomical pathology lab providing tracking capabilities streamline integrate lab work information flow greater productivity patient safety addition new antibodies various cancer diagnostics launched complement portfolio see business report information roches diagnostics products business areas sales regions overall sales continued grow ahead line total market regions innorth america increase includes percentage points ventana driven theprofessional diagnostics applied science tissue diagnostics business areas compensated decline diabetes care north american market japan grew significantly market increase strong performance also seen emerging markets europe asiapacific latin america diagnostics division sales region sales change region mchf sales local currencies emea north america asiapacific latin america japan regions total europe middle east africa operating results royalties operating income income million swiss francs lower local curren cies compared included higher outlicensing income diagnostics division royalties operating income change mchf mchf local currencies royalty income income outlicensing agreements income disposal products total cost sales overall increase local currencies considerably higher sales growth primarily result number impacts acquisitions made division last two years firstly amortisation product intangibles increased local currencies partly due including full twelve months amortisation charge acquisitions months ventana secondly manufacturing cost goods sold period costs includes acquisition accounting effect million swiss francs expenses relating fairvalue writeup ventanas inventory fully written first half finally royalty expenses include reversal million swiss francs bioveris royalty accruals excluding acquisition accounting impacts underlying manufacturing cost goods sold period costs grew local currencies primarily driven continued investment instrument meter placements expand market share total cost sales percentage sales increased comparedto diagnostics division cost sales change mchf mchf local currencies manufacturing cost goods sold period costs royalty expenses collaboration profitsharing agreements amortisation product intangibles impairment property plant equipment impairment product intangibles total marketing distribution increase local currencies mainly due investments increase market share especially diabetes care competitively fund sequencing array businesses applied science excluding impact newly acquired tissue diagnostics business marketing distribution costs grew local currencies marketing distribution percentage ofsales compared research development costs increased local currencies reflecting investments sequencing array businesses molecular oncology tests tissue diagnostics contributed percentage points growth percentage sales research development costs increased diagnostics division investments research development change mchf mchf local currencies research development expenses less noncash items amortisation intangible assets impairment intangible assets research development expenses excluding noncash items wwwglobalreportscom roche finance report roche group financial review general administration general administration costs decreased local currencies administration growth local currencies exclusively due acquired tissue diagnostics business first half million swiss francs transaction expenses relating ventana acquisition restructuring costs lower mainly due including million swiss francs postacquisition restructuring expenses bioveris restructuring costs million swiss francs mainly relating transfer production professional diagnostics united states germany switzerland moreover expenses legal environmental settlements significantly lower diagnostics division general administration change mchf mchf local currencies administration legal environmental settlements business combinations transaction expenses restructuring expenses gains losses disposal property plant equipment general items total operating free cash flow lower operating profit main driver decline operating free cash flow higher investments property plant equipment particularly instrument placements compensated lower invest ments intangible assets diagnostics division operating free cash flow mchf mchf operating profit operating profit cash adjustments increasedecrease net working capital investments property plant equipment investments intangible assets operating free cash flow sales operating profit cash adjustments consist elimination depreciation amortisation impairment charges replacement operating incomeexpenses provisions equity compensation plans disposals property plant equipment intangibles assets cash equivalents adetailed breakdown provided pages corporate operating costs general administration costs higher million swiss francs million swissfrancs results include million swiss francs costs due realignment divisional human resource activities corporate human resources costs part pharmaceuticals diagnostics divisional results operating free cash flow net outflow million swiss francs net outflow million swiss francs foreign exchange impact operating results groups exposure movements foreign currencies affecting operating results expressed swiss francs summarised following key figures comments growth change local currencies change chf sales operating profit exceptional items exchange rates swiss franc december average december average usd eur jpy us dollar significantly weakened swiss franc year recovered final quarter swiss franc strengthened euro many economies currencies although weakening yen particularly fourth quarter result sales growth operat ing profit growth expressed swiss francs percentage points respectively lower local currencies sensitivity group sales operating profit exceptional items absolute terms movement foreign currencies swiss franc shown table currency sensitivities operating profit impact change average exchange rate sales exceptional items versus swiss franc mchf mchf us dollar euro japanese yen currencies nonoperating results nonoperating results change mchf mchf chf operating profit associates financial income financing costs profit taxes income taxes net income attributable roche shareholders noncontrolling interests wwwglobalreportscom roche finance report roche group financial review groups treasury operations delivered positive net financial income net income financial assets foreign exchange management exceeding financing costs million swiss francs groups effective tax rate declined compared due mainly declines local tax rates net income decreased due unfavourable exchange rate impacts lower net financial income partially compensated lower effective tax rate net financial income millions chf financing costs financial income net financial income financial income financial income million swiss francs declining compared interest income income debt securities million swiss francs due lower holdings lower us interest rates weaker us dollar compared swiss franc also contributing lower result losses onthesale debt securities caused limited investor demand current financial market crisis losses million swiss francs incurred fixed income securities carried fairvaluethrough profitandloss losses million swiss francs incurred derivatives relating todebt securities impairments million swiss francs recorded debt securities net income equity securities million swiss francs compared million swiss francs result includes impairments million swiss francs equity securities funds continue invested aconservative risk profile low exposures equities expected returns pension plan assets million swiss francs compared net foreign exchange losses million swiss francs compared losses mil lion swiss francs second half erosion certainemerging market currencies caused significant increase corresponding hedge expenses afullanalysis financial income given note consolidated financial statements financial costs financing costs million swiss francs lower compared reflecting redemption several debt instruments well weaker us dollar compared swiss franc time costs provisions million swiss francs million swiss francs lower reflecting settlement ofthe city hope litigation second quarter interest cost pension plans million swiss francs increase compared due changes discount rates used actuarial calculations full analysis financing costs given note consolidated financial statements income taxes groups effective tax rate declined compared rate main driver sig nificantly lower tax rate roche underlying effective tax rate compared reflects lower taxable profits certain high tax jurisdictions certain onetime effects notably favourable change tax rates basel effective improvement despite increasing pretax profit contribution genentech analysis groups effective tax rate profit income profit income tax taxes tax rate tax taxes tax rate mchf mchf mchf mchf roche excl genentech chugai genentech chugai groups effective tax rate net income earnings per share net income billions chf core eps chf group net income decreased billion swiss francs total million swiss francs noncontrolling interests million swiss francs attributable genentech noncontrolling interests million swiss francs chugai noncontrolling interests net impact ofexceptional items net income minor impact net income growth rate absolute amount billion swiss francs diluted eps chf chf change group core decrease diluted eps due decrease net income attributable roche shareholders asdescribed core eps excludes exceptional items amortisation impairment intangible assets decreased local currencies core eps increased supplementary net income eps information given includes calculations core eps reconciles groups published ifrs results cash flows net cash free cash flow billions chf net cash billions chf free cash flow pharmaceuticals diagnostics corporate group mchf mchf mchf mchf operating profit operating profit cash adjustments increasedecrease net working capital investments property plant equipment investments intangible assets operating free cash flow treasury activities taxes paid dividends paid free cash flow wwwglobalreportscom roche finance report roche group financial review pharmaceuticals diagnostics corporate group mchf mchf mchf mchf operating profit operating profit cash adjustments increasedecrease net working capital investments property plant equipment investments intangible assets operating free cash flow treasury activities taxes paid dividends paid free cash flow free cash flow group strong increased billion swiss francs billion swiss francs increase primarily due higher operating free cash flow lower tax payments factors compensated lower cash generation treasury activities higher dividend payments operating free cash flow increased mainly due significantly lower net cash outflow equity compensation plans despite strong currency translation effects underlying business continues good cash generation partly absorbed growth net working capital business expands operating profit cash adjustments consist elimination depreciation amortisation impairment charges replacement operating incomeexpenses provisions equity compensation plans disposals property plant equipment intangible assets cash equivalents includes net impact groups equity compensation plans including cash received employees upon exercise cash used roche purchase equity delivery employees cash used genentech stock repurchase programme maintains roches ownership percentage detailed breakdown pro vided pages operating free cash flow also includes cash movements working capital thecash payments capital expenditure property plant equipment intangible assets latter mainly arising inlicensing deals treasury operations showed positive cash generation mainly interest income cash flows treasury activities decreased due lower interest received driven lower funds held lower interest rates weaker us dollar swiss franc total taxes paid decreased considerably compared included significant final settlement payments previously accrued amounts dividend payments increased billion swiss francs compared net cash roche genentech chugai group mchf mchf mchf mchf december cash cash equivalents marketable securities longterm debt shortterm debt net cash beginning period free cash flow transactions equity instruments business combinations changes ownership interests subsidiaries currency translation fair value movements net change net cash roche genentech chugai group mchf mchf mchf mchf december cash cash equivalents marketable securities longterm debt shortterm debt net cash end period net cash position group billion swiss francs billion swiss francs free cash flow billion swiss francs primarily used finance acquisitions ventana billion swiss francs increase ownership chugai billion swiss francs release previously restricted cash relating city hope litigation genentech increased net cash billion swiss francs offsetting billion swiss francs paid city hope included within operating free cash flow group also repaid debt billion swiss francs mainly rodeo bonds eurodenominated european medium term notes reduced debt liquid assets impact net cash balance sheet balance sheet billions chf liabilities assets net assets equity condensed balance sheet december december mchf mchf change property plant equipment goodwill intangible assets noncurrent assets cash marketable securities current assets total assets debt current noncurrent noncurrent liabilities current liabilities total liabilities total net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity full consolidated balance sheet given consolidated financial statements wwwglobalreportscom roche finance report roche group financial review noncurrent assets property plant equipment increased due capital expenditure new production facilities genentech diagnostics division chugai partly offset exchange rate impacts primarily due us dollar euro lower december compared december goodwill intangible assets increased billion swiss francs mainly ventana piramed mirus arius acquisitions inlicensing transactions current assets within current assets inventories accounts receivable slightly higher local currencies significant decrease cash marketable securities shown net cash debt reduction debt billion swiss francs billion swiss francs relates redemption maturity rodeo swiss franc bonds billion swiss francs redemption maturity eurodenominated european medium term notes remaining decrease due exchange rate impacts noncurrent current liabilities overall balance stable increase billion swiss francs pension obligations largely offset reduction billion swiss francs legal provisions following settlements made notably genentech city hope litigation total net assetsequity significant movements equity net income billion swiss francs dividend payments billion swiss francs currency translation losses billion swiss francs impact change ownership interests ventana chugai billion swiss francs total impact actuarial losses postemployment plans billion swiss francs net tax strong financial condition group remains solidly financed equity including noncontrolling interests representing total assets total assets financed longterm pensions postemployment benefits postemployment benefit plans classified defined contribution plans group pays fixed contribu tions separate fund thirdparty financial institution legal constructive obligation pay contributions expenses groups defined contribution plans million swiss francs million swiss francs plans classified defined benefit plans even groups potential obligation relatively minor relatively remote possibility arising funding asset management groups vari ous defined benefit plans overseen corporate level plans usually established trusts independent group funded payments group employees cases plan unfunded group pays pensions retired employees directly financial resources funding status defined benefit pension postemployment benefit plans mchf mchf funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation funding status overall groups defined benefit plans continue adequately funded despite financial turbulence funding status compared beginning year main movements came reduction fair value plan assets following declines global financial markets expenses recorded income statement total pension expenses relating groups defined benefit plans million swiss francs compared million swiss francs decrease mainly due changes discount rates adopted end based revised actuarial assumptions end total pension expenses expected increase compared due lower expected return plan assets full details groups pensions postemployment benefits given note consolidated financial statements roche securities roche securities performed broadly line msci europe pharmaceutical index global pharmaceutical sector share price market capitalisation december change share price chf nonvoting equity security genussscheinprice chf market capitalisation billions chf roche ranked number among peer group healthcare companiesas listed terms total shareholder return tsr ie share price growth plus dividends measured swiss francs actual exchange rates yearend return roche share roche nonvoting equity security combined performance share nonvoting equity security compared aweighted average return peer group actual exchange rates peer group abbott laboratories amgen astellas astrazeneca bayer becton dickinson biogen idec bristolmyers squibb eli lilly gilead glaxosmithkline johnson johnson merck co novartis pfizer roche sanofiaventis scheringplough takeda wyeth total shareholder return development dec march june sept dec roche share roche gs peer set index wwwglobalreportscom roche finance report roche group financial review proposed dividend board directors proposing increase dividend swiss francs per share nonvoting equity security swiss francs approval annual general meeting ndconsecutive increase dividend dividend proposal approved shareholders dividend payments shares nonvoting equity securities issue amount billion swiss francs billion swiss francs resulting payout ratio based prices year end dividend yield roche share yield nonvoting equity security information roche securities given pages finance report information per share nonvoting equity security chf chf change basic eps diluted eps core eps equity attributable roche shareholders per share dividend per share details please refer notes consolidated financial statements ofthe finance report financial risks group manages financial assets liabilities conservative way treasury activities servicing groups business requirements without materially affecting groups risk profile asset allocation surplus liquid funds either held cash invested highquality investment grade fixed income securities majority holdings liquid short term instruments maturities ofupto three months longerterm holdings roche experiences wider credit spreads reduced liquidity caused current financial markets situation first quarter roche sold almostall remaining equity positions classified marketable securities share declined less onepercent december total liquid funds addition group owns equity securities classified financial longterm assets see note consolidated financial statements venture capital positions connection groups strategic alliance efforts positions total billion swiss francs december billion swiss francs cash marketable securities mchf total mchf total cash cash equivalents money market instruments bonds debentures investments shares total cash marketable securities credit risk credit risk arises possibility counterparties transactions may default obligations causing financial losses group despite significant market difficulties rating profile groups billion swiss francs fixed income marketable securities remained strong invested aaaa range counterparty profile groups billion swiss francs tradereceivables remains well diversified across types customer regions wholesaler concentration us market risks market risk arises changing market prices groups financial assets financial liabilities exposures predominantly related changes foreign exchange rates interest rates equity prices group uses valueatrisk var assess impact market risk financial instruments var data indicates value range within given financial instrument fluctuate apreset probability result movements market prices var data table indicate theloss level period one month probability exceeded actual future gainsand losses associated treasury activities may differ materially var analyses performeddue inherent limitations associated predicting timing amount changes tointerest rates foreign currency exchanges rates equity investment prices particularly periods highmarket volatilities furthermore var numbers include credit risk component market risk financial instruments december december mchf mchf var foreign exchange component var interest rate component var price component diversification var total december total var financial assets liabilities million swiss francs december million swiss francs foreign exchange var increased comes mainly hedging nonus dollar cash flows future royalty income next five years genentech thelower contribution interest rate component caused ageing fixedterm liabilities price risk arises mainly movements prices equity securities decrease price component due significantly reduced equity security holdings december group held equity securities market value billion swiss francs december billion swiss francs number includes holdings biotechnology companies acquired contextof licensing transactions scientific collaborations lower holdings equity securities resulted ina lower var price risk information financial risk management financial risks var methodology included innote consolidated financial statements international financial reporting standards roche group using international financial reporting standards ifrs report con solidated results since group made changes accounting policies respect new andrevised international financial reporting standards interpretations group implemented therevised versions ifrs business combinations ias consolidated separate financial statements main impacts results transaction costs business combinations expensed instead included part acquisition price group alsoimplemented ifric interpretation relates ias employee benefits results anincrease pension assets recorded groups balance sheet corresponding increase inthegroups equity wwwglobalreportscom roche finance report roche group roche group consolidated financial statements roche group consolidated financial statements roche group consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income cost sales marketing distribution research development general administration operating profit exceptional items major legal cases changes group organisation operating profit associates financial income financing costs profit taxes income taxes net income attributable roche shareholders noncontrolling interests earnings per share nonvoting equity security basic chf diluted chf reference numbers indicate corresponding notes consolidated financial statements roche group consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income cost sales marketing distribution research development general administration operating profit associates financial income financing costs profit taxes income taxes net income attributable roche shareholders noncontrolling interests earnings per share nonvoting equity security basic chf diluted chf wwwglobalreportscom roche finance report roche group roche group consolidated financial statements roche group consolidated balance sheet millions chf december december noncurrent assets property plant equipment goodwill intangible assets associates financial longterm assets longterm assets deferred income tax assets postemployment benefit assets total noncurrent assets current assets inventories accounts receivable current income tax assets current assets marketable securities cash cash equivalents total current assets total assets noncurrent liabilities longterm debt deferred income tax liabilities postemployment benefit liabilities provisions noncurrent liabilities total noncurrent liabilities current liabilities shortterm debt current income tax liabilities provisions accounts payable accrued current liabilities total current liabilities total liabilities total net assets equity capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity disclosed note postemployment benefit assets deferred tax liabilities equity restatedin december balance sheet following adoption ifric interpretation areconciliation previously published balance sheet provided note roche group consolidated cash flow statement millions chf year ended december cash flows operating activities cash generated operations increase decrease working capital payments made defined benefit postemployment plans utilisation provisions operating cash flows cash flows operating activities income taxes paid income taxes paid total cash flows operating activities cash flows investing activities purchase property plant equipment purchase intangible assets disposal property plant equipment disposal intangible assets disposal products business combinations divestments subsidiaries interest dividends received sales marketable securities purchases marketable securities investing cash flows total cash flows investing activities cash flows financing activities proceeds issue longterm debt instruments repayment redemption longterm debt instruments increase decrease longterm debt increase decrease shortterm borrowings transactions equity instruments change ownership interest subsidiaries chugai ventana interest dividends paid exercises equitysettled equity compensation plans genentech chugai share repurchases financing cash flows total cash flows financing activities net effect currency translation cash cash equivalents increase decrease cash cash equivalents cash cash equivalents january cash cash equivalents december wwwglobalreportscom roche finance report roche group roche group consolidated financial statements roche group consolidated statement recognised income expense millions chf year ended december availableforsale investments valuation gains losses taken equity transferred income statement sale impairment cash flow hedges gains losses taken equity transferred income statement transferred initial balance sheet carrying value hedged items currency translation foreign operations exchange differences accumulated differences transferred income statement divestment defined benefit postemployment plans actuarial gains losses limit asset recognition income taxes items taken directly transferred equity net income recognised directly equity net income recognised income statement total recognised income expense attributable roche shareholders noncontrolling interests total effect changes accounting policy attributable roche shareholders noncontrolling interests total disclosed note entries defined benefit postemployment plans restated statement recognised income expense following adoption ifric interpretation reconciliation previously published statement ofrecognised income expense provided note roche group consolidated statement changes equity millions chf roche noncontrolling shareholders interests total year ended december january previously published changes accounting policy january restated net income recognised directly equity net income recognised income statement total recognised income expense dividends paid transactions equity instruments equity compensation plans genentech chugai share repurchases convertible debt instruments changes noncontrolling interests december year ended december january net income recognised directly equity net income recognised income statement total recognised income expense ventana acquisition dividends paid transactions equity instruments equity compensation plans genentech chugai share repurchases changes ownership interests subsidiaries chugai ventana changes noncontrolling interests december disclosed note equity january entries defined benefit postemployment plans restated inthestatement recognised income expense following adoption ifric interpretation reconciliation tothe previously published statement recognised income expense provided note wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements summary significant accounting policies basis preparation consolidated financial statements consolidated financial statements roche group prepared accordance international financial reporting standards ifrs comply swiss law prepared using historical cost convention except disclosed accounting policies certain itemsincluding derivatives availableforsale investments shown fair value approved issue board directors january subject approval annual general meeting shareholders march preparation consolidated financial statements requires management make estimates assumptions affect reported amounts revenues expenses assets liabilities disclosure contingent liabilities date financial statements future estimates assumptions based managements best judgement date financial statements deviate actual circumstances original estimates assumptions modified appropriate year inwhich circumstances change changes accounting policies arise application new revised standards interpreta tions applied retrospectively unless otherwise specified transitional requirements particular standard interpretation retrospective application requires results ofthe comparative period opening balances period restated new accounting policy always applied insome cases transitional requirements particular standard interpretation specify changes applied prospectively prospective application requires new accounting policy onlybe applied results current period comparative period isnot restated addition comparatives reclassified extended previously reported results take account anypresentational changes consolidation policy financial statements consolidated financial statements roche holding ltd company registered switzerland subsidiaries group subsidiaries companies controlled directly indirectly roche holding ltd control isdefined power govern financial operating policies enterprise obtain benefits activities control normally evidenced roche holding ltd owns either directly indirectly voting rights currently exercisable potential voting rights companys share capital special purpose entities consolidated substance relationship special purpose entity controlled group companies acquired year consolidated date control transferred group subsidiaries divested included thedate control passes group intercompany balances transactions resulting unrealised income eliminated full changes ownership interests subsidiaries accounted asequity transactions occur control already obtained result alossof control reference numbers indicate corresponding notes consolidated financial statements investments associates accounted using equity method companies group exercises power exercise significant influence control normally evidenced group owns voting rights currently exercisable potential voting rights company balances transactions associates result unrealised income areeliminated extent groups interest associate interests joint ventures reported using linebyline proportionate consolidation method segment reporting determination groups operating segments based organisation units infor mationis reported groups management group two divisions pharmaceuticals diagnostics revenues primarily generated sale prescription pharmaceutical products anddiagnostic instruments reagents consumables respectively divisions also derive revenue sale licensing products technology third parties within pharmaceuticals division three sub divisions roche pharmaceuticals genentech chugai three subdivisions separate management reporting structures within pharmaceuticals division considered separately reportable operat ing segments certain headquarter activities reported corporate consist ofcorporate headquarters including corporate executive committee corporate communications corporate human resources corporate finance including treasury taxes pension fund management corporate legal corporate safety environmental services transfer prices operating segments set arms length basis operating assets liabi litiesconsist property plant equipment goodwill intangible assets trade receivablespayables inventories assets liabilities provisions reasonably attributed reported operating segments nonoperating assets liabilities mainly include current deferred income tax balances postemployment benefit assetsliabilities financial assetsliabilities cash marketable securities investments debt foreign currency translation group companies use local currency functional currency certain group companies use currencies us dollars swiss francs euros functional currency currency primary economic environment entity operates local transactions currencies initially reported using exchange rate date transaction gains losses settlement transactions gains losses translation monetary assets liabilities denominated currencies included income except qualifying cash flow hedges orarise monetary items substance form part groups net investment foreign entity insuch cases gains losses deferred equity upon consolidation assets liabilities group companies using functional currencies swiss francs foreign entities translated swiss francs using yearend rates exchange sales costs expenses net income cash flows translated average rates exchange year translation differences due changes exchange rates beginning end year difference net income translated average yearend exchange rates taken directly equity disposal foreign entity identified cumulative currency translation differences within equity relating foreign entity recognised income part gain loss divestment revenues sales represent amounts received receivable goods supplied customers deducting trade discounts cash discounts volume rebates exclude value added taxes taxes directly linked sales revenues sale products recognised upon transfer customer significant risksand rewards trade discounts cash discounts volume rebates recorded accrual basis consistent recognition related sales estimates expected sales returns chargebacks rebates including medicaid united states similar rebates countries also deducted sales recorded accrued liabilities provisions deduction accounts receiv able estimates based analyses existing contractual legislatively mandated obligations historical trends groups experience revenues recorded earned services wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements performed necessary single transactions split separately identifiable components reflect substance transaction conversely two transactions may considered together revenue recognition purposes commercial effect understood without reference series transactions whole cost sales cost sales includes corresponding direct production costs related production overheads goodssold services rendered royalties alliance collaboration expenses including collaboration profitsharing arrangements also reported part cost sales startup costs validation andthe achievement normal production capacity expensed incurred research development addition internal research development activities group also party inlicensing similar arrangements alliance partners group may also acquire inprocess research develop ment assets either business combinations purchases specific assets internal research costs charged income incurred internal development costs capitalised asintangible assets identifiable asset completed generate probable future economic benefits cost asset measured reliably group currently internal development costs qualify capitalisation intangible assets internal development costs therefore charged income incurred since criteria recognition asset met inprocess research development assets acquired either inlicensing arrangements business combinations separate purchases capitalised intangible assets described available use intangible assets amortised straightline basis period expected benefit reviewed impairment reporting date licensing milestone upfront receipts payments royalty income recognised accrual basis accordance substance respective licensing agreements collectability royalty amount reasonably assured royalties recognised revenue cash received certain group companies receive third parties upfront milestone similar payments relating sale licensing products technology revenue associated performance milestones recognised based achievement deliverables defined respective agreements upfront payments licence fees subsequent deliverables initially reported deferred income recognised income earned period develop ment collaboration manufacturing obligation payments made group companies third parties associates items capitalised intangible assets accounting reporting transactions roche genentech chugai within groups consolidated financial statements transactions balances consolidated subsidiaries genentech chugai roche group subsidiaries eliminated consolidation genentech chugai considered separately reportable operating segments purposes groups operating segment disclosures note additional information relating genentech chugai results given notes respectively profits product sales roche pharmaceuticals genentech chugai operating segments arerecorded part segment results operating segment making sale unrealised internal profits inventories sold one operating segment another yet beensold external customers balance sheet date eliminated consolidation entry atapharmaceuticals division level additionally results operating segment may include income received another operating segment respect royalties licensing milestone upfront payments transfers respect research collaborations recognised income segment results operating segment receiving income consistently accounting policies applied thirdparty transactions set financial statements corresponding expenses recorded operating segment eliminate atapharmaceuticals division level employee benefits wages salaries social security contributions paid annual leave sick leave bonuses nonmonetary benefits accrued year associated services rendered employees group group provides longterm employee benefits cost accrued match rendering theservices employees concerned liabilities longterm employee benefits discounted take account time value money material pensions postemployment benefits employees covered defined benefit defined contribution postemployment plans sponsored group companies groups contributions defined contribution plans charged appropriate income statement heading within operating results year relate accounting reporting defined benefit plans based recent actuarial valuations defined benefit obligations service costs calculated using projected unit credit method reflects service rendered employees dates valuation incorporates actuarial assumptions primarily regarding discount rates used determining present value benefits projected rates remuneration growth longterm expected rates return plan assets discount rates based market yields highquality corpo rate bonds country concerned past service costs allocated average period benefits become vested current past service costs charged appropriate income statement heading within operating results pension plan administration funding overseen corporate leveland settlement gains losses resulting changes funding arrangements reported general administration expenses within corporate segment expected returns plan assets interest costs charged financial income financing costs respectively actuarial gains losses consist differences assumptions actual experiences effects changes actuarial assumptions recorded directly equity pension assets liabilities different defined benefit plans offset unless group legally enforceable right use surplus one plan settle obligations plan recognition pension assets limited total present value ofany future refunds plans reductions future contributions plans cumulative unrecognised past service costs adjustments arising limit recognition assets defined benefit plans recorded directly equity equity compensation plans certain employees group participate equity compensation plans including separate plans genentech chugai fair value equity compensation awards granted employees estimated atthe grant date recorded expense vesting period expense charged appro priate income statement heading within operating results equitysettled plans increase equity isrecorded expense subsequent cash flows exercises vested awards recorded aschanges equity cashsettled plans liability recorded measured fair value balance sheet date movements fair value recorded appropriate income statement heading within operating results subsequent cash flows exercise vested awards recorded reduction liability wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements property plant equipment property plant equipment initially recorded cost purchase construction include costsdirectly attributable bringing asset location condition necessary capable ofoperating manner intended management include items costs site preparation installation assembly costs professional fees net costs testing whether asset functioning properly including validation costs also included initially recorded cost construction interest borrowing costs incurred respect qualifying assets capitalised included carrying value assets property plant equipment depreciated straightline basis except land depreciated estimated useful lives major classes depreciable assets follows land improvements years buildings years machinery equipment years diagnostic instruments years office equipment years motor vehicles years parts item property plant equipment different useful lives accounted separate components estimated useful life assets regularly reviewed necessary future depreciation charge accelerated repairs maintenance costs expensed incurred leases group lessee leases property plant equipment group substantially risks rewards ownership classified finance leases finance leases capitalised start lease fair value present value minimum lease payments lower rental obliga tion net finance charges reported within debt assets acquired finance leases depreciated inaccordance groups policy property plant equipment reasonable certainty group obtain ownership end lease term asset depreciated shorter ofthe lease term useful life interest element lease payment charged income overthe lease term based effective interest rate method leases substantially risks andrewards ownership transferred group classified operating leases payments made operating leases charged income straightline basis period lease group lessor primarily occurs diagnostics division assets subject finance leases initially reported receivables amount equal net investment lease assets subject operating leases reported within property plant equipment lease income finance leases subsequently recognised earned income term lease based effective interest rate method lease income operating leases recognised lease term straightline basis business combinations goodwill business combinations accounted using purchase method accounting cost acquisition consideration given exchange control identifiable assets liabilities contingent liabilities acquired company consideration includes cash paid plus fair value date exchange assets given liabilities incurred assumed equity instruments issued group contingent con sideration arrangements included cost acquisition fair value directly attributable transaction costs expensed current period reported within general administration expenses acquired net assets identifiable assets liabilities contingent liabilities initially recognised fair value group acquire ownership acquired company noncontrolling interests recorded proportion fair value acquired net assets attributable noncontrolling interest goodwill recorded surplus cost acquisition groups interest fair value acquired net assets goodwill fair value adjustments recorded assets liabil ities acquired company functional currency company goodwill amortised assessed possible impairment balance sheet date additionally tested annually impairment goodwill may also arise upon investments associates surplus cost investment thegroups share fair value net identifiable assets goodwill recorded within investments associates changes ownership interests subsidiaries accounted equity transactions occur control already obtained result loss control intangible assets purchased patents licences trademarks intangible assets initially recorded cost theseassets acquired business combination fair value allocated theacquisition accounting intangible assets amortised useful lives straightline basis beginning point available use estimated useful life lower legal duration economic useful life estimated useful life intangible assets regularly reviewed impairment property plant equipment intangible assets impairment assessment carried evidence asset may impaired addition intangible assets yet available use tested impairment annually recoverable amount asset higher fair value less costs sell value use less carrying value carrying value reduced recoverable amount reduction reported income statement impairment loss value use calculated using estimated cash flows generally overa fiveyear period extrapolating projections subsequent years discounted using appropriate longterm pretax interest rate impairment loss arises useful life asset question reviewed necessary future depreciationamortisation charge accelerated impairment financial assets discussed financial assets policy impairment goodwill goodwill assessed possible impairment balance sheet date additionally tested annually impairment goodwill allocated cashgenerating units described note recoverable amount cashgenerating unit higher fair value less costs sell value use isless carrying value carrying value goodwill reduced recoverable amount reduction reported income statement impairment loss methodology used impairment testing described note inventories inventories stated lower cost net realisable value cost finished goods work process includes raw materials direct labour directly attributable costs overheads based uponthe normal capacity production facilities cost determined using weighted average method netrealisable value estimated selling price less cost completion selling expenses accounts receivable accounts receivable carried original invoice amount less allowances made doubtful accounts trade discounts cash discounts volume rebates similar allowances allowance doubtful accounts recorded difference carrying value recoverable amount objective evidence group able collect amounts due trade discounts cash discounts volume rebates similar allowances recorded accrual basis consistent recognition related sales using estimates based existing contractual obligations historical trends groups experience longterm accounts receivable discounted take account time value money material cash cash equivalents cash cash equivalents include cash hand time call current balances banks similar institutions balances reported cash readily convertible known amounts cash subject insignificant risk changes value maturity three months less date acquisition definition also used cash flow statement wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements provisions provisions recognised legal constructive obligation incurred probably leadto outflow resources reasonably estimated particular restructuring provisions recognised group detailed formal plan either commenced implementation announced provisions recorded estimated ultimate liability expected arise taking account foreign currency effects arising translation functional currency swiss francs time value money material contingent liability disclosed existence obligation confirmed future events amount obligation measured reasonable reliability contingent assets recognised disclosed inflow economic benefits probable fair values fair value amount financial asset liability instrument could exchanged knowledgeable willing parties arms length transaction determined reference quoted market prices use established valuation techniques option pricing models discounted cash flow method quoted prices active market available valuation techniques typically used derivative financial instruments fair values financial assets liabilities balance sheet date materially different reported carrying values unless specifically mentioned notes consolidated financial statements financial assets financial assets principally investments including marketable securities classified either fairvalue throughprofitorloss availableforsale heldtomaturity loans receivables fairvaluethrough profitorloss financial assets either classified heldfortrading designated upon initial recognition heldfortrading financial assets acquired principally generate profit shortterm fluctuations price financial assets designated fairvaluethroughprofitorloss results relevant information eliminating measurement recognition inconsistency heldtomaturity financial assets aresecurities fixed maturity group intent ability hold maturity loans receivables financial assets created group acquired issuer primary market theyare nonderivative financial assets fixed determinable payments quoted active market financial assets considered availableforsale financial assets initially recorded fair value including transaction costs except assets fairvaluethroughprofitorloss exclude transaction costs purchases sales recognised onthe settlement date fairvaluethroughprofitorloss financial assets subsequently carried fair value changes fair value recorded financial income period arise heldto maturity financial assets subsequently carried amortised cost using effective interest rate method availableforsale financial assets subsequently carried fair value unrealised changes fair value recorded equity except interest calculated using effective interest rate method foreign exchange components availableforsale financial assets sold impaired otherwise disposed thecumulative gains losses previously recognised equity included financial income current period loans receivables subsequently carried amortised cost using effective interestrate method financial assets individually assessed possible impairment balance sheet date impair ment charge recorded objective evidence impairment issuer bankruptcy default significant financial difficulty addition availableforsale equity securities market value original cost net previous impairment considered impaired availableforsale equity securities market value original cost net previous impairment sustained sixmonth period also considered impaired decreases market price less original cost net previous impairment arealso less sustained sixmonth period considered objective evidence ofimpairment movements fair value recorded equity objective evidence impair ment asset sold otherwise disposed financial assets carried amortised cost impairment charge difference carrying value recoverable amount calculated usingestimated future cash flows discounted using original effective interest rate availableforsale financialassets impairment charge amount currently carried equity difference original cost net previous impairment fair value impairment loss reversed reversal related objectively event occurring impairment loss recognised debt securities measured amortised cost availableforsale reversal recognised income equity securities held availableforsale reversal recognised directly equity financial asset derecognised contractual cash flows asset expire group transfers rights receive contractual cash flows financial assets transaction substantially risks rewards ownership financial asset transferred interest trans ferred financial assets created retained group recognised separate asset liability derivatives derivative financial instruments initially recorded subsequently carried fair value apart derivatives designated qualifying cash flow hedging instruments discussed hedging policy changes fair value recorded financial income period arise embedded derivatives recognised separately closely related host contract host contract iscarried amortised cost hedging purposes hedge accounting hedging relationships may three types fair value hedges hedges particular risks may change fair value recognised asset liability cash flow hedges hedges particular risks may change amount timing future cash flows hedges net investment foreign entity hedges particular risks may change carrying value net assets foreign entity qualify hedge accounting hedging relationship must meet several strict conditions documenta tion probability occurrence cash flow hedges hedge effectiveness reliability measurement ifthese conditions met relationship qualify hedge accounting case hedging instrument hedged item reported independently hedging relationship particular derivatives reported fair value changes fair value included financial income qualifying fair value hedges hedging instrument recorded fair value hedged item isrecorded previous carrying value adjusted changes fair value attributable hedged risk changes fair values reported financial income qualifying cash flow hedges hedging instrument recorded fair value portion change fair value effective hedge included equity remaining ineffective portion reported infinancial income hedging relationship hedge foreign currency risk firm commitment highly probable forecasted transaction results recognition nonfinancial asset liability thecumulative changes fair value hedging instrument recorded equity included initial carrying value asset liability date recognition qualifying cash flow hedges cumulative changes fair value hedging instrument recordedin equity included financial income forecasted transaction affects net income qualifying hedges net investment foreign entity hedging instrument recorded fair valuethe portion change fair value effective hedge included equity remain ing ineffective portion recorded financial income hedging instrument derivative equity cases entity disposed cumulative changes fair value hedging instrumentthat recorded equity reclassified income wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements debt instruments debt instruments initially recorded cost proceeds received net transaction costs sub sequently reported amortised cost discount net proceeds received principal value due redemption amortised duration debt instrument recognised aspart financing costs using effective interest rate method certain debt instruments may designated fairvaluethroughprofitorloss results relevant information eliminates significantly reduces measurement recognition inconsistencies debt instruments reported fair value based quoted prices active market movements fair value reported within financial income debt instruments designated fairvaluethroughprofitorloss disclosed note group derecognises financial liability contractual obligations discharged cancelled expired taxation income taxes include taxes based upon taxable profits group including withholding taxes payable distribution retained earnings within group taxes based income suchasproperty capital taxes included within general administration expenses liabilities income taxes mainly withholding taxes could arise remittance retained earnings principally relating subsidiaries recognised probable earnings willbe remitted foreseeable future deferred income tax assets liabilities recognised temporary differences tax bases assets liabilities carrying values financial statements deferred income tax assets relating carryforward unused tax losses recognised extent probable future taxable profit available unused tax losses utilised current deferred income tax assets liabilities offset income taxes levied sametaxation authority legally enforceable right offset deferred income taxes determined based currently enacted tax rates applicable tax jurisdiction groupoperates discontinued businesses noncurrent assets held sale discontinued business component groups business represents separate major line business geographical area operations subsidiary acquired exclusively view resale reclassification discontinued business occurs upon disposal operation meets criteria tobe classified held sale earlier disposal group group assets disposed group single transaction together liabilities directly associated assets transferred transaction assets liabilities disposal group reclassified held sale value recovered principally sale rather continuing use disposal group must available sale current condition sale must highly probable immediately classification held sale measurement assets liabilities disposal group updated accordance applicable accounting policies initial classification heldforsale disposal groups recognised lower carrying value fair value less costs sell impairment losses initial classification held sale included income statement equity instruments groups holdings equity instruments recorded deduction equity original purchase cost consideration received subsequent resale equity instruments movements reported changes equity instruments acquired primarily meet potential obligations employees may arise respect certain groups equity compensation plans management judgements made applying accounting policies application groups accounting policies may require management make judgements apart involving estimates significant effect amounts recognised consolidated finan cial statements management judgement particularly required assessing substance transactions complicated structure legal form include limited following areas revenue recognition nature groups business many sales transactions simple structure sales agreements may consist multiple components occurring different times group also party various outlicensing agreements involve upfront milestone payments may occur several years agreements may also involve certain future obligations revenue recognised managements judgement significant risks rewards ownership transferred group retain continuing managerial involvement effective control goods sold obligation fulfilled transactions result cash receipts initially recognised deferred income released income subsequent periods basis performance conditions specified agreement consolidation subsidiaries associates group periodically undertakes transactions may involve obtaining right control significantly influence operations companies trans actions include acquisition part equity companies purchase certain assets assumption certain liabilities contingent liabilities companies entering alliance agreements companies also included transactions involving special purpose entities similar vehicles cases management makes assessment whether group right tocontrol significantly influence companys operations based assessment company consolidated subsidiary associated company making assessment management considers underlying economic substance transaction contractual terms business combinations group acquires control another business cost acquisition hasto allocated assets liabilities contingent liabilities acquired business residual recorded goodwill process involves management making assessment fair value items management judgement particularly involved recognition measurement following items intellectual property may include patents licences trademarks similar rights currently marketed products also rights scientific knowledge associated projects currently inresearch development phases contingencies legal environmental matters contingent consideration arrangements recoverability accumulated tax losses previously incurred acquired company cases management makes assessment based underlying economic substance items concerned contractual terms order fairly present items leases group party leasing arrangements lessee lessor treatment leasing transactions financial statements mainly determined whether lease considered bean operating lease finance lease making assessment management looks substance ofthe lease well legal form makes judgement whether substantially risks rewards ownership transferred arrangements take legal form lease nevertheless convey right use asset also covered assessments key assumptions sources estimation uncertainty preparation consolidated financial statements conformity ifrs requires management tomake estimates assumptions affect application policies reported amounts assets liabilities income expenses related disclosures estimates underlying assumptions based onhistorical experience various factors believed reasonable circumstances results form basis making judgements carrying values assets liabilities readily apparent sources actual results may differ estimates wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements estimates underlying assumptions reviewed ongoing basis changes accounting estimates may necessary changes circumstances estimate based orasa result new information experience changes recognised period whichtheestimate revised key assumptions future key sources estimation uncertainty significant risk ofcausing material adjustment carrying value assets liabilities within next twelve months described sales allowances group provisions accruals expected sales returns chargebacks andother rebates including medicaid united states similar rebates countries atdecember total million swiss francs estimates based analyses existing contractual legislativelymandated obligations historical trends groups experience management believes total provisions accruals items adequate based upon currently available information deductions based management estimates may subject change better information becomes available changes arise could impact provisions accruals recognised balance sheet future periods consequently level sales recognised income statement future periods property plant equipment intangible assets including goodwill group property plantand equipment carrying value million swiss francs disclosed note goodwill hasa carrying value million swiss francs see note intangible assets carrying value million swiss francs see note assets reviewed annually impairment described assess whether impairment exists estimates made future cash flows expected result use asset eventual disposal actual outcomes could vary significantly estimates discounted future cash flows factors changes planned useof buildings machinery equipment closure facilities presence absence competition technical obsolescence lower anticipated sales products capitalised rights could result inshortened useful lives impairment changes discount rates used could also lead impairments pensions postemployment benefits many groups employees participate post employment defined benefit plans calculations recognised assets liabilities plans based upon statistical actuarial calculations particular present value defined benefit obligation impacted assumptions discount rates used arrive present value future pension liabilities assumptions future increases salaries benefits furthermore groups independent actuaries use statistically based assumptions covering areas future withdrawals participants plan estimates life expectancy december present value groups defined benefit obligation million swiss francs funded plans million swiss francs unfunded plans see note actuarial assumptions used may differ materially actual results due changes market economic conditions higher lower withdrawal rates longer shorter life spans participants changes factors assessed differences could impact assets orliabilities recognised balance sheet future periods legal provisions group companies party various legal proceedings including claims arising trade significant matters described note legal provisions december total million swiss francs additional claims could made might covered existing provisions insurance assurance increase scope matters future lawsuits claims proceedings investigations material changes arise could impact provisions recognised balance sheet future periods environmental provisions group provisions environmental remediation costs december total million swiss francs disclosed note material components environmental provisions consist costs fully clean refurbish contaminated sites treat contain contamination certain sites future remediation expenses affected number uncertainties include limited detection previously unknown contaminated sites themethod extent remediation percentage waste material attributable group remediation sites relative attributable parties financial capabilities potentially responsible parties management believes total provisions environmental matters adequate based upon currently available information however given inherent difficulties estimating liabilities area guaranteed additional costs incurred beyond amounts accrued effect resolution environmental matters results operations predicted due uncertainty concerning amount timing future expenditures changes arise could impact provisions recognised balance sheet future periods income taxes december net liability current income taxes million swiss francs net asset deferred income taxes million swiss francs disclosed note significant estimates required determine current deferred assets liabilities income taxes ofthese estimates based interpretations existing tax laws regulations management believes theestimates reasonable recognised liabilities income taxrelated uncertainties adequate various internal external factors may favourable unfavourable effects income tax assets liabilities factors include limited changes tax laws regulations andor rates changing interpretations existing tax laws regulations future levels research development spending changes overall levels pretax earnings changes arise could impact assets liabilities recognised balance sheet future periods changes accounting policies group early adopted ifrs operating segments ias revised borrowing costs required implemented january latest group early adopted revised versions ifrs business combinations ias consolidated separate financial state ments published early required implemented january atthe latest group implemented amendments ias financial instruments recognition andmeasurement ifrs financial instruments disclosures published october relating reclassification financial assets group also adopted ifric interpretation relates toias employee benefits group currently assessing potential impacts new revised standards interpre tations effective january beyond group early adopted include revisions ias presentation financial statements revisions ifrs share based payment group anticipate material impact groups overall results financial position ifrs revised business combinations amongst matters revised standard requires directly attributable transaction costs expensed current period rather included inthe cost acquisition previously revised standard also requires contingent consideration arrange ments included acquisition accounting fair value expands disclosure requirements business combinations group applied revised standard prospectively business combinations since january directly attributable transaction costs totalling million swiss francs expensed would included cost acquisition previous accounting policy business combinations prior periods restated new accounting policy applied group would expensed additional million swiss francs directly attributable transaction costs year goodwill would reduced amount change negative impact swiss francs earnings per share nonvoting equity security basic diluted would negative impact swiss francs revised standard applied retrospectively ias revised consolidated separate financial statements amongst matters revised standard requires changes ownership interests subsidiaries accounted equity transactions occur control already obtained result loss control additionally revised standard renames minority interests noncontrolling interests group applied revised standard retrospectively transactions required restatement wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements ias financial instruments recognition measurement ifrs financial instruments disclosures amendments relate reclassification financial assets applied prospectively group july application amendments significant impactonthe groups results ifric interpretation ias employee benefits interpretation adds existing require ments ias regarding interaction limits recognition assets defined benefit postemployment plans minimum funding requirement plans groups plans dohave minimum funding requirement application interpretation results increase theassets recorded groups balance sheet corresponding increase groups equity thegroup applied revised standard retrospectively results impact million swiss francs equity january impacts previously published december balance sheet statement recognised income expense year ended shown tables application interpretation impact net income earnings per share restated balance sheet selected items december millions chf originally application group published ifric restated postemployment benefit assets deferred tax liabilities capital reserves attributable roche shareholders restated statement recognised income expense year ended december millions chf originally application group published ifric restated availableforsale investments valuation gains losses taken equity transferred income statement sale impairment cash flow hedges gains losses taken equity transferred income statement transferred initial balance sheet carrying value hedged items exchange differences translation foreign operations defined benefit postemployment plans actuarial gains losses limit asset recognition income taxes items taken directly transferred equity net income recognised directly equity net income recognised income statement total recognised income expense attributable roche shareholders noncontrolling interests total operating segment information divisional information millions chf pharmaceuticals diagnostics division division corporate group revenues external customers sales royalties operating income total revenues operating segments sales royalties operating income elimination interdivisional revenue total segment results operating profit exceptional items major legal cases changes group organisation operating profit capital expenditure business combinations additions property plant equipment additions intangible assets total capital expenditure research development research development costs segment information depreciation property plant equipment amortisation intangible assets impairment property plant equipment impairment goodwill impairment intangible assets equity compensation plan expenses wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements pharmaceutical subdivisional information millions chf roche pharmaceuticals pharmaceuticals genentech chugai division revenues external customers sales royalties operating income total revenues operating segments sales royalties operating income elimination revenue within division total segment results operating profit exceptional items elimination profit within division subtotal major legal cases changes group organisation operating profit capital expenditure business combinations additions property plant equipment additions intangible assets total capital expenditure research development research development costs elimination costs within division total segment information depreciation property plant equipment amortisation intangible assets impairment property plant equipment impairment goodwill impairment intangible assets equity compensation plan expenses net operating assets millions chf assets liabilities net assets roche pharmaceuticals genentech chugai elimination within division pharmaceuticals division diagnostics division corporate total operating nonoperating group information geographical area millions chf revenues external customers noncurrent assets royalties operating property plant goodwill sales income equipment intangible assets switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements revenues external customers noncurrent assets royalties operating property plant goodwill sales income equipment intangible assets switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total sales allocated geographical areas destination according location customer royalties operating income allocated according location group company receives revenue european union information based members eu december major customers us national wholesale distributor amerisourcebergen corp represented approximately billion swissfrancs billion swiss francs groups revenues revenues genentech operating segment residual roche pharmaceuticals diagnostics segments thegroup also reported substantial revenues us national wholesale distributors cardinal health inc mckesson corp total three customers represented approximately quarter groups revenues majority genentech genentech effective september roche group acquired majority interest approximately genentech inc biotechnology company united states june group exercised option acquire remaining shares genentech june point genentech became owned subsidiary group july october march group completed public offerings genentechs common stock reduced groups majority interest groups ownership genentech decreased due conversion redemption ofthelyons iv us dollar exchangeable notes december groups interest genentech common stock genentech publicly traded listed new york stock exchange symbol dna genentech prepares financial statements conformity accounting principles generally accepted united states us gaap filed quarterly basis us securities exchange commission sec roches proposal fully purchase genentech july group announced proposal purchase outstanding shares genentech common stock owned roche price usd cash per share equivalent total cash payment approximately billion us dollars roche proposal july genentech announced special committee board directors composed independent directors thespecial committee formed review evaluate special committees discretion negotiate recommend recommend acceptance roche proposal august genentech announced special committee support proposal impacts roche proposal results described note roches relationship genentech genentech entered certain agreements roche discussed affiliation arrangements result june redemption genentechs special common stock subsequent public offerings genentech amended certificate incorporation bylaws entered amended certain affiliation arrangements roche amongst matters cover thefollowing areas roches rights shareholder roches rights nominate members genentechs board directors certain limitations roches ability buy sell genentechs common stock process roche may effect merger genentech roche approval directors designated roche genentech seek make significant business acquisitions divestments approval directors designated roche genentech seek issue repurchase redeem capital stock genentech issues additional shares common stock connection equity compensation plans andmay issue additional shares purposes affects roches percentage ownership interest theaffiliation agreement roche genentech provides amongst matters genentech establishes stock repurchase programme maintain roches percentage ownership interest genentech licensing agreements july roche genentech agreed amended restated licensing andmarketing agreement granting roche option license use sell genentechs products nonusmarkets licensing marketing agreement subsequently amended delete add certaingenentech products roches commercialisation marketing rights canada addition rocheand genentech july licensing marketing agreement relating antiher antibodies herceptin pertuzumab providing roche exclusive marketing rights outside us depending specific circumstances terms agreement may result payments anarmslength basis roche genentech following matters fees extend roches option license product partial reimbursement genentechs previously incurred development costs roche exercises option license product milestones similar payments dependent upon achievement agreed objectives performance targets royalties roches aggregate sales product manufacturing agreements genentech agreed general manufacture supply roche itsclinical requirements cost commercial requirements cost plus basis roche right tomanufacture genentechs products certain circumstances july roche genentech signed two new product supply agreements umbrella manufacturing supply agreement umbrella agreement supersedes existing product supply agreements agreement roche agreed topurchase specified amounts herceptin avastin perpetual basis either partymay order collaboration products including herceptin avastin wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements theshortterm supply agreement shortterm agreement supplements terms umbrella agreement agreement roche agreed purchase specified amounts herceptin avastin mabtherarituxan research collaboration agreement april roche genentech entered research collabo ration agreement outlines process parties may agree conduct share costs jointresearch certain molecules agreement outlines development commercial isation efforts coordinated respect select molecules including financial provisions anumber ofdifferent development commercialisation scenarios undertaken either parties tax sharing agreement roche genentech tax sharing agreement relates us state andlocal tax returns consolidated combined genentech calculates tax liability orrefund group state local jurisdictions genentech standalone entity differences ifrs us gaap due certain consolidation entries differences requirements international financial reporting stan dards ifrs us gaap differences genentechs standalone financial results aus gaap basis financial results genentech consolidated roche group accordance ifrs reconciliation genentech results usd chf usd chf millions millions millions millions operating income us gaap basis redemption tanox costs equity compensation plan expenses us gaap basis tanox acquisition accounting us gaap basis special litigation items roche proposal costs operating income nonus gaap basis add deduct differences consolidation entries add back redemption tanox costs equity compensation plan expenses ifrs basis capitalised inprocess research development changes group organisation reclassification differences consolidation entries operating profit exceptional items ifrs basis add deduct exceptional items major legal cases changes group organisation segment resultoperating profit ifrs basis add deduct nonoperating items ifrs basis financial income financing costs consolidation entries income taxes net income ifrs basis noncontrolling interest calculation noncontrolling interest percentage average year income applicable noncontrolling interest ifrs basis translated usd chf usd chf effective january group implemented ifrs sharebased payment ifrs financial state ments amongst matters standard required fair value equity compensation plans awarded employees estimated grant date recorded expense vesting period expense charged appropriate income statement heading standard also required retro spective application within certain transitional requirements pretax expense million usdollars million swiss francs relating plans genentech recorded million usdollars million swiss francs effective january genentech implemented us statement financial accounting standards r sharebased payment fas r us gaap financial statements amongst matters required companies reporting us gaap recognise com pensation expenses plans due different dates first application measurement requirements transitional arrangements fas r ifrs expenses recorded genentech usgaapfinancial statements equity compensation plans expenses recorded inthe roche group ifrs financial statements plans group implemented ias revised intangible assets ifrs financial statements amongstother matters revised standard typically results intangible assets recognised frominlicensing arrangements similar research development alliances genentechs us gaap financial statements expenditure would usually recorded research development expenses differences ifrs us gaap relatively minor impact genentech share repurchases april genentechs board directors approved extension existing stock repurchase programme authorising genentech repurchase million shares genentechs common stock foratotal billion us dollars june since programmes inception genentech repurchased approximately million shares total approximately billion us dollars net cash outflow repurchases genentech common stock million us dollars million swiss francs million us dollars million swiss francs includes million us dollars prepaid share repurchase program manufacturing agreements lonza effective december genentech sold whollyowned subsidiary genentech espaa including themanufacturing facility porrio spain lonza group ltd lonza million us dollars part ofthis agreement genentech entered shortterm supply contract lonza production ofavastin using portion production capacity porrio facility time genentech entered supply agreement manufacture certain genentech products lonzas facility construction singapore currently expected receive us food drug administration fda licensure genentech committed fund precommissioning production qualification costs atthis facility upon fda licensure genentech committed purchase products successfully manufactured facility period three years commissioning facility estimated totalcost pre postcommissioning commitments approximately million us dollars genentech also received exclusive option purchase lonza singapore facility period one year fda licensure purchase price million usdollars regardless ofwhether purchase option exercised genentech obliged make amilestone payment ofmillion us dollars certain performance milestones met facility constructed foraccounting purposes due nature supply agreement genentechs involvement construction buildings genentech considered owner assets theconstruction period even though funds construct building shell infrastructure costs paid lonza wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements genentech also entered loan agreement lonza advance million us dollars lonza construction singapore facility december total million us dollars advanced million us dollars genentech exercises option purchase facility outstanding advances may offset purchase price genentech exercise purchase option advances may offset supply purchases december construction progress totalling million swiss francs million swiss francs capitalised net financing obligation totalling million swiss francs million swiss francs recorded leasing arrangements december genentech entered master lease agreement slough ssf llc subsequently acquired health care properties hcp development property adjacent genentechs south san francisco site development includes total eight buildings subject separate agreements contemplated master lease agreement hcp developer construct building shell building genentech finish interior building labora tory office space applicable construction first buildings completed point lease term buildings deemed begin construction final buildings com pleted lease term expires twelve years occupation final building genentech two fiveyear renewal options building option purchase various buildings different dates genentech also right first refusal respect building ortheentire development hcp consider selling part development december based status development date total carrying value property plant equipment agreement million swiss francs million swiss francs carrying value leasing obligation million swiss francs million swiss francs estimates total future minimum lease payments anticipated entire master lease agreement shown estimated total future minimum lease payments hcp leases millions chf total minimum principal ground lease interest lease payment within one year one five years five years total matters details genentech matters given following notes acquisition tanox note changes group organisation note genentechs equity compensation plans note genentech legal cases note genentechs senior notes commercial paper program note chugai effective october roche group chugai completed alliance create leading research driven japanese pharmaceutical company formed merger chugai roches japanese pharmaceuticals subsidiary nippon roche merged company known chugai fully consolidated subsidiary group december groups interest chugai common stock chugai publicly traded listed tokyo stock exchange stock code tse chugai prepares financial statements conformity accounting principles generally accepted japan jgaap filed quarterly basis tokyo stock exchange roches relationship chugai chugai entered certain agreements roche discussed basic alliance agreement part basic alliance agreement signed december roche andchugai entered certain arrangements covering future operation governance chugai amongst matters cover following areas structuring alliance roches rights shareholder roches rights nominate members chugais board directors certain limitations roches ability buy sell chugais common stock chugai issues additional shares common stock connection convertible debt equity compensation plans may issue additional shares purposes affects roches percentage ownership interest basic alliance agreement provides amongst matters chugai guaranteeroches right maintain shareholding percentage chugai less licensing agreements japan umbrella rights agreement signed december chugai hasexclusive rights market roches pharmaceutical products japan chugai also first right refusalon development marketing japan development compounds advanced roche rest world umbrella rights agreement signed may roche right first refusal development marketing chugais development compounds markets outside japan excluding south korea chugai decides requires partner activities agreements roche chugai signed series separate agreements certain specific products depending specific circumstances terms agreement may result inpayments armslength basis roche chugai following matters upfront payments right first refusal license product exercised milestone payments dependent upon achievement agreed performance targets royalties future product sales specific product agreements may also cover manufacture supply respective products tomeet partys clinical andor commercial requirements armslength basis research collaboration agreements roche chugai entered research collaboration agreements areas small molecule synthetic drug research biotechnology based drug discovery differences ifrs jgaap due certain consolidation entries differences requirements international financial reporting standards ifrs jgaap differences chugais standalone financial results onajgaap basis financial results chugai consolidated roche group accordance withifrs acquisition roche interest chugai treated business combination ifrs forjgaap alliance treated merger chugai nippon roche therefore jgaap results chugai include goodwill fair value adjustments recorded roches results quantified table moreover acquisition accounting includes roches fair value adjustments based applicable ifrs time therefore impact net income needs added back noncontrolling interest calculations roches ifrs results wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements roches ifrs results depreciation property plant equipment calculated using straightline method chugais jgaap results reducing balance method used additionally certain income andexpenses notably restructuring costs required jgaap reported extraordinary items inchugais jgaap results extraordinary items reported operating profit line rochesifrs results items normally included part operating profit treated extraordinary orexceptional items differences ifrs jgaap havearelatively minor impact reconciliation chugai results jpy chf jpy chf billions millions billions millions operating profit jgaap basis depreciation basis difference classification extraordinary items differences consolidation entries operating profit acquisition accounting impacts ifrs basis depreciation property plant equipment amortisation intangible assets arising business combinations operating profit ifrs basis add deduct corporate nonoperating items ifrs basis financial income financing costs income taxes net income ifrs basis noncontrolling interest calculation add back acquisition accounting impact net income net income excluding acquisition accounting noncontrolling interest percentage average year income applicable noncontrolling interest ifrs basis translated jpy chf chf dividends dividends distributed third parties holding chugai shares totalled million swiss francs million swiss francs recorded noncontrolling interests see note dividends paid chugai roche eliminated consolidation intercompany items tender offer chugai shares may group announced tender offer acquire additional common shares chugai increase groups ownership chugais issued shares tender offer fully subscribed offer price japanese yen per share june group acquired million common shares chugai cash consideration billion japanese yen million swiss francs taking account shares previously repurchased chugai retired thegroups ownership chugais outstanding shares increased total cash outflow mil lion swiss francs including directly attributable costs million swiss francs recorded equity change ownership interest subsidiaries chugai share repurchases share repurchases chugai repurchased million common sharesfor total consideration billion japanese yen million swiss francs result groups ownership chugai increased matters details chugais equity compensation plans given note details series chugai pharmaceutical unsecured convertible bonds given note financial income financing costs financial income millions chf year ended december gains sale equity securities losses sale equity securities dividend income gains losses equity security derivatives net writedowns impairments equity securities net income equity securities interest income gains sale debt securities losses sale debt securities gains losses debt security derivatives net net gains losses financial assets fairvaluethroughprofitorloss writedowns impairments debt securities net interest income income debt securities expected return plan assets defined benefit plans foreign exchange gains losses net gains losses foreign currency derivatives net net foreign exchange gains losses net financial income expense total financial income financing costs millions chf year ended december interest expense amortisation discount debt instruments gains losses debt derivatives net net gains losses financial liabilities fairvaluethroughprofitorloss time cost provisions interest cost defined benefit plans total financing costs wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements net financial income millions chf year ended december financial income financing costs net financial income financial result treasury management financial result pension management net financial income net gains losses financial liabilities fairvaluethroughprofitorloss includes change fair value attributable changes liabilities credit risk component calculated comparing difference present value future cash flows bonds discounted using swap yield curve based libor market prices bonds due widening credit spread relative swap yield curve change fair value attributable changes liabilities credit risk component gain million swiss francs gain million swiss francs cumulative change fair value attributable change credit risk since issuance instruments gain million swiss francs gain million swiss francs interest expense onliabilities fairvaluethroughprofitorloss million swiss francs million swiss francs interest income includes interest financial assets held fairvaluethroughprofitandloss amount million swiss francs million swiss francs income taxes income tax expenses millions chf current income taxes adjustments recognised current tax prior periods deferred income taxes total income expense since group operates internationally subject income taxes many different tax jurisdictions thegroup calculates average expected tax rate weighted average tax rates tax juris dictions group operates rate changes year year due changes mix groups taxable income changes local tax rates average expected rate decreased compared due lower taxable profits certain high tax jurisdictions certain onetime effects notably favourable change tax rates basel effective groups effective tax rate canbe reconciled groups average expected tax rate follows reconciliation groups effective tax rate average expected tax rate tax effect utilisation previously unrecognised tax losses nontaxable incomenondeductible expenses genentech equity compensation plans differences groups effective tax rate exceptional items profit income profit income tax taxes tax rate tax taxes tax rate mchf mchf mchf mchf roche excluding genentech chugai genentech chugai groups effective tax rate exceptional items major legal cases changes group organisation groups effective tax rate income tax assets liabilities millions chf current income taxes assets liabilities net current income tax assets liabilities deferred income taxes assets liabilities net deferred income tax assets liabilities disclosed note postemployment benefit assets deferred tax liabilities equity restated december balance sheet following adoption ifric interpretation reconciliation previously published balance sheet provided note deferred income tax assets recognised tax loss carry forwards extent realisation oftherelated tax benefit probable group unrecognised tax losses including valuation allowances asfollows unrecognised tax losses expiry millions chf applicable applicable amount tax rate amount tax rate within one year one five years five years total unrecognised tax losses deferred income tax liabilities established withholding tax taxes would payable unremitted earnings certain foreign subsidiaries amounts currently regarded permanently reinvested unremitted earnings totalled billion swiss francs december billion swiss francs deferred income tax assets liabilities deferred income tax charges credits attributable tothe following items wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements deferred income taxes movements recognised net assets liabilities millions chf property plant equipment temporary intangible assets differences total year ended december net deferred income tax asset liability january restated bioveris acquisition tanox acquisition business combinations charged credited income statement charged credited equity recognised gains losses charged credited equity equity compensation plans transactions shareholders currency translation effects net deferred income tax asset liability december year ended december net deferred income tax asset liability january ventana acquisition business combinations charged credited income statement charged credited equity recognised gains losses charged credited equity equity compensation plans transactions shareholders currency translation effects net deferred income tax asset liability december business combinations acquisitions ventana ventana medical systems inc ventana publicly owned us company based tucson arizona listed nasdaq symbol vmsi prior february group owned shares ventana representing outstanding shares ventana effective february group acquired outstanding shares ventana obtained control ventana ventana develops manufactures markets instrumentreagent systems automate slide preparation andstaining clinical histology drug discovery laboratories ventanas clinical systems used diagnosis treatment cancer infectious diseases drug discovery systems used pharmaceutical biotechnology companies accelerate discovery new drug targets evaluate safety new drug compounds ventana reported part diagnostics operating segment acquisition ventana leader fastgrowing histopathology tissuebased diagnostics business segment allow group broaden diagnostic offerings complement world leadership bothinvitro diagnostic systems oncology therapies purchase consideration million swiss francs cash allocated follows ventana acquisition net assets acquired millions chf carrying value fair value carrying value prior acquisition adjustments upon acquisition property plant equipment goodwill intangible assets product intangibles use product intangibles available use inventories deferred income taxes cash net assets liabilities net identifiable assets noncontrolling interests goodwill purchase consideration goodwill represents strategic value group entering tissue diagnostics business area italsorepresents premium paid traded market price obtain control business none goodwill recognised expected deductible income tax purposes noncontrolling interests ventana measured proportionate share ventanas identifiable net assets fair value net assets liabilities includes receivables fair value million swiss francs included within fair value allowance doubtful trade accounts receivable million swiss francs finance lease receivables totalling million swiss francs also included total gross amount due contracts million swiss francs group recognised gain million swiss francs result measuring fair value equity interest ventana held prior acquisition date gain included financial income directly attributable acquisitionrelated costs million swiss francs incurred transaction reported within general administration expenses current period part operating result diagnostics operating segment subsequent effective date acquisition february group purchased remaining shares ventana held third parties give group interest ventana cash consideration million swiss francs recorded equity change ownership interest subsidiaries acquisitions effective may group acquired controlling interest piramed ltd piramed privately owned biotechnology company based uk piramed discovers develops newmedicines primarily treatment cancer immune inflammatory disorders arthritis asthma piramed leading company discovery highly selective drugs inhibit different isoforms pik enzymes increasingly recognised key players wide variety disease processes piramed reported part roche pharmaceuticals operating segment acquisition strengthen groups research development pipeline oncology inflammatory disease purchase consideration million swiss francs consisted million swiss francs paid cash million swiss francs contingent consideration arrangement contingent consideration arrangement consists potential milestone payment million us dollars due upon commencement phase ii clinical trials pirameds oncology programme liability million us dollars million swiss francs recognised acquisition date based managements best estimate theprobabilityadjusted expected cash outflow arrangement december amount recognised arrangement unchanged based recent management estimates wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements effective september group acquired controlling interest arius research inc arius publicly owned canadian biotechnology company listed tsx symbol ari arius discovers develops antibody therapeutics treat cancer diseases including proprietary antibody platform rapidly identifies selects antibodies based functional ability affect disease progressing clinical development arius reported part ofthe roche pharmaceuticals operating segment acquisition strengthen groups develop mental portfolio initially within areas oncology inflammatory diseases new technique offers potentially broad therapeutic applications purchase consideration million swiss francs paid cash effective september group acquired controlling interest mirus bio corporation mirus privately owned us biotechnology company based madison wisconsin mirus renamed roche madison inc focuses discovery development innovative nucleic acid based techno logies including proprietary rnai ribonucleic acid interference delivery platform mirus reported part roche pharmaceuticals operating segment acquisition strengthen groups research development pipeline rnai therapeutics provides capabilities target complex diseases cancer respiratory metabolic disorders purchase consideration million swiss francs paid cash minor business combinations total purchase consideration million swiss francs combined purchase consideration acquisitions allocated shown acquisitions net assets acquired millions chf carrying value fair value carrying value prior acquisition adjustments upon acquisition property plant equipment intangible assets product intangibles use product intangibles available use technology intangibles use deferred income taxes cash net assets liabilities net identifiable assets goodwill purchase consideration goodwill represents control premium synergies obtained groups existing business none goodwill recognised expected deductible income tax purposes fair value net assets liabilities includes receivables fair value million swiss francs expected fully collectable directly attributable transaction costs million swiss francs incurred transactions arereported within general administration expenses current period part operating result roche pharmaceuticals operating segment acquisitions impact results millions chf revenues inventory external fair value amortisation customers adjustment intangible assets operating profit net income impact reported results piramed arius mirus pharmaceuticals division ventana minor business combinations diagnostics division group estimated impact results acquisition assumed effective january piramed arius mirus pharmaceuticals division ventanaa minor business combinations diagnostics division group figures exclude directly attributable transaction costs million swiss francs related acquisitions pharmaceuticals division million swiss francs related acquisitions diagnostics division corresponding tax impacts also excluded figures exclude inventory fair value adjustments million swiss francs integration costs million swiss francs related ventana corresponding tax impacts also excluded acquisitions net cash outflow millions chf cash consideration cash net cash paid acquired company outflow ventana acquisitions total cash consideration paid ventana include subsequent payment million swiss francs purchase remaining shares ventana held third parties give group interest ventana reported financing cash flow cash flow statement within heading change ownership interest subsidiaries wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements future acquisitions group announced number minor business combinations expected completed first half subject shareholder approval regulatory clearance appropriate total purchase consideration excluding transaction costs estimated approximately million swiss francs cash funds provided groups cash hand time closing acquisitions bioveris effective june group acquired controlling interest bioveris corporation bioveris publicly owned us company listed nasdaq symbol biov bioveris healthcare biosecurity company based gaithersburg maryland specialises developing proprietary technologies diagnostics bioveris reported part diagnostics operating segment purchase consideration million swiss francs consisted million swiss francs cash million swiss francs directly attributable costs allocated asfollows bioveris acquisition net assets acquired millions chf carrying value fair value carrying value prior acquisition adjustments upon acquisition property plant equipment intangible assets product intangibles use deferred income taxes cash net assets liabilities net identifiable assets goodwill purchase consideration goodwill represents assets recognised separately measured reliably synergies canbe obtained groups existing electrochemiluminescence ecl immunochemistry business italso represents premium paid traded market price obtain control business following acquisition restructuring expenses million swiss francs incurred reported within general administration expenses part operating result diagnostics operating segment tanox effective august genentech acquired controlling interest tanox inc tanox apublicly owned us company listed nasdaq symbol tnox tanox isabiotechnology company based houston texas specialises discovery development biotherapeutics based monoclonal antibody technology genentech tanox working together collaboration novartis since develop commercialise xolair purchase consideration million swiss francs consisted million swiss francs cash million swiss francs directly attributable costs allocated follows tanox acquisition net assets acquired millions chf carrying value fair value carrying value prior acquisition adjustments upon acquisition property plant equipment intangible assets product intangibles use product intangibles available use deferred income taxes cash marketable securities net assets liabilities net identifiable assets goodwill purchase consideration goodwill represents assets recognised separately measured reliably earlystage research projects also represents premium paid traded market price obtain control business acquisitions effective march group acquired controlling interest therapeutic human polyclonals inc thp privately owned us biotechnology company based california germany thp reported part roche pharmaceuticals operating segment purchase considera tion paid million swiss francs cash effective may group acquired controlling interest life sciences majorityowned us subsidiary curagen corporation life sciences develops commercialises novel instrumentation highthroughput dna sequencing based branford connecticut life sciences reported aspart diagnostics operating segment purchase consideration paid million swiss francs cash consisted million swiss francs cash million swiss francs directly attributable costs effective august group acquired controlling interest nimblegen systems inc nimblegen privately owned us company nimblegen develops commercialises high density dna microarrays based madison wisconsin nimblegen reported part diagnostics operating segment purchase consideration million swiss francs cash minor business combinations total purchase consideration million swiss francs combined purchase consideration acquisitions allocated shown acquisitions net assets acquired millions chf carrying value fair value carrying value prior acquisition adjustments upon acquisition property plant equipment intangible assets product intangibles use product intangibles available use technology intangibles use deferred income taxes cash net assets liabilities net identifiable assets goodwill purchase consideration wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements goodwill represents assets recognised separately measured reliably earlystage research projects control premium synergies obtained groups existing business acquisitions net cash outflow millions chf cash consideration cash net cash paid acquired company outflow bioveris tanox acquisitions total changes group organisation described note july group announced offer purchase outstanding shares ofgenentech following closing transaction genentechs south san francisco site would become theheadquarters groups combined pharmaceuticals operations united states july group also announced roche pharmaceuticals business us would close manufacturing operations site nutley new jersey commercial operations would moved genentech theresearch site palo alto california would closed research activities transferred nutley genentech current status offer described note significant costs incurred connec tion proposed genentech transaction us reorganisation described disclosed separately income statement due materiality amounts order fairly present groups results costs restructuring programmes less material anddo funda mentally change groups organisation expensed current period reported within general andadministration expenses changes group organisation millions chf roche pharmaceuticals operating segment us reorganisation costs total roche pharmaceuticals operating segment genentech operating segment genentech employee retention program expenses total genentech operating segment total pharmaceuticals division total income tax benefit recorded respect changes group organisation million swiss francs see note roche pharmaceuticals us reorganisation costs incurred shown table independent completion proposed genentech transaction mainly relate theclosure palo alto site closure manufacturing nutley site also include costs associated reorganisation including transfer research operations palo alto activities roche pharmaceuticals us reorganisation costs millions chf employeerelated costs termination costs pensions postemployment benefits retention plans employee benefits employeerelated costs total employeerelated costs site closure costs impairment property plant equipment accelerated depreciation property plant equipment site closure costs total site closure costs reorganisation expenses total us reorganisation costs genentech employee retention program august genentech announced broadbased employee retention program consisting two retention plans together cover substantially employees company program estimated cost approximately million us dollars payable cash implemented lieu genentechs annual stock option grant timing payments related program depend outcome roche proposal merger genentech roche oran affiliate roche occurred june genentech pay retention bonus time accordance terms program costs retention program currently recognised straightline basis period august june merger genentech roche affiliate roche occurred june timing thepayments recognition expense depend terms merger totalcosts retention program million swiss francs million swiss francs expensed million swiss francs capitalised inventory recognised cost ofsales products manufactured initiation retention program sold genentech granted annual stock option award previous years total value retention pro gram costs would expensed four year vesting period amount expensed would approximately million swiss francs accordingly additional incremental costs incurred retention plan reported part changes group organisation since aredirectly attributable announcement roche proposal genentech employee retention program expenses millions chf marketing distribution research development general administration total included operating profit exceptional items changes group organisation total genentech employee retention program expenses wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements employee benefits employee remuneration millions chf wages salaries social security costs defined contribution postemployment plans operating expenses defined benefit postemployment plans equity compensation plans genentech employee retention program termination costs roche pharmaceuticals us reorganisation employee benefits employee remuneration included operating results expected return plan assets defined benefit postemployment plans interest cost defined benefit postemployment plans total employee remuneration employee benefits consist mainly life insurance schemes certain insurance schemes providing medical coverage longterm shortterm disability benefits charges employee benefits operating results included relevant expenditure line function expected returnon plan assets interest cost defined benefit plans included part financial income andfinancing costs respectively see note pensions postemployment benefits groups objective provide attractive competitive postemployment benefits employees whileat time ensuring various plans appropriately financed managing potential impacts groups longterm financial position employees covered pension plans sponsored group companies nature plans varies according legal regulations fiscal requirements market practice countries employees employed postemployment benefits consist mostly postretirement healthcare life insurance schemes principally united states postemployment benefit plans classified ifrs defined contribution plans group pays fixed contributions separate fund thirdparty financial institution legal constructive obligation pay contributions plans classified defined benefit plans even groups potential obligation relatively minor relatively remote possibility arising consequently groups postemployment benefit plans classified defined benefit plans forthe purpose financial statements defined contribution plans defined contribution plans typically consist payments employees group funds admin istered third parties payments group million swiss francs million swiss francs assets liabilities recognised groups balance sheet respect plans apartfrom regular prepayments accruals contributions withheld employees wages salaries groups contributions defined benefit plans groups major defined benefit plans located switzerland united states germany united kingdom japan plans usually established trusts independent group funded payments group employees cases notably major defined benefit plans ingermany plan unfunded group pays pensions retired employees directly financial resources current past service costs charged appropriate income statement heading within operating results pension plan administration funding overseen corporate level settlement gains losses resulting changes funding arrangements reported general administration expenses within corporate segment expected returns plan assets interest costs charged financial income financing costs respectively actuarial gains losses recorded directly equity recognition pension assets limited total present value future refunds plans reductions future contributions plans cumulative unrecognised past service costs adjustments arising limit recognition assets defined benefit plans recorded directly equity defined benefit plans expenses millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total current service cost past service cost gain loss curtailment gain loss settlement total operating expenses expected return plan assets interest cost total financial income expense total expense recognised income statement funding groups various defined benefit plans overseen corporate level qualified independ ent actuaries carry valuations regular basis major plans annually balance sheet datefor funded plans usually trusts independent groups finances net assetliability recognised groups balance sheet corresponds overunder funding plan adjusted unrecognised past service costs unfunded plans group meets pension obligations directly financial resources liability defined benefit obligation recorded groups balance sheet pension assets liabilities different defined benefit plans offset unless group legally enforceable right use surplus one plan settle obligations plan amounts recognised balance sheet postemployment benefits predominantly noncurrent reported noncurrent assets liabilities wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements defined benefit plans funding status december millions chf funded unfunded funded unfunded plans plans total plans plans total fair value plan assets defined benefit obligation funding unrecognised past service costs limit asset recognition reimbursement rights net recognised asset liability reported defined benefit plans reimbursement rights postemployment benefit assets postemployment benefit liabilities net recognised asset liability disclosed note postemployment benefit assets deferred tax liabilities equity restated december balance sheet following adoption ifric interpretation reconciliation previously published balance sheet provided note detailed information plan assets defined benefit obligation given defined benefit plans fair value plan assets reimbursement rights millions chf fair value reim fair value reim plan bursement plan bursement assets rights total assets rights total january expected return plan assets actuarial gains losses currency translation effects employer contributions employee contributions benefits paid funded plans past service cost business combinations divestment subsidiaries curtailments settlements december invested shares equity instruments bonds debentures debt instruments property assets total included within fair value plan assets thousand groups nonvoting equity securities fair value million swiss francs thousand nonvoting equity securities total fair value million swiss francs defined benefit plans defined benefit obligation millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total january current service cost interest cost employee contributions actuarial gains losses currency translation effects benefits paid funded plans benefits paid unfunded plans past service cost business combinations divestment subsidiaries curtailments settlements december funded plans unfunded plans actuarial assumptions actuarial assumptions unbiased mutually compatible estimates variables determine ultimate cost providing postemployment benefits set annual basis local management actuaries subject approval corporate management groups actuaries actuarial assumptions consist demographic assumptions matters mortality employee turnover andfinancial assumptions matters salary benefit levels interest rates return investments costs medical benefits group operates defined benefit plans many countries actuarial assumptions vary based upon local economic social conditions demographic assumptions significant demographic assumptions relate mortality rates thegroups actuaries use mortality tables take account historic patterns expected changes increases longevity mortality tables used major schemes germany heubeck tables g japan national census life table switzerland bvg united kingdom nonpensioners pac rated one year united kingdom pensioners pac rated one year united states rp projected rates employee turnover disability early retirement based historical behaviour within group companies financial assumptions based market expectations period obligations settled ranges assumptions used actuarial valuations significant plans countries stable currencies interest rates shown wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements defined benefit plans financial actuarial assumptions weighted weighted average range average range discount rates expected rates return plan assets expected rates salary increases medical cost trend rate discount rates used calculate discounted present value defined benefit obligation aredetermined reference market yields high quality corporate bonds government bonds incountries deep market corporate bonds currency term bonds consistent obligation discounted interest cost included income statement iscalculated multiplying discount rate defined benefit obligation expected returns plan assets based market expectations expected returns assets funded plans duration related obligation takes account split plan assets equities bonds property investments calculation includes assumptions concerning expected dividend interest income realised unrealised gains plan assets taxes adminis tration costs borne plan based longterm market expectations actual per formance continually monitored corporate management due longterm nature obligations assumptions used matters returns investments may necessarily consistent withrecent historical patterns expected return plan assets included income statement calculated multiplying expected rate return fair value plan assets difference bet ween expected return actual return twelve month period actuarial gainloss recorded directly equity actual return plan assets loss million swiss francs gain million swiss francs expected rates salary increases used calculate defined benefit obligation current service cost included income statement based latest expectation historical behaviour within group companies medical cost trend rates used calculate defined benefit obligation current service cost included income statement postemployment medical plans take account benefits setout plan terms expected future changes medical costs since groups major post employment medical plans us employees rates driven developments united states effect one percentage point increase decrease medical cost trend rate shown defined benefit plans sensitivity medical cost trend rate millions chf current service cost interest cost defined benefit obligation funding summary fiveyear summary funding status groups defined benefit plans shown table defined benefit plans summary funding status millions chf funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation increase decrease funding status arising experience adjustments fair value plan assets defined benefit obligation increase decrease funding status arising changes actuarial assumptions fair value plan assets defined benefit obligation cash flows group incurred cash flows defined benefit plans shown table defined benefit plans cash flows millions chf employer contributions funded plans benefits paid unfunded plans total cash inflow outflow based recent actuarial valuations group expects employer contributions funded plans approximately million swiss francs include estimated million swiss francs additional contributions benefits paid unfunded plans estimated approximately million swiss francs amounts recorded equity actuarial gains losses recognised statement recognised income expense losses million swiss francs gains million swiss francs total amount december accumulated loss million swiss francs accumulated gain million swiss francs addition recognition pension assets limited total present value future refunds plans reductions future contributions plans cumulative unrecognised past service costs adjustments arising limit asset recognition recorded directly equity adjustment increase million swiss francs decrease million swiss francs wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements employee stock options equity compensation benefits group operates several equity compensation plans including separate plans genentech chugai effective january group adopted ifrs sharebased payment amongst matters standard requires fair value equity compensation plan awards granted employees estimated grant date recorded expense vesting period expense charged againstthe appropriate income statement heading expenses equity compensation plans millions chf cost sales marketing distribution research development general administration total operating expenses share option plans roche option plan genentech stock option plan chugai stock acquisition rights total share option plans equity compensation plans roche connect genentech employee stock purchase program roche stocksettled stock appreciation rights roche performance share plan roche stock appreciation rights total equity compensation plans total operating expenses equitysettled cashsettled cash inflow outflow equity compensation plans millions chf share option plans roche option plan genentech stock option plan chugai stock acquisition rights total share option plans equity compensation plans roche connect genentech employee stock purchase program roche stocksettled stock appreciation rights roche performance share plan roche stock appreciation rights total equity compensation plans total cash inflow outflow equitysettled cashsettled roche longterm group implemented new global longterm incentive programme whichisavailable certain directors management employees selected discretion group programme consists stocksettled stock appreciation rights ssars group alternative granting awards existing roche option plan share option plans roche option plan awards plan give employees right purchase nonvoting equity securities exercise price specified grant date options nontradable equitysettled awards sevenyear duration vest phased basis three years subject continued employment group covers obligations purchasing nonvoting equity securities derivatives thereon see note introduction roche longterm number options granted roche option plan significantly reduced eligible employees receive roche stocksettled stock appreciation rights instead roche option plan movement number options outstanding number weighted average number weighted average options exercise price options exercise price thousands chf thousands chf outstanding january granted forfeited exercised expired outstanding december exercisable wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements roche option plan terms options outstanding december options outstanding options exercisable number weighted average weighted average number weighted average outstanding years remaining exercise exercisable exercise year grant thousands contractual life price chf thousands price chf total genentech stock option plan genentech stock option plan adopted amended thereafter april genentechs shareholders approved equity incentive plan plans allow granting various stock options incentive stock options stock purchase rights employees directors consultants genentech incentive stock options stock purchase rights granted plan date options granted nontradable equitysettled awards tenyear duration vest phased basis four years subject continued employment genentech stock option plan movement number options outstanding number weighted average number weighted average options exercise price options exercise price millions usd millions usd outstanding january granted forfeited exercised expired outstanding december exercisable genentech stock option plan terms options outstanding december options outstanding options exercisable number weighted average weighted average number weighted average outstanding years remaining exercise exercisable exercise range exercise prices usd millions contractual life price usd millions price usd total chugai stock acquisition rights chugai adopted stock acquisition rights programme theprogramme allows granting rights employees directors chugai right entitles holder purchase chugai shares specified exercise price options nontradable equitysettled awards tenyear duration vest two years chugai stock acquisition rights movement number rights outstanding weighted average weighted average number exercise price number exercise price options jpy options jpy outstanding january granted forfeited exercised expired outstanding december exercisable chugai stock acquisition rights terms rights outstanding december rights outstanding rights exercisable weighted average weighted average weighted average number years remaining exercise number exercise year grant outstanding contractual life price jpy exercisable price jpy total issues share options issues share options including methodology used calculate fair value main inputs valuation models described issues share option plans roche genentech stock option plan option plan number options granted thousand million underlying equity roche nonvoting equity securities genentech common stock currency swiss francs us dollars vesting period progressively progressively years years contractual life years years weighted average fair value options issued option pricing model used binomial binomial inputs option pricing model share price grant date exercise price expected volatility expected dividend yield early exercise factor expected exit rate volatility roche options determined primarily reference historically observed prices lying equity volatility genentech options determined primarily reference implied volatility genentechs traded options riskfree interest rates derived zero coupon swap rates grant date taken datastream early exercise factor describes ratio expected market price exercise date exercise price early exercises expected based historically observed behaviour wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements equity compensation plans roche connect programme enables employees worldwide except united states certain countries make regular deductions salaries purchase nonvoting equity securities administered independent third parties group contributes programme allows employees purchase nonvoting equity securities discount usually administrator purchases necessary nonvoting equity securities directly market december administrator held million nonvoting equity securities million programme operational since october year cost plan million swiss francs million swiss francs reported within relevant expenditure line function genentech employee stock purchase program espp genentech employee stock purchase programme allows employees purchase genentechs common stock lower market value grant date purchase date total million shares genentech common stock purchased million shares resulting cash inflow million swiss francs million swiss francs year cost plan million swiss francs million swiss francs reported within relevant expenditure line function roche stocksettled stock appreciation rights introduction roche longterm thegroup offers stocksettled stock appreciation rights ssars certain directors management employees selected discretion group ssars give employees right receive nonvoting equity securities reflecting value appreciation market price nonvoting equity securi ties grant date exercise date options nontradable equitysettled awards sevenyear duration vest phased basis three years subject continued employment group covers obligations purchasing nonvoting equity securities derivatives thereon seenote roche ssars movement number rights outstanding number weighted average number weighted average rights exercise price rights exercise price thousands chf thousands chf outstanding january granted forfeited exercised expired outstanding december exercisable roche ssars terms rights outstanding december rights outstanding rights exercisable weighted weighted number weighted average average number average outstanding years remaining exercise exercisable exercise year grant thousands contractual life price chf thousands price chf total weighted average fair value options granted calculated using binomial model inputs model consistent used roche option plan awards given previously resulting weighted average fair value per right chf giving total fair value million swiss francs charged vesting period three years roche performance share plan group offers future nonvoting equity security awards discretion board directors cash equivalent certain directors key senior managers theprogramme established beginning effect three years theboard directors approved new threeyear cycle roche performance share plan psp operateduring additional cycles psp similar conditions approved operate terms awards set table amount nonvoting equity securities allocated depend upon individuals salary level achievement performance targets linked groups total shareholder return shares nonvoting equity securities combined relative groups peers threeyear period date grant discretion board directors nontradable equitysettled awards award result zero two nonvoting equity securities depending upon achievement performance targets roche performance share plan terms outstanding awards december number awards outstanding thousands vesting period years years years allocated recipients feb feb feb fair value per unit grant chf total fair value grant chf millions weighted average fair value awards granted calculated using monte carlo simulation input parameters model covariance matrix roche individual companies peer group based threeyear history riskfree rate valuation also takes account defined rank performance structure determines payout psp roche stock appreciation rights employees certain north american subsidiaries group receive stock appreciation rights sars part compensation sars nontradable cashsettled awards may exercised vesting period one three years cash payment based upon amount market price groups american depositary receipts adrs point exercise exceeds strike price grant price issuance following implementa tion roche longterm see group plan award cashsettled sars awards made since january ratio adrs nonvoting equity securities genussscheinewas changed information restated change roche stock appreciation rights millions chf liability december intrinsic value vested rights december roche stock appreciation rights terms rights outstanding december rights outstanding exercisable number outstanding exercisable weighted average year grant thousands expiry price usd feb feb total fair value december calculated using binomial model inputs model theadr price december usd change exchange ratio january exercise prices given table inputs consistent used roche option plan awards given previously wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements property plant equipment property plant equipment movements carrying value assets millions chf buildings land machinery construction land improvements equipment progress total january cost accumulated depreciation impairment net book value year ended december january additions disposals bioveris acquisition tanox acquisition business combinations transfers depreciation charge impairment charge currency translation effects december cost accumulated depreciation impairment net book value year ended december january additions disposals ventana acquisition business combinations divestments subsidiaries transfers depreciation charge impairment charge currency translation effects december cost accumulated depreciation impairment net book value impairment charges arise changes estimates future cash flows expected result use asset eventual disposal factors changes planned use buildings machinery equipment closure facilities presence absence competition technical obsolescence could result shortened useful lives impairment impairment charges million swiss francs million swiss francs reported part cost sales impairment charges million swiss francs zero reported part changes group organisation see note borrowing costs totalling million swiss francs using rate million swiss francs using arate capitalised property plant equipment leasing arrangements group lessee finance leases december capitalised cost property plant equipment finance leases million swiss francs million swiss francs net book value assets million swiss francs million swiss francs finance leases future minimum lease payments noncancellable leases millions chf future minimum lease present value future payments minimum lease payments within one year one five years five years total future finance charges total future minimum lease payments undiscounted addition genentech leasing arrangements disclosed note operating leases group companies party number operating leases mainly plant machinery including motor vehicles certain shortterm property rentals arrangements impose significant restrictions group total operating lease rental expense million swissfrancs million swiss francs operating leases future minimum lease payments noncancellable leases millions chf within one year one five years five years total minimum payments leasing arrangements group lessor finance leases certain assets mainly diagnostics instruments leased third parties finance lease arrangements assets reported receivables amount equal net investment thelease lease income finance leases recognised term lease based effective interest rate method wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements finance leases future minimum lease payments noncancellable leases millions chf present value future gross investment lease minimum lease payments within one year one five years five years total unearned finance income na na unguaranteed residual value na na net investment lease accumulated allowance uncollectible minimum lease payments million swiss francs million swiss francs contingent rents recognised income operating leases certain assets mainly diagnostics instruments leased third parties operating lease arrangements assets reported within property plant equipment lease income operating leases recognised lease term straight line basis operating leases future minimum lease payments noncancellable leases millions chf within one year one five years five years total minimum payments december machinery equipment original cost million swiss francs million swiss francs net book value million swiss francs million swiss francs leased third parties contingent rent recognised income capital commitments group noncancellable capital commitments purchase construction property plant equipment totalling billion swiss francs billion swiss francs addition genentechs capital commitments respect manufacturing agreements lonza leasing arrangements described note goodwill goodwill movements carrying value assets millions chf january bioveris acquisition tanox acquisition ventana acquisition business combinations impairment charge currency translation effects december allocated following cashgenerating units pharmaceuticals division roche pharmaceuticals genentech chugai total pharmaceuticals division diagnostics division diabetes care professional diagnostics molecular diagnostics applied science tissue diagnostics strategic goodwill held divisional level allocated business areas total diagnostics division total group accumulated impairment losses goodwill goodwill arising investments associates classified part investments associates see note goodwill impairment testing pharmaceuticals division divisions reportable operating segments cashgenerating units used testing goodwill genentech chugai recoverable amount based fair value less costs sell determined reference publicly quoted share prices genentech chugai shares goodwill roche pharmaceuticals significant comparison groups total carrying value goodwill diagnostics division divisions business areas cashgenerating units used testing goodwill goodwill arising corangeboehringer mannheim acquisition part goodwill ventana acquisition recorded monitored divisional level relates strategic development whole division meaningfully allocated divisions business areas therefore cash generating unit goodwill entire division recoverable amount used impairment testing isbased value use cash flow projections used based recent business plans approved management assume significant changes organisation division include manage ments latest estimates sales volume pricing production operating costs reflect past experience projected five years estimates tissue diagnostics business area projected ten years management believes reflects longterm nature business cash flow projections used extend beyond managements recent business plans discount rate used based rate derived capital asset pricing model using data swiss capital markets including swiss federal government tenyear bonds swiss market index weighted average tax rate used calculations management believes reasonably possible change key assumptions would cause carrying value goodwill exceed recoverable amount wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements intangible assets intangible assets movements carrying value assets millions chf product product intangibles technology intangibles available intangibles use use use total january cost accumulated amortisation impairment net book value year ended december january bioveris acquisition tanox acquisition business combinations additions disposals amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocation operating segment roche pharmaceuticals genentech chugai diagnostics total group year ended december january ventana acquisition business combinations additions disposals amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocation operating segment roche pharmaceuticals genentech chugai diagnostics total group significant intangible assets december millions chf operating net book remaining segment value amortisation period product intangibles use tanox acquisition genentech years chugai acquisition chugai years corangeboehringer mannheim acquisition diagnostics years igen acquisition diagnostics years ventana acquisition diagnostics years product intangibles available use alnylam alliance roche pharmaceuticals na ventana acquisition diagnostics na classification amortisation impairment expenses millions chf amortisation impairment amortisation impairment cost sales pharmaceuticals diagnostics research development pharmaceuticals diagnostics total internally generated intangible assets group currently internally generated intangible assets development criteria recognition asset met intangible assets indefinite useful lives group currently intangible assets indefinite useful lives impairment intangible assets impairment charges arise changes estimates future cash flows expected result use asset eventual disposal factors presence absence competition technical obsolescence lower anticipated sales products capitalised rights could result shortened useful lives impairment roche pharmaceuticals operating segment impairment charge million swiss francs recorded first half million swiss francs recorded second half relate product intangibles available use follow decisions terminate development three compounds alliance partners assets concerned yet amortised fully writtendown charges diagnostics operating segment impairment charge million swiss francs recorded second half relating product intangible assets use followed theregular updating divisions business plans technology assessments second half theassets written recoverable amount million swiss francs based value usecalculation using discount rate genentech operating segment impairment charge million swiss francs recorded second half relates decision terminate development compounds two alliance partners roche pharmaceuticals operating segment impairment charge million swiss francs recorded first half relates decision terminate development one compound alliance partner assets concerned yet amortised fully writtendown charges wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements intangible assets yet available use mostly represent inprocess research development assets acquired either inlicensing arrangements business combinations separate purchases asat december carrying value assets pharmaceuticals division million swiss francs amount approximately represents projects potential decision points withinthe next twelve months certain circumstances could lead toimpairment due inherent uncertainties research development process assets particularly risk impairment theproject question result commercialised product potential commitments alliance collaborations group party inlicensing similar arrangements alliance partners arrangements may require group make certain milestone similar payments dependent upon achievement agreed objectives performance targets defined collaboration agreements groups current estimate future thirdparty commitments payments set table figures risk adjusted meaning include potential payments arise assuming projects currently development successful timing based groups current best estimate figures include potential commitments within group mayarise roche pharmaceuticals genentech chugai businesses potential future thirdparty collaboration payments december millions chf pharmaceuticals diagnostics group within one year one two years two three years total associates groups investments associates accounted using equity method goodwill arising investments associates classified part investments associates investments associates millions chf share net income balance sheet value total investments associates group significant investments associates material transactions thegroup associates additional information associates given note financial longterm assets financial longterm assets millions chf availableforsale investments heldtomaturity investments loans receivable longterm trade receivables restricted cash total financial longterm assets longterm employee benefits total longterm assets financial longterm assets held strategic purposes classified noncurrent available forsale investments mainly equity investments unquoted equity investments classified available forsale generally measured cost fair value measured reliably primarily investments private biotechnology companies kept part groups strategic alliance efforts carrying value equity investments held cost million swiss francs million swissfrancs average effective interest rate heldtomaturity investments loansreceivable comprise loans third parties term one year inventories inventories millions chf raw materials supplies work process finished goods intermediates less provision slowmoving obsolete inventory total inventories expenses relating inventories expensed cost sales totalled million swiss francs million swiss francs accounts receivable accounts receivable millions chf trade accounts receivable notes receivable less allowances total accounts receivable wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements december accounts receivable include amounts denominated us dollars equivalent billion swiss francs billion swiss francs amounts denominated euros equivalent billion swiss francs billion swiss francs net bad debt expense million swiss francs million swiss francs significant concentrations within trade receivables counterparty credit risk described note current assets current assets millions chf accrued interest income derivative financial instruments restricted cash total financial current assets prepaid expenses total nonfinancial current assets total current assets restricted cash includes million swiss francs surety bond posted genentech con nection city hope litigation see note following settlement litigation entirety ofthepledged amount became unrestricted cash available use genentechs operations thethird quarter marketable securities marketable securities millions chf financial assets fairvaluethroughprofitorloss heldfortrading investments bonds debentures designated fairvaluethroughprofitorloss bonds debentures money market instruments time accounts three months investments total financial assets fairvaluethroughprofitorloss availableforsale financial assets shares bonds debentures money market instruments time accounts three months investments total availableforsale financial assets total marketable securities marketable securities held fund management purposes classified current primarilydenominated us dollars euros investments held strategic purposes classified asnoncurrent see note shares consist primarily readily saleable equity securities bonds debentures carrying values contract maturity average effective interest rate debt securities shown bonds debentures millions chf average effective average effective contracted maturity amount interest rate amount interest rate within one year one five years five years total bonds debentures money market instruments generally fixed interest rates ranging depending upon currency denominated contracted tomature within one year december cash cash equivalents cash cash equivalents millions chf cash cash hand current call accounts cash equivalents time accounts maturity three months less total cash cash equivalents accounts payable accounts payable millions chf trade accounts payable taxes payable dividends payable accounts payable total accounts payable wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements accrued current liabilities accrued liabilities current liabilities millions chf deferred income accrued payroll related items interest payable derivative financial instruments accrued liabilities total accrued current liabilities derivative financial instruments group uses derivative financial instruments part risk management trading strategies thisisdiscussed note derivative financial instruments carried fair value methods used fordetermining fair value described note derivative financial instruments millions chf assets liabilities foreign currency derivatives forward exchange contracts swaps interest rate derivatives swaps derivatives total derivative financial instruments hedge accounting groups accounting policy hedge accounting described note requires qualify hedge accounting hedging relationship must meet several strict conditions documentation probability occurrence hedge effectiveness reliability measurement described note group financial risk management policies foreign exchange risk interest rate risk market risk credit risk liquidity risk deemed appropriate certain risks aremanaged use derivatives many transactions considered hedges economic terms required conditions met relationship qualify hedge accounting case hedging instrument hedged item reported independently hedging relationship means derivatives reported fair value changes infairvalue included financial income group generally limits use hedge accounting certain significant transactions consequently december group fair value hedges cash flow hedges hedges net investment eign entity meet strict requirements qualify hedge accounting apart described group hedged fixedterm debt instruments interest rate swaps december instruments designated qualify fair value hedges recorded balance sheet asset fair value million swiss francs asset million swiss francs gain million swiss francs recorded interest rate swaps gain mil lion swiss francs fair value hedge highly effective since inception result interest rate swaps largely offset changes fair value hedged debt instruments genentech nonus dollar cash flows future royalty income development expenses expected next one five years hedge part foreign exchange risk genentech enters derivative financial instruments options forward contracts genentech equity investments various biotechnology companies subject greater risk market fluctuation stock market general manage part exposure genentech enters derivative financial instruments zero cost collars forward contracts december instruments designated qualify hedge accounting recorded assets fair value million swiss francs assets million swiss matters also described genentechs annual report quarterly sec filings movements fair value reserve designated cash flow hedges included note provisions contingent liabilities provisions movements recognised liabilities millions chf legal environmental restructuring employee provisions provisions provisions provisions provisions total year ended december january additional provisions created unused amounts reversed utilised year unwinding discount currency translation effects december current portion noncurrent portion total provisions year ended december january additional provisions created unused amounts reversed utilised year unwinding discount currency translation effects december current portion noncurrent portion total provisions expected outflow resources within one year one two years two three years three years total provisions wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements major legal cases income expense major legal cases disclosed separately income statement due mate riality amounts order fairly present groups results income million swiss francs wasrecorded following april california supreme court decision city hope litigation see consists million us dollars released income favourable litigation settlement net amounts recorded respect final settlement negotiations city hope national medical center costs litigation matters less material expensed current period andreported within general administration expenses total income tax expense recorded respect ofmajor legal cases million swiss francs see note legal provisions legal provisions consist number separate legal matters including claims arising trade various group companies majority cash outflows matters expected occur within thenext one three years although dependent development various litigations significant provisions discounted time value money material environmental provisions provisions environmental matters include various separate environmental issues number countries nature amounts timing outflows difficult predict estimated timings cash outflows shown table significant provisions discounted time value money material restructuring provisions arise planned programmes materially change scope business undertaken group manner business conducted provisions include costs necessarily entailed bythe restructuring associated recurring activities group timings cash outflows reasonably certain global basis shown table significant pro visions discounted time value money material employee provisions mostly relate certain employee benefit obligations sabbatical leave longservice benefits timings cash outflows reasonably estimated based past performance areshown table significant provisions discounted time value money ismaterial provisions provisions mostly relate sales returns various provisions group companies notfit categories timings cash outflows nature uncertain best estimates shown table provisions discounted time value money notmaterial matters contingent liabilities operations earnings group continue time time varying degrees affected political legislative fiscal regulatory developments including relating environmental protec tion countries operates industries group operates also subject risks various kinds nature frequency developments events covered insurance well effect future operations earnings predictable group entered strategic alliances various companies order gain access potential new products utilise companies help develop groups potential new products potential future payments may become due certain collaboration partners achieving certain milestones defined inthe collaboration agreements groups best estimates future commitments payments given note roche pharmaceuticals legal cases hoffmannla roche inc hlr various roche affiliates named defendants numerous legal actions united states elsewhere relating acne medication accutane litigation alleges accutane caused certain serious conditions including limited inflammatory bowel disease ibd birth defects psychiatric disorders december hlr defending approximately actions brought various federal state courts throughout united states personal injuries allegedly resulting use accutane actions allege ibd result ofaccutane use actions pending federal court alleging ibd consolidated pretrial proceedings multidistrict litigation united states district court middle district florida tampa division injuly district court granted summary judgment favour hlr lead federal ibd cases theplaintiffs appealed august rulings affirmed united states court appealsforthe eleventh circuit actions pending state court new jersey alleging ibd consolidated pretrial proceed ings superior court new jersey law division atlantic county december juries superior court ruled favour plaintiff five cases assessing total compensatory damages totalling million us dollars hlr appealed one case superior court new jersey appellate division reviewing posttrial option cases october jury circuit court escambia county florida returned verdict favour plaintiff assessing total compensatory damages million us dollars subsequently reduced million us dollars court company hlr appealed district court appeal state offlorida december group recorded provisions totalling million us dollars million swiss francs respect matters additional trials scheduled individual trial results depend ona variety factors including many unique particular case therefore trial results todate may predictive future trial results group continues defend vigorously remaining personal injury cases claims genentech legal cases june genentech announced los angeles county superior court jury voted award city hope national medical center city hope approximately million us dollars compensatory damages based finding breach agreement genentech city hope june jury voted award city hope million us dollars punitive damages case september genentech filed notice appeal jury verdict damages awards california court appeal october court appeal affirmed verdict damages awards respects also october genentech announced would seek review california supreme court discretion cases review november genentech filed petition review california supreme court february california supreme court granted petition appeal california supreme court heard february april overturned award million us dollars punitive damages city hope upheld award million us dollars compensatory damages may genentech paid million us dollars city hope reflecting amount compensatory damages awarded plus interest thereon date original decision june appeals process interest accrued total amount damages simple annual rate interest million swiss francs million swiss francs recorded time cost provisions within financing costs wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements full provision totalling million us dollars december recorded awards result april california supreme court decision provisions totalling million us dollars released income favourable litigation settlement million us dollars relates original award recorded exceptional major legal case expense million us dollars relates interest accrued charge financing costs intervening periods october genentech entered arrangement thirdparty insurance companies post surety bond connection judgment part arrangement genentech pledged million us dollars cash investments secure bond amount equivalent million swiss francs december recorded restricted cash within current assets annual financial statements third quarter court completed certain administrative procedures dismiss case result restrictions lifted restricted cash investments funds became available use genentechs operations genentech city hope discussions yet reached agreement regarding additional royalties amounts genentech owes city hope agreement thirdparty product sales settlement thirdparty patent litigation occurred judgement additional accruals made representing managements best estimate final obligation october genentech received subpoena united states department justice requesting documents related promotion rituxan genentech cooperating associated investigation counsel genentech discussions government representatives status investigation genentechs views matter including potential resolution previously investigation civil criminal nature genentech informed august criminal prose cutor handled matter government declined prosecute genentech criminally connection investigation civil matter still ongoing outcome matter determined time april medimmune inc medimmune filed lawsuit genentech city hope national medical center celltech rd ltd us district court central district california los angeles lawsuit relates us patent cabilly patent coowned genentech city hope national medical center medimmune companies licensed paying royalties lawsuit included claims violation antitrust patent unfair competition laws june genentech announced settled patent litigation withmedimmune terms settlement agreement litigation pending us district court central district california fully resolved dismissed may request filed third party reexamination cabilly patent july us patent trademark office ordered reexamination patent september patent office issued initial nonfinal office action rejecting claims patent genentech filed response november second reexamination request patent filed december another third party january patent office granted examination request june two reexaminations combined patent office single reexamination august patent office issued nonfinal office action merged proceeding rejecting claims cabilly patent based issues raised two reexamination requests genentech filed response october february patent office mailed final office action rejecting thirty six claims cabilly patent may genentech responded tothe final office action petitioned continued reexamination may patent office granted genentechs petition withdrew finality february office action agreed treat genentechs may filing response first office action february patent office mailed final patent office action rejecting claims cabilly patent genentech filed response tothat final patent office action june july patent office mailed advisory action replying genentechs response confirming rejection claims cabilly patent genentech filed notice appeal challenging rejection august genentechs opening appeal brief december cabilly patent expires relates methods used genentech others make certain antibodies antibody fragments well cells dna used methods genentech licensed cabilly patent companies derives significant royalties licences claims cabilly patent remain valid enforceable throughout reexamination appeals processes provisions recorded respect litigation outcome mat ter determined time fourth quarter process recognising revenue cabilly patents changed estimated accruals basis cash basis result change net royalties decreased approximately million us dollars equivalent million swiss francs fourth quarter compared third quarter cabilly patent licences contributed operating profit million us dollars equivalent million swiss francs million us dollars equivalent million swiss francs may centocor inc filed patent lawsuit genentech city hope us district court central district california lawsuit relates cabilly patent seeks declara tory judgment patent invalidity unenforceability regard cabilly patent patent non infringement regard certain centocors products centocor filed amended complaint september genentech answered complaint september also filed counterclaims centocor alleging four centocor products infringe certain genentech patents genentech filedanamendment counterclaims october centocor answered counterclaims november status conference set case february outcome thismatter determined time genentech made development decisions involving humanised anticd programme collaborator biogen idec inc disagreed certain genentechs development decisions related humanised anticd products genentechs collaboration agreement biogen idec genentech believe permitted proceed trials certain humanised anticd anti bodies biogen idec disagreed genentechs position disputed issues submitted arbitration arbitration biogen idec filed motions preliminary injunction summary judgment seeking stop genentech proceeding certain development activities including planned clinical trials april arbitration panel denied biogen idecs motion preliminary injunction biogen idecs motion summary judgment resolution arbitration could require parties agree certain development decisions moving forward humanised anticd antibody clinical trials possibly clinical trials collaboration products including rituxan case genentech may alter cancel planned clinical trials order obtain biogen idecs approval party also seeking monetary damages arbitrators held hearings matter several days september closing arguments december hearings formally closed january final decision arbitrators expected later july outcome matter determined time june mr ubaldo bao martinez filed lawsuit porrio town council genentech espaa sl contentious administrative court number one pontevedra spain lawsuit challenges town councils decision grant licenses genentech espaa sl construction operation warehouse biopharmaceutical manufacturing facility porrio spain january administrative court ruled favour mr bao one claims lawsuit ordered closing demolition facility subject certain legal proceedings february genentech town council filed appeals administrative court decision high court galicia spain addition genentech evaluating legal counsel spain whether may administrative remedies available overcome administrative courts ruling genentech sold assets genentech espaa sl including porrio facility lonza group ltd lonza december lonza operated facility since time terms sale genentech retained control defence lawsuit agreed indemnify lonza certain contractually defined liabilities specified limit currently estimated approximately million us dollars provisions recorded respect litigation outcome matter genentechs indemnification obligation lonza determined time wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements may june august september genentech named defendant along intermune inc former chief executive officer w scott harkonen four separate classaction complaints filed us district court northern district california behalf plaintiffs allegedly paid part purchase price product licensed genentech connectics corporation subsequently assigned intermune complaints related part royalties genentech received may june august complaints consolidated single amended complaint claims seeks damages violations federal racketeering laws unfair competition laws consumer protection laws unjust enrichment september complaint includes six claims names genentech defendant one claim damages unjust enrichment matter formally related consolidated complaint december genentechs motion dismiss matters currently scheduled hearing february outcome matters determined time subsequent roche proposal thirty shareholder lawsuits filed genentech andor members board directors various roche entities including roche holdings inc rhi roche holding ltd roche holding ag lawsuits currently pending various state courts including delaware court chancery san mateo county superior court well united states district court northern district california lawsuits generally assert classaction claims breach fiduciary duty aiding abetting breaches fiduciary duty based part allegations connection roches offer purchase remaining shares defendants failed properly value genentech failed solicit potential acquirers engaged improper selfdealing several suits also seek invalidation whole part july affiliation agreement genentech rhi affiliation agreement order deeming articles genentechs amended restated certificate incorporation inapplicable invalid potential transaction roche outcome matters determined time october genentech biogen idec inc filed complaint sanofiaventis deutschland gmbh sanofi sanofiaventis us llc sanofiaventis us inc northern district california seeking declaratory judgement certain genentech products including rituxan infringe sanofis us patents patent patent declaratory judgement patents invalid december sanofi filed motion dismiss complaint lack jurisdiction discovery hearing relating motion currently set february also october sanofi filed suit genentech biogen idec eastern district texas lufkin division claiming rituxan least eight genentech products infringe patents january genentech filed motion transfer matter northern district california sanofi seeking preliminary permanent injunctions compensatory exemplary damages relief addition october hoechst gmbh filed icc international court arbitration paris request arbitration genentech relating terminated agreement hoechsts pre decessors genentech pertained patents related patents outside united states genentechs answer arbitration request filed january hoechst seeking pay ments royalties sales genentech products damages breach contract relief genentech intends vigorously defend outcome matters determined time genentechs annual report quarterly sec filings contain detailed disclosures litigation matters required us gaap include details matters well including information litigation currently significant matters referred noncurrent liabilities noncurrent liabilities millions chf deferred income longterm liabilities total noncurrent liabilities debt debt recognised liabilities millions chf debt instruments amounts due banks financial institutions genentech leasing obligations finance lease obligations borrowings total debt reported longterm debt shortterm debt total debt debt repayment terms millions chf within one year one two years two three years three four years four five years five years total debt fair value debt instruments billion swiss francs billion swiss francs fair value total debt billion swiss francs billion swiss francs calculated based theobservable market prices debt instruments present value future cash flows instrument discounted market rate interest instruments similar credit status cash flows andmaturity periods pledges groups assets connection debt amounts due banks financial institutions amounts denominated various currencies notably chinese renminbi average interest rate average interest rate balance primarily denominated ineuros repayment dates five years million swiss francs million swiss francs due within one year wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements debt instruments recognised liabilities effective interest rates debt instruments millions chf effective interest rate european medium term note programme bonds due october principal million euros bonds due august principal million pounds sterling swiss franc bonds rodeo due march principal billion swiss francs us dollar bonds chameleon due july principal million us dollars genentech senior notes senior notes due july principal million us dollars senior notes due july principal billion us dollars senior notes due july principal million us dollars genentech commercial paper notes due various dates january principal million us dollars principal million us dollars due january japanese yen convertible bonds issued chugai series chugai pharmaceutical unsecured convertible bonds due september outstanding principal amount million japanese yen total debt instruments unamortised discount included carrying value debt instruments millions chf sterling bonds total unamortised discount fair value option group applied fair value option three outstanding debt instruments group applying fair value hedge accounting past debt instruments european medium term note programme euro bonds chameleon us dollar bonds rodeo swiss franc bonds fair value option treatment based elimination accounting mismatch recognised hedging swaps reported fair value hedged bonds reported atamortised cost difference carrying value principal amount debt instruments totals million swiss francs million swiss francs issuance new debt instruments genentech commercial paper program october genentech established commercial paper pro gram issue billion us dollars unsecured commercial paper notes maturities program generally vary overnight five weeks exceed days asat december unsecured commercial paper notes principal amount million us dollars million us dollars average interest rate outstanding genentech intends use proceeds general corporate purposes repayments redemptions conversions debt instruments redemption rodeo swiss franc bonds due date march group redeemed thesebonds original issue amount plus accrued original issue discount oid effective interest rate bonds cash outflow million swiss francs gain orloss recorded redemption redemption european medium term note programme euro bonds due date october group redeemed original issue amount plus accrued original issue discount oid theeffective interest rate bonds cash outflow million swiss francs therewas gain loss recorded redemption conversion redemption series chugai pharmaceutical unsecured convertible bonds remaining outstanding bonds face value million japanese yen million swissfrancs either converted shares chugai redeemed issue price due date september groups percentage ownership chugai unaffected conversion asthegroup bonds convertible chugai shares mirrored chugai outstanding withthird parties gain loss recorded income statement upon conversion andredemption cash outflow less million swiss francs repayments redemptions conversions debt instruments conversion redemption lyons v us dollar exchangeable notes june group announced would exercise option call notes redemption july originalissue amount plus accrued original issue discount oid period july notes aprincipal amount million us dollars converted million nonvoting equity securities andthe remaining notes redeemed cash july total million swiss francs recorded equity consists million swiss francs cash used purchase nonvoting equity securities used conversion redemption less million swiss francs carrying value ofthe converted bonds related tax effects million swiss francs gain loss recorded income statement upon conversion redemption redemption european medium term note programme us dollar bonds due date october group redeemed bonds principal value million us dollars original issue amount plus accrued original issue discount oid cash outflow million swissfrancs gain loss recorded income statement upon redemption partial conversion series chugai pharmaceutical unsecured convertible bonds bonds face value billion japanese yen million swiss francs converted shares ofchugai groups percentage ownership chugai unaffected conversion group hasbonds convertible chugai shares mirror chugai outstanding third parties gain loss recorded income statement upon partial conversion cash outflows repayments redemptions conversions debt instruments millions chf lyons v us dollar exchangeable notes european medium term note programme us dollar bonds rodeo swiss franc bonds european medium term note programme euro bonds genentech commercial paper net repayment japanese yen convertible bonds issued chugai total cash outflows repayments redemptions year wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements equity attributable roche shareholders changes equity attributable roche shareholders millions chf share equity retained fair value hedging translation year ended december capital instruments earnings reserve reserve reserve total january restated availableforsale investments valuation gains losses taken equity transferred income statement sale impairment cash flow hedges gains losses taken equity transferred income statementa transferred initial balance sheet carrying value hedged items exchange differences translation foreign operations defined benefit plans actuarial gains losses limit asset recognition income taxes items taken directly transferred equity noncontrolling interests net income recognised directly equity net income recognised income statement total recognised income expense dividends paid transactions equity instruments equity compensation plans genentech chugai share repurchases convertible debt instruments changes noncontrolling interests december amounts transferred income statement losses million swiss francs reported royalties operating income gains million swiss francs financial income disclosed note postemployment benefit assets deferred tax liabilities equity restated december balance sheet following adoption ifric interpretation reconciliation previously published balance sheet provided note equity share instru retained fair value hedging translation year ended december capital ments earnings reserve reserve reserve total january availableforsale investments valuation gains losses taken equity transferred income statement sale impairment cash flow hedges gains losses taken equity transferred income statementa transferred initial balance sheet carrying value hedged items currency translation foreign operations exchange differences accumulated differences transferred income statement divestment defined benefit plans actuarial gains losses limit asset recognition income taxes items taken directly transferred equity noncontrolling interests net income recognised directly equity net income recognised income statement total recognised income expense dividends paid transactions equity instruments equity compensation plans genentech chugai share repurchases changes ownership interests subsidiaries chugai ventana changes noncontrolling interests december amounts transferred income statement losses million swiss francs reported royalties operating income gains million swiss francs financial income wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements share capital december authorised issued share capital roche holding ltd groups parent company consisted shares nominal value swiss franc preceding year shares bearer shares group maintain register shareholders based information supplied group shareholder group pooled voting rights owns issued shares described note based information supplied group novartis ltd basel affiliates owns participation issued shares nonvoting equity securities genussscheine december nonvoting equity securities authorised issue preceding year swiss company law nonvoting equity securities nominal value part share capital issued contribution would shown asset balance sheet roche holding ltd nonvoting equity security confers rights shares participate net profit remaining proceeds liquidation following repay ment nominal value shares participation certificates accordance law andthe articles incorporation roche holding ltd company entitled times exchange orsome nonvoting equity securities shares participation certificates dividends march shareholders approved distribution dividend swiss francs per share nonvoting equity securities swiss francs respect business year distribution holders outstanding shares nonvoting equity securities totalled million swiss francs million swiss francs recorded retained earnings board directors proposed dividends business year swiss francs per share nonvoting equity security subject approval annual general meeting march equity instruments holdings equity instruments equivalent number nonvoting equity securities december december millions millions nonvoting equity securities low exercise price options derivative instruments total equity instruments equity instruments recorded within equity original purchase cost details equity instruments held december shown table fair values disclosed information purposes equity instruments december supplementary information equivalent number nonvoting equity securities strike price market value millions maturity chf chf millions nonvoting equity securities na na low exercise price options derivative instruments feb feb total nonvoting equity securities derivative instruments held groups potential conversion obligations may arise roche option plan roche stocksettled stock appreciation rights see note mainly consist call options exercisable time maturity net cash outflow transactions equity instruments million swiss francs net cashinflow million swiss francs large cash inflow mainly arose reduction equity instrument holdings following conversion redemption lyons v notes group holds none shares reserves fair value reserve fair value reserve represents cumulative net change fair value available forsale financial assets asset sold impaired otherwise disposed hedging reserve hedging reserve represents effective portion cumulative net change fair value cash flow hedging instruments related hedged transactions yet occurred translation reserve translation reserve represents cumulative currency translation differences relating consolidation group companies use functional currencies swiss francs earnings per share nonvoting equity security basic earnings per share nonvoting equity security calculation basic earnings per share nonvoting equity security number shares non voting equity securities reduced weighted average number nonvoting equity securities held group period basic earnings per share nonvoting equity security group net income attributable roche shareholders chf millions number shares millions number nonvoting equity securities millions weighted average number nonvoting equity securities held millions weighted average number shares nonvoting equity securities issue millions basic earnings per share nonvoting equity security chf diluted earnings per share nonvoting equity security calculation diluted earnings per share nonvoting equity security net income weighted average number shares nonvoting equity securities outstanding adjusted effects dilutive potential shares nonvoting equity securities wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements potential dilutive effects arise convertible debt instruments employee stock option plans ifthe outstanding convertible debt instruments converted would lead reduction interest expense increase number shares may net dilutive effect earnings per share exercise outstanding vested employee stock options would dilutive effect exer cise outstanding vested genentech employee stock options would dilutive effect net income genentech positive diluted earnings per share nonvoting equity security reflects potential impacts dilutive effects earnings per share figures diluted earnings per share nonvoting equity security group net income attributable roche shareholders chf millions elimination interest expense net tax convertible debt instruments dilutive chf millions increase noncontrolling share group net income net tax assuming outstanding genentech chugai stock options exercised chf millions net income used calculate diluted earnings per share chf millions weighted average number shares nonvoting equity securities issue millions adjustment assumed conversion convertible debt instruments dilutive millions adjustment assumed exercise equity compensation plans dilutive millions weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share millions diluted earnings per share nonvoting equity security chf noncontrolling interests changes equity attributable noncontrolling interests millions chf january net income recognised directly equity net income recognised income statement genentech chugai noncontrolling interests total net income recognised income statement total recognised income expense ventana acquisition dividends paid noncontrolling shareholders chugai noncontrolling interests equity compensation plans genentech chugai share repurchases changes ownership interests subsidiaries chugai ventana changes noncontrolling interests december genentech chugai noncontrolling interests total noncontrolling interests cash flow statement cash flows operating activities cash flows operating activities arise groups primary activities pharmaceuticals diagnostics businesses calculated indirect method adjusting groups operating profit operating income expenses cash flows example depreciation amortisation andimpairment order derive cash generated operations operating cash flows shown cash flow statement operating cash flows also include income taxes paid activities wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements cash generated operations millions chf net income add back nonoperating income expense associates financial income financing costs income taxes major legal cases changes group organisation operating profit exceptional items depreciation property plant equipment amortisation intangible assets impairment intangible assets impairment property plant equipment operating expenses defined benefit postemployment plans operating expenses equitysettled equity compensation plans adjustments cash generated operations cash flows investing activities cash flows investing activities principally arising groups investments property plant equipment intangible assets acquisition divestment subsidiaries associates businesses cash flows connected groups portfolio marketable securities investments also included interest dividend payments received respect securities investments cash flows indicate groups net reinvestment operating assets andthe cash flow effects business combinations divestments well cash generated thegroups investments interest dividends received millions chf interest received dividends received total cash flows financing activities cash flows financing activities primarily proceeds issue repayment groupsequity debt instruments also include interest payments dividend payments instruments cash flows shortterm financing including finance leases also included cash flows indicate groups transactions providers equity debt financing cash flows fromshortterm borrowings shown net movement consist large number trans actions short maturity interest dividends paid millions chf interest paid dividends paid total significant noncash transactions increase property plant equipment million swiss francs million swiss francs wasrecorded genentech leasing arrangements see note corresponding increase inlongterm debt risk management group risk management risk management fundamental element groups business practice levels encompasses different types risks group level risk management integral part business planning controlling processes material risks monitored regularly discussed corporate executive committee audit committee board directors overall group risk management process includes performance risk assessment described detail business report onpage financial risk management specifically described detail financial risk management group exposed various financial risks arising underlying operations corporate financeactivities groups financial risk exposures predominantly related changes foreign exchange rates interest rates equity prices well creditworthiness solvency ofthegroups counterparties financial risk management within group governed policies reviewed boards directors ofroche genentech chugai appropriate areas statutory responsibility policies cover credit risk liquidity risk market risk policies provide guidance risk limits type authorised financial instruments monitoring procedures general principle policies prohibit use ofderivative financial instruments speculative trading purposes policy implementation daytoday riskmanagement carried relevant treasury functions regular reporting risks performed relevant accounting controlling functions within roche genentech chugai carrying value fair value financial assets millions chf carrying value asset class fvtpla available fvtpla held held loans fair line items notes forsale designated trading maturity receivables total value year ended december accounts receivable accrued interest income marketable securities money market instruments time accounts months bonds debentures shares investments cash cash equivalents derivative financial instruments availableforsale investments heldtomaturity investments loans receivable longterm trade receivables financial current assets restricted cash longterm assets total wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements carrying value asset class fvtpla available fvtpla held held loans fair line items notes forsale designated trading maturity receivables total value year ended december accounts receivable accrued interest income marketable securities money market instruments time accounts months bonds debentures shares investments cash cash equivalents derivative financial instruments availableforsale investments heldtomaturity investments loans receivable longterm trade receivables financial current assets restricted cash longterm assets total fairvaluethroughprofitorloss credit risk credit risk arises possibility counterparties transactions may default obligations causing financial losses group objective managing counterparty credit risk prevent losses liquid funds deposited invested counterparties maximum exposure credit risk resulting financial activities without considering netting agreements without taking account collateral held credit enhancements equal carrying value groups financial assets trade receivables subject policy active credit risk management focuses assessment country risk credit availability ongoing credit evaluation account monitoring procedures objective management trade receivables sustain growth profitability group byoptimising asset utilisation whilst maintaining risks acceptable level except noted significant concentration counterparty credit risk due groups large number customers wide geographical spread risk limits exposures continuously monitored country nature counterparties additionally group obtains credit insurance similar enhancements appropriate protect collection trade receivables december collateral held forloans receivables none december groups combined trade accounts receivable balance three us national wholesale distributors amerisourcebergen corp cardinal health inc mckesson corp equivalent billion swiss francs representing groups consolidated trade accounts receivable billion swiss francs representing nature geographical location trade receivables overdue counterparties millions chf whole whole salers salers regions total public distributors private total public distributors private switzerland european union rest europe north america latin america japan rest asia africa australia oceania total cash marketable securities subject policy restricting exposures highquality counterparties setting defined limits individual counterparties limits counterparty credit ratings reviewed regularly investments marketable securities entered basis guidelines regard liquidity quality maximum amount general rule group invests high qualitysecurities adequate liquidity cash shortterm time deposits subject rules limit groups exposure individual financial institutions group signs netting agreements isda international swaps derivatives association master agreement respective counterparties inorder control exposures derivative positions rating analysis cash fixed income marketable securities market values mchf total mchf total aaarange aarange arange bbbrange bbbrange total overdue assets financial assets past due impaired total billion swiss francs billion swiss francs analysis overdue impaired financial assets class millions chf total amount overdue month months months months year year ended december loans receivables year ended december loans receivables december financial assets whose terms renegotiated none wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements liquidity risk liquidity risk arises surplus financial obligations available financial assets due point intime groups approach liquidity risk maintain sufficient readily available reserves order tomeet liquidity requirements point time group liquidity reported senior management amonthly basis roche genentech chugai enjoy strong credit quality rated least one major credit rating agency ratings permit efficient access international capital markets event major financing requirements addition group unused committed credit lines various financial institutions totalling billion swiss francs billion swiss francs decline due changes inforeign currency translation rates contractual maturity analysis financial liabilities millions chf total months months months years years years years years year ended december total debta trade payables accruals derivative financial instruments liabilities current noncurrent total financial liabilities year ended december total debta trade payables accruals derivative financial instruments liabilities current noncurrent total financial liabilities total debt table shows undiscounted cash flows whereas carrying value consolidated balance sheet reflects discounted cash flows market risk market risk arises changing market prices groups financial assets financial liabilities market risk may affect group financial result value group equity group uses valueatrisk var measure impact market risk financial instruments rochehas defined var limits manage market risk var data reported monthly basis indicate value range within given financial instrument fluctuate preset probability result ofmovements market prices var statistical measure implicitly assumes value changes recent past indicative value changes future var figures represent actual expected losses possible worstcase losses stated period var figures calculated using historical simulation approach scenario financial instruments fully valued total change value earnings determined var calculations based ona confidence level holding period trading days past ten years holding period reflects time required change corresponding risk exposure deemed appro priate longer holding periods increase probability higher value changes lead increased var figures actual future gains losses associated treasury activities may differ materially var analy ses performed due inherent limitations associated predicting timing amount changes tointerest rates foreign currency exchanges rates equity investment prices particularly periods high market volatilities furthermore var numbers include effect changes credit spreads market risk financial instruments millions chf december december var foreign exchange component var interest rate component var price component diversification var total market risk december total var financial assets liabilities million swiss francs million swiss francs foreign exchange var increased arises mainly hedging nonus dollar cash flows future royalty income next five years genentech lower contribution interest rate component caused ageing fixedterm liabilities price risk arises mainly movements prices equity securities decreased due significantly reduced equity security holdings december group held equity securities market value billion swiss francs billion swiss francs number includes holdings biotechnology companies acquired context licensing transactions scientific collaborations lower holdings equity securities resulted lower var price risk foreign exchange risk group operates across world exposed movements foreign currencies affecting groupfinancial result value groups equity foreign exchange risk arises amount local currency paid received transactions denominated foreign currencies may vary due changes inexchange rates transaction exposures foreign currency denominated financial state ments groups foreign subsidiaries may vary upon consolidation swiss franc denominated group financial statements translation exposures objective groups foreign exchange risk management activities preserve economic value ofits current future assets minimise volatility groups financial result primary focus groups foreign exchange risk management activities hedging transaction exposures arising foreign currency flows monetary positions held foreign currencies group currently hedge translation exposures using financial instruments group monitors transaction exposures daily basis net foreign exchange result corresponding var parameters reported monthly basis group uses forward contracts foreign exchange options crosscurrency swaps hedge transaction exposures application instruments intends continuously lock favourable developments foreign exchange rates thereby reducing exposure potential future movements rates wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements interest rate risk interest rate risk arises movements interest rates could affect group financial result thevalue group equity changes interest rates may cause variations interest income expense inaddition may affect market value certain financial assets liabilities hedging instruments primary objective groups interest rate management protect net interest result interest rate exposures corresponding var parameters reported monthly basis group uses forward contracts options swaps hedge interest rate exposures depending interest rate environment major currencies group use instruments generate appropriate mix offixed floating rate exposures price risk price risk arises mainly movements prices equity securities held roche genentech chugai december group held equity securities market value billion swiss francs billion swiss francs amount includes holdings biotechnology companies acquired context licensing transactions scientific collaborations due nature business biotechnology companies exposed greater equity volatilities general stock market fluctuations group manages price risk placing limits individual total equity investments limits defined percentage total liquid funds absolute number individual equity investments equity price risk reported var figure monthly basis senior management impairment financial assets impairments shares triggered significant prolonged price decline cost value impairments debt securities recorded due significant financial difficulties issuers impairment losses asset classes millions chf loans receivables availableforsale financial assets shares investments debt securities total impairment losses capital group defines capital manages groups total equity including noncontrolling interests groups objectives managing capital safeguard groups ability continue going concern continue provide benefits patients returns investors provide adequate return investors based level risk undertaken available necessary financial resources allow group invest areas may deliver future benefits patients returns investors maintain sufficient financial resources mitigate risks unforeseen events capital monitored basis equity ratio calculated equity including noncontrolling interests percentage total assets reported senior management part groups regular internal management reporting groups capital equity ratio shown tablebelow capital millions chf capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity total assets equity ratio group subject regulatory capital adequacy requirements known financial services industry group majority shareholdings genentech see note chugai see note genentech chugai public companies objectives policies processes managing capital determined local management related parties controlling shareholders share capital roche holding ltd groups parent company consists bearer shares based information supplied shareholder group pooled voting rights comprising ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri ms beatrice oeri ms maja oeri group holds shares pre ceding year represents issued shares figure include shares without pooled voting rights held outside group individual members group onjanuary pool members announced effective april ms beatrice oeri would leave thepool mrjrg duschmal mr lukas duschmal would join pool group would continue hold total shares pooled voting rights previously mr andr hoffmann dr andreas oeri members board directors roche holding ltd mrhoffmann received remuneration totalling swiss francs swiss francs dr oeri received remuneration totalling swiss francs swiss francs transactions group individual members shareholder group subsidiaries associates listing major group subsidiaries associates included note transactions parent company subsidiaries subsidiaries eliminated consolidation nosignificant transactions group associates wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements key management personnel members board directors roche holding ltd receive annual remuneration payment time expenses related membership board committees total remuneration board ofdirectors excluding chairman totalled million swiss francs million swiss francs chairman board directors members corporate executive committee roche holding ltd receive remuneration consists annual salary bonus expense allowance group pays social insurance contributions respect remuneration pays contributions pension postemployment benefit plans chairman board directors members corporate executive committee chairman board directors members corporate executive committee also participate certain equity compensation plans described terms vesting conditions fair value awards disclosed note remuneration chairman board directors members corporate executive committee millions chf salaries including bonuses expenses social security costs pensions postemployment benefits equity compensation plans employee benefits total roche longterm members corporate executive committee granted stocksettled stock appreciation rights ssars roche option plan rop awards ssars rop awards roche connect contributions paid group respect chairman boardofdirectors members corporate executive committee totalled million swiss francs million swiss francs roche performance share plan members corporate executive committee targeted awards cycle awards cycle eachaward result zero two nonvoting equity securities depending upon achievement ofthe performance targets transactions former members corporate executive committee pensions totalling million swiss francs million swiss francs paid group two former corporate executive committee members detailed disclosures regarding executive remuneration required swiss law included inthefinancial statements roche holding ltd basel pages postemployment benefit plans transactions group various postemployment defined benefit plans employees ofthe group described note subsidiaries associates divestments subsidiaries effective october group sold whollyowned subsidiary cenexi sas cenexi including manufacturing facility fontenaysousbois france million swiss francs cash loss divestment cenexi millions chf consideration net assets disposed property plant equipment cash net assets accumulated currency translation adjustments gain loss divestment total loss divestment reported within general administration expenses current period part segment result roche pharmaceuticals operating segment net cash inflow divestment million swiss francs listed companies share capital equity interest country company city millions switzerland roche holding ltd basel chf stock exchange six zurich valor share valor genussscheine isin share ch isin genussscheine ch market capitalisation chf basilea pharmaceutica ltd basel chf stock exchange six zurich valor isin ch market capitalisation chf united states genentech inc south san francisco usd stock exchange new york incorporated delaware isin us market capitalisation usd japan chugai pharmaceutical co ltd tokyo jpy stock exchange tokyo isin jp market capitalisation jpy nonlisted companies share capital equity interest country company city millions argentina productos roche sa qumica e industrial buenos aires ars australia roche diagnostics australia pty limited castle hill aud roche products pty limited dee aud austria roche austria gmbh vienna eur roche diagnostics gmbh vienna eur roche diagnostics graz gmbh graz eur belgium nv roche sa brussels eur roche diagnostics belgium sa brussels eur wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements share capital equity interest country company city millions bermuda chemical manufacturing trading company limited hamilton usd roche capital services ltd hamilton rub roche catalyst investments ltd hamilton usd roche financial investments ltd hamilton usd roche financial management ltd hamilton usd roche financial services ltd hamilton usd roche international ltd hamilton usd roche intertrade limited hamilton usd roche operations ltd hamilton usd roche services holdings ltd hamilton usd syntex pharmaceuticals international ltd hamilton usd brazil produtos roche qumicos e farmacuticos sa paulo brl roche diagnostica brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn canada chempharm limited toronto cad hoffmannla roche limited toronto cad sapac corporation ltd st john cad chile roche chile limitada santiago de chile clp china roche diagnostics hong kong limited hong kong hkd roche diagnostics shanghai limited shanghai usd roche hong kong limited hong kong hkd roche rd center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia productos roche sa bogot cop costa rica roche servicios sa heredia usd croatia roche doo zagreb hrk czech republic roche sro prague czk denmark roche hvidovre dkk roche diagnostics hvidovre dkk dominican republic productos roche dominicana sa santo domingo dop ecuador roche ecuador sa quito usd el salvador productos roche el salvador sa san salvador svc estonia roche eesti tallinn eek finland roche diagnostics oy espoo eur roche oy espoo eur france roche diagnostics sa meylan eur roche sas neuillysurseine eur ventana medical systems sa illkirch eur germany galenus mannheim gmbh mannheim eur nimblegen systems gmbh pleiskirchen eur roche beteiligungs gmbh grenzachwyhlen eur roche deutschland holding gmbh grenzachwyhlen dem roche diagnostics gmbh mannheim eur roche kulmbach gmbh kulmbach eur roche pharma ag grenzachwyhlen eur swisslab gmbh berlin eur greece roche hellas sa athens eur roche diagnostics hellas sa athens eur guatemala productos roche guatemala sa guatemala gtq honduras productos roche honduras sa tegucigalpa hnl hungary roche hungary ltd budapest huf roche services europe ltd budapest huf india roche diagnostics india pvt ltd mumbai inr roche scientific company india pvt ltd mumbai inr indonesia pt roche indonesia jakarta idr ireland roche ireland limited clarecastle eur roche products ireland limited dublin eur italy roche diagnostics spa milan eur roche spa milan eur japan roche diagnostics kk tokyo jpy latvia roche latvija sia riga lvl lithuania uab roche lietuva vilnius lit luxembourg pharminvest sa luxembourg eur malaysia roche malaysia sdn bhd kuala lumpur myr roche diagnostics malaysia sdn bhd kuala lumpur myr mexico grupo roche syntex de mxico sa de cv mexico city mxn lakeside de mxico sa de cv mexico city mxn productos roche sa de cv mexico city mxn syntex sa de cv mexico city mxn morocco roche sa casablanca mad share capital equity interest country company city millions netherlands roche diagnostics nederland bv almere eur roche finance europe bv woerden eur roche nederland bv woerden eur roche pharmholding bv woerden eur new zealand roche diagnostics nz limited auckland nzd roche products new zealand limited auckland nzd nicaragua productos roche nicaragua sa managua nio norway roche diagnostics norge oslo nok roche norge oslo nok pakistan roche pakistan limited karachi pkr panama productos roche interamericana sa panama city usd productos roche panam sa panama city pab syntex corporation panama city usd syntex puerto rico inc panama city usd technical development corp panama city chf peru productos roche qumica farmacutica sa lima pen philippines roche philippines inc makati php poland roche diagnostics polska sp z oo warsaw pln roche polska sp z oo warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas de diagnsticos sociedade unipessoal lda amadora eur puerto rico roche operations ltd puerto rico branch ponce usd romania roche romania srl bucharest ron russian federation roche moscow ltd moscow rub serbia roche doo beograd belgrade eur singapore roche diagnostics asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd slovakia roche slovensko sro bratislava skk slovenia roche doo pharmaceutical company ljubljana eur south africa roche products proprietary limited johannesburg zar south korea roche diagnostics korea co ltd seoul krw roche korea company ltd seoul krw spain andreu roche sa madrid eur roche diagnostics sl barcelona eur roche farma sa madrid eur syntex roche sa madrid eur sweden roche ab stockholm sek roche diagnostics scandinavia ab bromma sek switzerland disetronic handels ag burgdorf chf disetronic holding ag burgdorf chf disetronic licensing ag burgdorf chf disetronic medical systems ag burgdorf chf f hoffmannla roche ltd basel chf glycart biotechnology ltd schlieren chf hoffmannla roche ltd basel chf imib institute medical informatics biostatistics ltd basel chf rabbitair ltd zurichkloten chf roche capital market ltd basel chf roche diagnostics switzerland ltd rotkreuz chf roche diagnostics ag rotkreuz chf roche diagnostics international ltd steinhausen chf roche finance ltd basel chf roche long term foundation basel chf roche pharma switzerland ltd reinach chf syntex corporation basel chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostics thailand limited bangkok thb roche thailand limited bangkok thb turkey roche diagnostik sistemleri ticaret istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try united kingdom piramed limited berkshire gbp roche diagnostics ltd lewes gbp roche holding uk limited welwyn garden city gbp roche products limited welwyn garden city gbp roche registration limited welwyn garden city gbp wwwglobalreportscom roche finance report roche group notes roche group consolidated financial statements share capital equity interest country company city millions united states life sciences corporation branford usd bioveris corporation gaithersburg usd disetronic medical systems inc fishers usd hoffmannla roche inc nutley usd igen international inc wilmington usd roche carolina inc florence usd roche colorado corporation boulder usd roche diagnostics corporation indianapolis usd roche diagnostics operations inc indianapolis usd roche finance america inc little falls usd roche finance usa inc little falls usd roche holdings inc wilmington usd roche laboratories inc nutley usd roche madison inc madison usd roche molecular systems inc pleasanton usd roche nimblegen inc madison usd roche palo alto llc palo alto usd spring bioscience corp fremont usd therapeutic human polyclonals inc palo alto usd ventana medical systems inc tucson usd uruguay roche international ltd montevideo branch montevideo uyu venezuela productos roche sa caracas vef share capital less local currency units roche group report roche management internal control overfinancial reporting roche finance report report roche management internal control financial reporting report roche management internal control financial reporting board directors management roche holding ltd responsible establishing maintain ing adequate control financial reporting internal control system designed provide reasonable assurance reliability financial reporting preparation fair presentation consolidated financial statements accordance international financial reporting standards internal control systems matter well designed inherent limitations therefore even systems determined effective may prevent detect misstatements provide reason ableassurance respect financial statement preparation presentation also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate management assessed effectiveness system internal control financial reporting december based criteria effective internal control financial reporting described internal control integrated frameworkissued committee sponsoring organizations treadway commission coso based assessment management concluded system internal control financial reporting effective december statutory auditor kpmg klynveld peat marwick goerdeler sa audited consolidated financial statements roche holding ltd year ended december accordance swiss auditing standards international standards auditing isa also issued report effectiveness groups system internal control financial reporting report set pages franz b humer erich hunziker chairman board directors chief financial officer deputy head corporate executive committee basel january wwwglobalreportscom roche finance report roche group report statutory auditor consolidated financial statements report statutory auditor consolidated financial statements report statutory auditor consolidated financial statements annual general meeting roche holding ltd basel statutory auditor audited consolidated financial statements income statement balance sheet cash flow statement statement recognised income expense statement changes equity notes pages roche holding ltd year ended december board directors responsibility board directors responsible preparation fair presentation consolidated financial statements accordance international financial reporting standards ifrs requirements swiss law responsibility includes designing implementing andmaintaining internal control system relevant preparation fair presentation consolidated financial statements free material misstatement whether due fraud error board directors responsible selecting applying appropriate accounting policies making accounting estimates reasonable circumstances auditors responsibility responsibility express opinion consolidated financial statements based audit conducted audit accordance swiss law swiss auditing standards international standards auditing standards require plan perform audit obtain reasonable assurance whether consolidated financial statements free material misstatement audit involves performing procedures obtain audit evidence amounts disclosures consolidated financial statements procedures selected depend auditors judgment including assessment risks material misstatement consolidated financial statements whether due fraud error making risk assessments auditor considers internal control system relevant entitys preparation fair presentation consolidated financial statements order design audit procedures appropriate circumstances audit also includes evaluating appropriateness accounting policies used reasonableness accounting estimates made well evaluating overall presentation consolidated financial statements believe audit evidence obtained sufficient appropriate provide basis audit opinion opinion opinion consolidated financial statements year ended december give atrue fair view financial position results operations cash flows accordance international financial reporting standards ifrs comply swiss law report legal requirements confirm meet legal requirements licensing according auditor oversight act aoa independence article co article aoa circumstances incompatible independence accordance article paragraph item co swiss auditing standard confirm aninternal control system exists designed preparation consolidated financial statements according instructions board directors recommend consolidated financial statements submitted approved kpmg klynveld peat marwick goerdeler sa john morris franois rouiller licensed audit expert licensed audit expert auditor charge basel january wwwglobalreportscom roche finance report roche group report independent auditor internal control financial reporting report independent auditor internal control financial reporting report independent auditor internal control financial reporting annual general meeting roche holding ltd basel examined roche groups system internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso board directors management roche holding ltd responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying report roche management internal control financial reporting responsibility express opinion companys internal control financial reporting based examination entitys internal control financial reporting process effected entitys board directors management personnel designed provide reasonable assurance regarding reliability financial statements prepared accordance international financial reporting standards ifrs includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets entity provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance applicable financial reporting framework provide reasonable assurance regarding prevention timely detection unauthorised acquisition use disposition entity 's assets could amaterial effect entitys financial statements conducted examination accordance international standard assurance engagements isae standard requires plan perform examination obtain reasonable assurance whether effective internal control financial reporting maintained material respects examination included obtaining understanding internal control financial reporting testing evaluating design operating effectiveness internal control performing procedures considered necessary circumstances believe examination provides areasonable basis opinion inherent limitations internal control financial reporting including possibility management override controls misstatements due error fraud may occur detected also projections evaluation internal control financial reporting future periods subject risk internal control may become inadequate changes conditions degree ofcompliance policies procedures may deteriorate opinion roche group maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso also audited accordance swiss auditing standards international standards auditing consolidated financial statements roche holding ltd year ended december report dated january expressed unqualified opinion consolidated financial statements kpmg klynveld peat marwick goerdeler sa john morris franois rouiller basel january wwwglobalreportscom roche finance report roche group multiyear overview supplementary information multiyear overview supplementary information multiyear overview statistics reported statement income millions chf sales ebitda operating profit net income attributable roche shareholders research development balance sheet millions chf noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests additions property plant equipment personnel number employees end year key ratios net income attributable roche shareholders sales net income equity attributable roche shareholders research development sales current ratio equity noncontrolling interests total assets sales per employee thousands chf data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf information table stated reported changes accounting policies arising changes international financial reporting standards stock split applied retrospectively b b dividend include special dividend relating spinoff fragrances flavours division b dividend proposed board directors wwwglobalreportscom roche finance report roche group multiyear overview supplementary information sales division millions chf pharmaceuticals diagnostics consumer health otc total sales geographical area millions chf switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total additions property plant equipment division millions chf pharmaceuticals diagnostics consumer health otc corporate total additions property plant equipment geographical area millions chf switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total european union information based members eu december comparative information restated toinclude new eu members whole fiveyear period wwwglobalreportscom roche finance report roche group multiyear overview supplementary information supplementary net income eps information groups basic diluted earnings per share information given note consolidated financial statements pages supplementary eps information given net income exceptional items also core net income additionally excludes amortisation intangible assetsand related impacts income taxes noncontrolling interests profit continuing businesses exceptional items core net income millions chf net income major legal cases income taxes changes group organisation income taxes profit continuing businesses exceptional items noncontrolling interests net income exceptional items major legal cases exceptional items changes group organisation net income attributable roche shareholders exceptional items amortisation impairment intangible assets income taxes noncontrolling interests core net income eps continuing businesses exceptional items core eps eps continuing businesses exceptional items core eps net income attributable roche shareholdersmillions chf elimination interest expense net tax convertible debt instruments dilutive increase noncontrolling share net income net tax assuming outstanding genentech chugai stock options exercised net income used calculate diluted earnings per share per share informationmillions shares nonvoting equity securities weighted average number shares nonvoting equity securities issue adjustment assumed conversion convertible debt instruments dilutive adjustment assumed exercise equity compensation plans dilutive weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share earnings per share diluted chf supplementary operating free cash flow information divisional operating free cash flow information millions chf pharmaceuticals diagnostics division division corporate group depreciation amortisation impairments depreciation property plant equipment amortisation intangible assets impairment property plant equipment impairment intangible assets total adjustments add back expenses equitysettled equity compensation plans net incomeexpense provisions net gain disposals deduct net cash flow equity compensation plans utilisation provisions proceeds disposals total operating profit cash adjustments ebitda operating profit exceptional items depreciation amortisation impairments total group add back exceptional item ebitda margin sales wwwglobalreportscom roche finance report roche group multiyear overview supplementary information pharmaceutical subdivisional operating free cash flow information millions chf roche pharmaceuticals pharmaceuticals genentech chugai division depreciation amortisation impairments depreciation property plant equipment amortisation intangible assets impairment property plant equipment impairment intangible assets total adjustments add back expenses equitysettled equity compensation plans net incomeexpense provisions net gain disposals deduct net cash flow equity compensation plans utilisation provisions proceeds disposals total operating profit cash adjustments ebitda operating profit exceptional items elimination within division total depreciation amortisation impairments total group add back exceptional item ebitda margin sales unrealised internal profits inventories sold one subdivision another yet sold ontoexternal customers balance sheet date eliminated consolidation entry roche group roche securities roche finance report roche securities price development share chf roche share swiss market index rebased price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebased price development american depositary receipt adr usd roche adr sp index rebased four roche american depositary receipts adrs equivalent one nonvoting equity security genussschein adrs traded united states overthecounter market since july information tables restated stock split roche shares nonvoting equity securities genussscheine effective may change ratio adrs effective january change ratio adrs effective january wwwglobalreportscom roche finance report roche group roche securities number shares nonvoting equity securitiesa number shares nominal value chf number nonvoting equity securities genussscheineno nominal value total data per share nonvoting equity security chf net income equity dividend c stock price shareb opening high low yearend stock price nonvoting equity security genussscheinb opening high low yearend market capitalisation millions chf year end key ratios yearend net income equity dividend yield shares dividend yield nonvoting equity securities genussscheinein priceearnings shares priceearnings nonvoting equity securities genussscheine nonvoting equity security genussscheinconfers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value shares participation certificate capital shares nonvoting equity securities listed swiss exchange roche holding ltd restrictions astoownership shares nonvoting equity securities b stock price data reflect daily closing prices c dividend proposed board directors ticker symbols share nonvoting equity security american depositary receipt reuters ros rogvx rhhbypk bloomberg ro sw rog vx rhhby us six swiss exchange ro rog roche holding ltd basel financial statements roche finance report roche holding ltd basel financial statements income statement millions chf income income participations interest income loans group companies interest investment income income total income expenses financial expenses administration expenses expenses total expenses profit year taxes taxes net profit year wwwglobalreportscom roche finance report roche holding ltd basel financial statements balance sheet december millions chf noncurrent assets participations longterm loans group companies total noncurrent assets current assets shortterm loans group companies accounts receivable group companies accounts receivable marketable securities liquid funds total current assets total assets equity share capital nonvoting equity securities genussscheine pm pm general legal reserve free reserve special reserve available earnings balance brought forward previous year net profit year total equity noncurrent liabilities provisions total noncurrent liabilities current liabilities accounts payable group companies unrealised foreign currency gains liabilities total current liabilities total liabilities total equity liabilities pm pro memoria nonvoting equity securities nominal value roche holding ltd basel notes financial statements roche finance report notes financial statements summary significant accounting policies basis preparation financial statements financial statements roche holding ltd basel prepared accordance provisions ofswisslaw participations major participations company listed note roche group consolidated financial statements valuation methods translation foreign currencies marketable securities reported lower cost market value assets including partici pations reported cost less appropriate writedowns assets liabilities denominated foreign currencies translated swiss francs using yearend rates exchange except participations translated historical rates transactions year denominated foreign currencies aretranslated exchange rates effective relevant transaction dates resulting exchange gains losses recognised income statement exception unrealised gains deferred taxes tax charge includes corporate income capital taxes equity share capital previous year share capital amounts million swiss francs share capital consists bearer shares nominal value swiss franc included equity nonvoting equity securities genussscheine part share capital confer voting rights however nonvoting equity security genussscheinconfers rights shares participate available earnings remaining proceeds liquidation following repayment ofthe nominal value share capital participation certificates wwwglobalreportscom roche finance report roche holding ltd basel notes financial statements movement recognised amounts millions chf general share legal free special available total capital reserve reserve reserve earnings equity january net income dividends paid transfer free reserve december net income dividends paid transfer free reserve december net income dividends paid transfer free reserve december contingent liabilities guarantees within framework european medium term note emtn programme company issued guar antees favour group companies amounting million swiss francs million swiss francs significant shareholders shares company bearer shares reason company keep register ofshareholders following figures based information shareholders shareholder validation check annual general meeting march information available company shares shareholder group pooled voting rights comprising ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri ms beatrice oeri ms maja oeriab shares participation novartis ltd basel including affiliates thereofc information supplied shareholders figure shares include shares without pooled voting rights held outside group individual members group b january pool members announced effective april ms beatrice oeri would leave pool mr jrg duschmal mr lukas duschmal would join pool group would continue hold total shares pooled voting rights previously c figures december supplied novartis ltd basel risk management detailed disclosures regarding risk management required swiss law included rochegroup consolidated financial statements pages board executive remuneration board directors members board directors roche holding ltd receive annual remuneration payment time expenses related membership board committees remuneration members board directors thousands chf b gehrig hoffmann p baschera ji bell p brabeckletmathe ljr de vink w frey da julius oeri w ruttenstorfer h teltschik b weder di mauro total remuneration board directors chairman board directors dr franz b humer received remuneration shown table remuneration chairman board directors thousands chf annual salary including bonuses expenses pensions postemployment benefits equity compensation plans employee benefits total remuneration received social security costs total dr humer received remuneration indirect benefits participated certain equity compensation plans totalling millionswiss francs corporate executive committee members corporate executive committee cec roche holding ltd receive remuneration indirect benefits participate certain equity compensation plans shown table march dr franz b humer handed executive function ceo dr severin schwansince drschwan wasthe member corporate executive committee highest total remuneration remu neration also disclosed dr humer member corporate executive committee thehighest total remuneration wwwglobalreportscom roche finance report roche holding ltd basel notes financial statements remuneration members corporate executive committee thousands chf total ceca schwan annual salary including bonuses expenses pensions postemployment benefits equity compensation plans employee benefits total remuneration received social security costs total amounts total cec include dr humer total remuneration corporate executive committee million swiss francs dr humer member corporate executive committee highest total remuneration total remuneration million swiss francs employer contribution social security schemes pension plans group pays social insurance contributions respect remuneration pays contributions pension post employment benefit plans chairman board directors members corporate executive committee equity compensation plans chairman board directors members corporate executive committee also participate certain equity compensation plans described terms andvesting conditions awards disclosed note consolidated financial statements fair values used consolidated financial statements represent cost company grant dateand reflect amongst matters observed exercise behaviour exit rate whole popula tion receive initial simulations performance conditions purposes remuneration disclosures fair values calculated based fair value employee receives taking account preliminary assessment completed performance conditions chairman board directors members corporate executive committee eligible participate roche connect programme enables employees make regular deductions salaries purchase nonvoting equity securities group contributes programme allows employees purchase nonvoting equity securities discount usually members corporate executive committee granted stocksettled stock appreciation rights ssars individual awards relating shown table fair value awards employee swiss francs calculated using blackscholes formula assuming holding maturity deducting average year vesting period chairman board directors granted ssars members corporate executive committee members senior management participate roche performance share plan psp group three overlapping threeyear psps target awards threeyear cycle defined beginning cycle awards considered form partof employees remuneration three equal annual amounts threeyear cycle award willresult zero two nonvoting equity securities genussscheine depending upon achievement performance targets discretion board directors individual awards relating shown table number awards calculated follows psp preliminary allocation based actual performance period shows nonvoting equity security genussscheinper award psp one nonvoting equity security genussscheinper award psp one nonvoting equity security genussscheinper award resulting allocations multiplied nonvoting equity security genussscheinprice december swiss francs give fair value remuneration received employee chairman board directors granted psps cycle remuneration equity compensation plans thousands chf roche connect ssar awards psp awards employer ssar ssar psp psp psp psp total contributions number fair value number number number fair value fair value total ceca schwan amounts total cec include dr humer total remuneration corporate executive committee equity compensation plans million swiss francs million swiss attributable dr humer member corporate executive committee highest total remuneration employee benefits includes tax advisory costs remuneration dr hunziker mr burns prof knowles serving chugai board directors transactions former members corporate executive committee pensions totalling million swiss francs paid group two former corporate executive committee members million swiss francs mr heino von prondzynski former member corporate executive committee received bonus million swiss francs respect services rendered andadditionally received total nonvoting equity securities based prorated roche performance share plan awards board executive shareholdings board directors directors mr andr hoffmann dr andreas oeri members founders families closely associated belong shareholder group pooled voting rights end group held shares issued shares detailed information group given note addition december members board directors persons closely associated held shares nonvoting equity securities genussscheineas shown table wwwglobalreportscom roche finance report roche holding ltd basel notes financial statements shareholdings members board directors nonvoting equity securities shares genussscheine fb humer b b gehrig hoffmann c cd p baschera ji bell p brabeckletmathe ljr de vink e w frey da julius oeri w ruttenstorfer h teltschik b weder di mauro total figure include shares held shareholder group pooled voting rights b equity compensation awards roche option plan ssars roche performance share plan see c reported swiss exchange august mr hoffmann entered call options agreement ubs roche nonvoting equity securities period august august mr hoffmann dr oeri hold ubs longshort certificates roche bearer shares ro versus roche nonvoting equity securities rog isin ch e mr de vink holds roche american depositary receipts adrs rhhby isin us corporate executive committee members corporate executive committee persons closely associated held shares nonvoting equity securities genussscheine shown table shareholdings members corporate executive committee nonvoting equity securities shares genussscheine schwan ab ayyoubi na na wm burns e hunziker ga keller ac jkc knowles j schwiezer na na total equity compensation awards roche option plan ssars roche performance share plan see b dr schwans close relatives hold roche nonvoting equity securities genussscheine zero c dr kellers close relatives hold roche nonvoting equity securities genussscheine december chairman board directors members corporate executive committee held stocksettled stock appreciation rights ssars first issued roche option plan awards issued shown table option entitles holder purchase one roche nonvoting equity security genussscheineat specified strike price terms vesting conditions awards disclosed note consolidated financial statements additional supplementary information remuneration report included business report pages roche option plan ssars awards held december year issue total schwan ayyoubi wm burns e hunziker ga keller jkc knowles j schwiezer total cec fb humer total strike price chf expiry date jan feb feb feb feb feb feb december chairman board directors members corporate executive com mittee held psp awards three psp performance cycles shown table terms vesting conditions awards disclosed note consolidated financial statements additional supplementary information remuneration report pages business report award result zero two nonvoting equity secu rities genussscheine depending upon achievement performance targets discretion board directors preliminary allocation ratio plan total target number ofawards cycles december shown table roche performance share plan awards held december psp psp psp schwan ayyoubi wm burns e hunziker ga keller jkc knowles j schwiezer total cec fb humer total awards granted allocation date feb feb feb estimated allocation december total estimated awards december december chairman board directors members corporate executive com mittee time held total stocksettled stock appreciation rights roche option plan awards outstanding total awards granted roche performance share plan wwwglobalreportscom roche finance report roche holding ltd basel appropriation available earnings appropriation available earnings proposals annual general meeting chf available earnings balance brought forward previous year net profit year transfer free reserve total available earnings appropriation available earnings distribution ordinary dividend chf gross per share nonvoting equity security genussschein chf last year transfer free reserve total appropriation available earnings carried forward account roche holding ltd basel report statutory auditor financial statements roche finance report report statutory auditor financial statements report statutory auditor financial statements annual general meeting roche holding ltd basel statutory auditor audited financial statements income statement balance sheet notes onpages roche holding ltd year ended december board directors responsibility board directors responsible preparation finan cial statements accordance requirements swiss law companys articles incorporation responsibility includes designing implementing maintaining internal control system relevant preparation financial statements free material misstatement whether due fraud error board directors responsible selecting applying appropriate accounting policies making accounting estimates reasonable circumstances auditors responsibility responsibility express opinion financial statements based audit weconducted audit accordance swiss law swiss auditing standards stan dards require plan perform audit obtain reasonable assurance whether financial state ments free material misstatement audit involves performing procedures obtain audit evidence amounts disclosures financial statements procedures selected depend auditors judgment including assessment risks material misstatement financial statements whether due fraud error making risk assessments auditor considers internal control system relevant entitys preparation financial statements order design audit procedures appropriate circumstances purpose expressing opinion effectiveness entitys internal control system audit also includes evaluating appropriateness accounting policies used reasonableness account ing estimates made well evaluating overall presentation financial statements believe audit evidence obtained sufficient appropriate provide basis audit opinion opinion opinion financial statements year ended december comply swiss law companys articles incorporation wwwglobalreportscom roche finance report roche holding ltd basel report statutory auditor financial statements report legal requirements confirm meet legal requirements licensing according auditor oversight act aoa independence article co article aoa circumstances incompatible independence accordance article paragraph item co swiss auditing standard confirm internal control system exists designed preparation financial statements according instructions board directors confirm proposed appropriation available earnings complies swiss law companys articles incorporation recommend financial statements submitted approved kpmg klynveld peat marwick goerdeler sa john morris franois rouiller licensed audit expert licensed audit expert auditor charge basel january wwwglobalreportscompublished cautionary statement regarding forwardlooking f hoffmannla roche ltd statements basel switzerland annual report contains certain forwardlooking tel statements forwardlooking statements may identi fax fied words believes expects anticipates projects intends seeks estimates future similar expressions discussion among things media office strategy goals plans intentions various factors may corporate communications causeactual results differ materially future basel switzerland reflected forwardlooking statements contained tel annual report among others pricing product fax initiatives competitors legislative regulatory devel opments economic conditions delay inability investor relations obtaining regulatory approvals bringing products market fluctuations currency exchange rates general basel switzerland financial market conditions uncertainties discovery tel development marketing new products new uses fax existing products including without limitation negative results clinical trials research projects unexpected side effects world wide web pipeline marketed products increased government httpwwwrochecom pricing pressures interruptions production loss ofor inability obtain adequate protection intellectual order publications property rights litigation loss key executives orother employees adverse publicity news tel coverage fax email baselwebmasterrochecom statement regarding earnings per share growth aprofit forecast interpreted mean next annual general meeting march thatroches earnings earnings per share subsequent period necessarily match exceed historical published earnings earnings per share roche trademarks mentioned enjoy legal protection roche annual report published german english printed nonchlorine bleached fsccertified paper roche annual report issued f hoffmannla roche ltd basel corporate communications wwwglobalreportscom